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In cancer, epithelial cell de-differentiation is a feature of rapidly dividing cells under         
non-controlled growth and it often reflects a change in the gene expression pattern; 
however, the relationship between proliferation and alterations in cellular differentiation has 
not yet been identified. This work examined how changes in the characteristics of cells that 
discriminate their differentiated and proliferative states can be used to improve on current 
pancreatic cancer chemotherapeutic strategies.  
PepT1, a high substrate-capacity and low-affinity transporter system, has been suggested 
as an attractive drug delivery target for pancreatic cancer. Through a combination of 
immunological assays, PepT1 normally restricted to the apical surfaces in polarised 
intestinal epithelial cells, was shown to distribute at the cell membrane of non-polarised 
cancerous ductal cells. Anti-inflammatory or anti-cancer agents, like ibuprofen or 
gemcitabine, were conjugated to selected amino acids to enhance their uptake via PepT1. 
Studies with these conjugates demonstrated enhanced uptake into pancreatic cancer cells, 
AsPc-1 and HPAFII. Subsequent studies investigated how cell polarity that is typically 
disrupted in cancer can be modulated to affect the balance of epithelial differentiation versus 
proliferation. Pharmacological attenuation of YAP (c-Yes associated protein) using a 
β-adrenergic agonist, dobutamine, increased functional tight junction (TJ) structures and 
diminished proliferation rates of two pancreatic cancer cells, AsPc-1 and HPAFII. 
Dobutamine also primed an apoptotic cell response. When given in combination with 
gemcitabine, dobutamine further reduced cell proliferation.  
Overall, these studies have provided support for using PepT1 as a method to target 
pancreatic cancer cells for the delivery of anti-cancer agents. Additionally, dobutamine was 
identified as a potential pharmacological agent to suppress the proliferation of pancreatic 
cancer cells by altering increasing cell programming that drives epithelial cell differentiation.   
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1.1 Pancreatic cancer  
1.1.1 Microscopic Structure and Functional Activity of the Pancreas  
 
The pancreas is a retroperitoneal organ surrounded by connective tissue that separates the 
parenchyma in lobules containing nerves, excretory ducts, lymphatic and blood vessels. 
Anatomically, the pancreas lies in the abdominal cavity behind the stomach (Figure 1.1). It is 
an endocrine gland and comprises two functional units that regulate two major physiological 
processes. The exocrine function assists in digestion and in the absorption of nutrients in the 
small intestine while the endocrine is primarily responsible for glucose metabolism.  
 
The exocrine pancreas has two main components: acinar cells and pancreatic ducts. The 
acini are rounded structures formed by 40-50 pyramidal-shaped cells (Rovasio, 2010) 
(Figure 1.2-b,c). Centroacinar cells are spindle-shaped cells resulting from an extension of 
the intercalated duct cells into each pancreatic acinus. The acinar lumen is separated from 
the intercellular space by zonula occludens, ZO (Figure 1.2 – d). Polarised gland cells are 
characterized by the presence of filamentous mitochondria, a highly developed  
endoplasmic reticulum and an extensive population of polyribosomes (Rovasio, 2010) 
(Figure 1.2 – c). The exocrine function of the pancreas is stimulated by food ingestion 
through neuro-hormonal signals. This secretory activity is reflected on the number of 
zymogen granules: high number during fasting and scarce number after food ingestion 
(Rovasio, 2010). After the secretory vesicles fuse with the plasma membrane, they release 
their pro-enzymatic contents by exocytosis and its membrane becomes part of the acinar 
cell plasma membrane. These functional units cumulatively produce around 1200 mL of 
pancreatic juice daily that contains digestive enzymes such as trypsin, chymotrypsin, lipase 
and amylase. In turn, this enzyme mixture travels through a series of ducts to reach the 





intra-lobular ducts which then converge to the main pancreatic duct having a wider lumen 
and being limited by a single layer of cubic epithelium. The main ducts of the pancreas are 
formed by cuboidal epithelium delimited by a consistent lamina propria.  
 
Figure 1.1 Anatomical position of the pancreas (Sircus, 2010). 
 
In humans, pancreatic secretory activity is regulated directly through the effect of hormones 
produced in the islets of Langerhans on the blood flow and indirectly through the effect of 
the autonomic nervous system on the blood flow. The islets of Langerhans are 
hormone-producing structural units and are scattered into the gland parenchyma resembling 
a light immunohistochemistry staining compared to the surrounding acinar cells (Figure 
1.3 - A).  Each small cluster of cells is separated from the surrounding pancreatic tissue by a 
thin fibrous connective tissue layer. Hormones produced in these functional units are 
secreted by at least five types of cells: alpha cells produce glucagon (15-20 % of total islet 
cells), beta cells produce insulin and amylin (65-80 %), delta cells are responsible for 
somatostatin production (3-10 %), pancreatic polypeptide (PP) cells produce pancreatic 
polypeptide (3-5 %) and finally epsilon cells produce ghrelin (1 %). Beta cells are coupled 
electrically to other beta cells and islets can communicate with each other through paracrine 





Branches of the mesenteric and celiac superior arteries, splenic and hepatic arteries, form 
the pancreatic vasculature. The lymphatic ganglia next to the splenic artery are responsible 
for the primary lymphatic drainage, whereas the secondary comes from the aortic, celiac, 
duodenal and sub-pyloric ganglia. Parasympathetic and sympathetic branches of the 
autonomic nervous system are responsible for the pancreas innervation. The sympathetic 
fibers are involved in vascular innervation and pain transmission while the parasympathetic 
fibers regulate the pancreatic exocrine secretion (Eynard, 2008). 
 
Figure 1.2 Schematic representation of the pancreas (a) Anatomy of the pancreas; (b) The 
exocrine pancreas; (c) Acinar and ductal cells arranged in a single acinus; (d) Exocrine compartment 
and Islet of Langerhans. Taken and reprinted by permission from Macmillan Publishers Ltd: Nat Rev 







Figure 1.3 Tissue section from normal human pancreas. Biopsy sample stained for YAP, Hippo 
signaling main effector (Sudol, 1994). Scale bar, 50 µm. (A) Islets of Langerhans; (B) Pancreatic 
duct; (C) Acinar cell.  
 
1.1.2  Development and structure of the pancreas 
 
The stomach, duodenum, biliary system, including the gallbladder, liver and pancreas are 
derived from closely related structures in early embryogenesis. The pancreatic gland starts 
to develop at week 5 of gestation with dorsal and ventral endodermic invaginations from the 
most caudal segment of the primitive foregut (Figure 1.4 - Formation). When the duodenum 
grows and rotates around its longitudinal axis, the organs enlarge and the ventral pancreas 
together with the common bile duct rotates. Then, the inferior part of the pancreas head 
fuses with the dorsal bud during the 6 to 7th week of gestation forming the pancreas gland 
(Figure 1.4 – Rotation). In most cases, after 8 weeks of gestation, the pancreatic duct from 
the dorsal pancreas fuses with the pancreatic duct from the ventral pancreas to form the 
main pancreatic duct (Figure 1.4 – Fusion).  After fusion, the pancreatic and biliary 






Figure 1.4 Structure and development of the pancreas. Taken and reprinted with permission from 
Morgan & Claypool Life Sciences (Pandol, 2010). 
 
1.1.3  The nature of pancreatic cancer 
 
More than 10 % of the total pancreatic cells form the pancreatic ducts. The 
best-characterized diseases of the exocrine pancreas are pancreatitis and cancer. It was not 
until the 19th century that the pancreas started to be appreciated as a vital organ. Nowadays, 
pancreatic cancer is recognized as one of the deadliest types of epithelial cancers. 
Pancreatic ductal adenocarcinoma (PDAC), commonly referred as pancreatic cancer, is a 
tumour type with ductal-cell histology and is by far the most common type of pancreatic 
neoplasms, accounting for more than 85 % of pancreatic cancers (Hruban et al., 2001). 
Pancreatic cancer carries one of the worst prognosis in the medicine field as it has a 5-year 
survival rate of only 3 % and a median survival of less than 6 months (Warshaw and 
Fernandezdelcastillo, 1992). Of greater concern is the statistics showing that these survival 
rates have not changed over the past 40 years.  
 
PDAC is a very aggressive type of tumour as it grows rapidly; due to its anatomical position 





PDAC include abdominal pain and jaundice due to tumour infiltration in nerves and the bile 
duct, however these are very vague (Erkan et al., 2013). Owing to the lack of specific 
symptoms, most of which are very subtle, allied to the limitations in diagnostic methods, 
pancreatic cancer often develops unperceived and is usually identified during a later, rather 




There are approximately 277,000 annual cases of pancreatic cancer, of which 266,000 are 
deaths, corresponding to a 96 % mortality rate (Pandol et al., 2012). It is the eighth or ninth 
most frequent cause of cancer-related deaths worldwide and the fourth or fifth in developed 
countries (Maisonneuve and Lowenfels, 2010). Worldwide, pancreatic cancer occurs more 
often in men than in women and in urban areas more than in rural places (Jiao and Li, 
2010). Patients diagnosed with pancreatic adenocarcinoma are usually between 60 and 80 
years old and the mean age is around 63 (Evans, 2001). 
 
In 2008, it was estimated that 37,700 patients in the US were diagnosed with PDAC of which 
34,300 patients died from the disease (Jemal et al., 2008). In 2012, there were an estimated 
43,920 new cases of pancreatic cancer of which 37,390 died (Siegel et al., 2012). In 2014, 
predictions point to 46,420 new cases with estimated death in 39,590 of these (Siegel et al., 
2014) (Figure 1.5). Quite clearly the death toll as a consequence of this lethal malignancy is 
increasing. Despite the extensive efforts that have been made to improve the targeting of 
therapies to pancreatic cancer, none of these approaches have been shown to provide 
clinical value. In sum, the dismal prognosis for PDAC results from the combination of issues 





resulting in a late diagnosis associated with metastatic dissemination of cancer cells that are 
noted for their resistance to systemic therapies (Feig et al., 2012). 
 
An effective prevention measure in pancreatic cancer relies on well-defined risk factors by 
epidemiological research. Age and cigarette smoking are a well-established risk factor; 
accumulating evidence suggests obesity and diabetes as another possible risk factor (Jiao 
et al., 2009). However, the associations of alcohol, pancreatitis, dietary factors, infection 
agents as well as occupational and hormonal factors and pancreatic cancer are yet to be 
confirmed (Jiao and Li, 2010) (Table 1.1). Pooled and large prospective studies have 
emerged to provide epidemiological evidence on risk factors of pancreatic cancer, 
suggesting that by adapting a healthy life style, pancreatic cancer can be prevented in 
almost 50 % of the cases (Jiao et al., 2009).  
 
Figure 1.5 Number of estimated new cases and deaths per year due to PDAC in USA 
1 
- (Jemal 
et al., 2003); 
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1.1.5 Pathologic classification and biological behavior of pancreatic neoplasia 
 
Pancreatic neoplasms are classified according to their characteristics. Some of these 
classifications include acinar cell carcinoma, ductal adenocarcinoma, endocrine tumours, 
solid pseudo-papillary tumours, lymphoplasmacytic sclerosing pancreatitis and primary 
pancreatic lymphoma (Mortenson et al., 2008). Studies have described other histological 
variants of pancreatic cancer comprising medullary carcinoma, hepatoid carcinoma, 
adenosquamous carcinoma and undifferentiated carcinoma (Degen et al., 2008).  
 
The endocrine pancreas is responsible for producing a variety of hormones but unlike the 
exocrine component, which releases enzymes locally to reach the duodenum, the hormones 
produced here are secreted into a rich capillary network that is associated with each islet. 
Endocrine cancers are far less common than ductal neoplasms, accounting for only 1 to 2 % 
of all pancreatic tumours (Basturk et al., 2010). Most of these neoplasms can be detected 
early as most of them secrete one or more active peptides that produce clinical symptoms 
(D'Onofrio et al., 2004). 
 
Despite the fact that acinar cells contribute to the vast majority of pancreatic tissue, acinar 
cell carcinoma is quite rare, representing only 5 % of all exocrine tumours (Tobias, 2010).  
Macroscopically, tumours formed by cancer cells derived from acinar cells are solid, well 
circumscribed; they occasionally display necrosis, hemorrhage or cystic characteristics. 
Acinar cancer cell tumours are well demarcated, having a higher rate of surgical resection 
(64 %) compared to ductal adenocarcinoma (Klimstra and Adsay, 2009).  
 
Although the ductal system is not a complex structure, it is the source of the majority of 





toward malignant transformation is probably due to many factors, one of which has 
suggested to result from the fact that the ductal system is the only component in the 
pancreas exposed to the outside environment, increasing its potential exposure to mutagens 
(Basturk et al., 2010). PDAC will be the focus of the remainder of this chapter. 
 
1.1.6  Invasive ductal neoplasia 
 
As previously mentioned, the ducts transport the acinar enzymes to the duodenum (Figure 
1.6); in order to be protected and lubricated, mucins form a stable network lining the 
pancreatic ducts (Basturk et al., 2010). Ductal differentiation can form different types of 
structures, which give the name to some of the resulting tumours. Tubular units (lumen 
forming), papilla (finger-like projections of the mucosa lining the ducts) and cysts are 
hallmarks of ductal differentiation. It has been speculated that PDAC originates not only in 
ductal cells but also in acinar (Guerra et al., 2007), islet (Pour, 2003) and centro-acinar cells 
(Stanger et al., 2005).  
 
Figure 1.6 Tissue section from normal pancreas. Biopsy sample stained for Slug, a highly 
conserved  zinc finger transcription repressor (Hemavathy et al., 2000). Acinar cells are arranged in 
lobules forming the majority of the parenchyma. As part of their normal secretory function, the nuclei 
are polarised to the periphery of the cells and arranged in round units forming the acinus (pointed by 
the black arrows). In the center, an intra-lobular duct lined by cuboidal-low epithelium can also be 






More than 85 % of pancreatic tumours are invasive ductal adenocarcinomas, also 
designated as scirrhous, tubular or pancreatobiliary type (Von Hoff et al., 2005). In general, 
these are all very aggressive cancers with only 20 % of the cases being considered for 
surgical resection at the time of diagnosis (Evans, 2001). Rapid growth, insidious infiltration 
and early dissemination contribute to the extremely low cure rate of PDAC (Evans, 2001) 
(Figure 1.7). Around 80 % of PDAC spread through nerves and vessels resulting in a 
phenomenon called perineural invasion, which is thought to be the reason for back pain, 
one of the most common symptoms of this tumour (Basturk et al., 2010). Vascular invasion 
is also very common in ductal neoplasia as cancer cells are capable of forming well 
delineated glandular structures in vascular spaces (Basturk, 2008) (Figure 1.8 – b).  
 
Figure 1.7 Tissue section from a patient diagnosed with invasive ductal neoplasia. Biopsy 
sample stained for PepT1, an oligopeptide transporter (Fei et al., 1994). The ducts (a) start to change 
morphologically and are no longer well defined. Acinar cells (b) are no longer polarised and are 
diluted in the highly intense fibrotic stroma (c). As the neoplasm becomes more evident, cells start to 








Figure 1.8 Tissue section from a patient diagnosed with low differentiated ductal neoplasia 
with vascular invasion. Biopsy sample stained for YAP, Hippo pathway main effector molecule 
(Sudol, 1994). Ductal cells demonstrating a low grade of differentiation (a) and vascular invasion (b) 
are identified. Scale bar, 50 µm. 
 
The diagnosis of PDAC can be quite problematic, not only from a clinical point of view but 
also microscopically. PDAC is characterized by a prominent desmoplastic response  
(Figure 1.7), in which a dense stroma makes it difficult to distinguish from inflammatory 
lesions of this organ, in particular types of chronic pancreatitis (CP) (Basturk et al., 2010). 
From the microscopic point of view, injured native ducts from non-inflamed or non-
cancerous pancreas can show substantial cytologic atypia comparable to that of ductal 
carcinomas; most ductal adenocarcinomas form well differentiated glandular structures that 
resemble benign ducts or that cause ductal obstruction leading to CP (Adsay and Zamboni, 
2004).  
 
1.1.7  Non-invasive ductal neoplasia 
 
Pancreatic intra-epithelial neoplasia (PanIN) is the most common precursor lesion of PDAC, 
being first described in 1998 (Brat et al., 1998). These abnormal intra-ductal proliferations 
that often accompany invasive ductal adenocarcinoma may also be seen in the absence of 
PDAC (Klöppel et al., 1980). Microscopically, PanINs are characterized by nuclear 





hyperchromasia. Altered cellular metabolism leads to the accumulation of genetic 
abnormalities including p53 mutations, glycoproteins, mainly mucins, loss of cell polarity and 
increased mitotic activity. The spectrum of changes is classified into different categories: 
PanINs 1,2 and 3 (Figure 1.9). PanIN1 are present in 70 % of normal pancreas at autopsy 
and are characterized by flat epithelial lesions composed of tall columnar cells with small 
nuclei, round to oval and may demonstrate mutations in the GTPase known as K-Ras. 
PanIN2 are papillary mucinous epithelial lesions with some nuclear abnormalities such as 
loss of polarity, nuclear crowding and hyperchromasia. PanIN3 are papillary or 
micropapillary but rarely flat and show loss of nuclear polarity, dystrophic goblet cells, 
abnormal mitoses, nuclear irregularities and prominent nuclei (Hruban et al., 2001) .  
 
Figure 1.9 Schematic diagram showing the molecular and anatomical evolution from non-
invasive to invasive PDAC. Grading of precursor lesions, PanINs, comprising a neoplastic 
transformation ranging from early mucinous change (PanIN1) to frank carcinoma in situ (PanIN3). 









1.1.8  Molecular relationship between chronic pancreatitis and pancreatic cancer 
 
The association between inflammation and cancer has been well defined in some organs 
(Mantovani et al., 2008). Nevertheless, the distinction between CP and PDAC is considered 
one of the most, if not the most, challenging differential diagnosis in pathology. The 
relationship between CP and PDAC is well established, although it remains controversial 
whether CP is a precursor or an independent pathology unrelated to PDAC (Logsdon et al., 
2010). Both pathological conditions share similar molecular traits such as the presence of 
stroma, inflammation with leucocyte infiltration, acinar cell atrophy and distorted and blocked 
ducts (Witt et al., 2007). Equally, the extent of fibrosis increases with the progression of the 
lesions and PanINs are present in most patients with CP alongside chromosomal instability 
and genomic damage, similarly to PDAC (Figure 1.9). CP provides a microenvironment that 
contains dendritic cells, activated leukocytes including macrophages, neutrophils, mast and 
T cells which secrete a wide variety of cytokines, chemokines and enzymes associated with 
the production of reactive oxygen species (Pelicano et al., 2004).  
 
K-Ras activity leads to the activation of NF-kB (Karin and Greten, 2005) and 
cyclooxygenase 2, Cox-2 (Harris, 2007), which is a major transcription factor that regulates 
genes responsible for both the innate and the adaptive immune response. Both K-Ras and 
NF-kB appear to be activated in CP; it has been suggested that they potentially provide the 
link between inflammation and PDAC (Rakonczay et al., 2008; Schlosser et al., 2002). 
Further evidence has suggested that treatment increasing K-Ras activity produces 
inflammation associated with fibrosis and accelerates the progression of PDAC (Guerra et 
al., 2007) and that K-Ras alone may be sufficient to trigger both of these pathological 
conditions (Logsdon and Ji, 2009). Thus, it is likely that K-Ras activity is a common 





diagnosed with CP, do not progress to PDAC, hence critical barriers are likely to exist 
between the mechanisms involved in CP development and the onset of PDAC (Logsdon et 
al., 2010).  
 
Chronic inflammation of the pancreas leads to irreversible deterioration of the organ 
structure and function. CP presents a rather challenging diagnosis as it occurs in many 
forms from different etiologies. From a histological perspective, CP is characterized by loss 
of parenchyma, extensive fibrosis and by the presence of inflammatory cells (Witt et al., 
2007) (Figure 1.10). Despite the primary clinical manifestation of fibrosis, CP events appear 
to initiate in the acinar cells (Logsdon et al., 2010). Although it is common to identify regions 
that would be defined as CP within histological sections of PDAC, this association does not 
define a required dependent mechanism between CP and PDAC.   
 
Figure 1.10 Tissue section from a patient diagnosed with CP. Biopsy sample stained for c-Yes, 
non-receptor tyrosine kinase. Presence of an intense fibrotic response (a) and loss of normal 
parenchyma characterized by acinar cell displacement imbedded in an abundant stroma (b). Scale 
bar, 50 µm. 
 
Different etiological factors are involved in the development of CP; alcohol consumption, 
autoimmune cystic fibrosis, heredity, tropical and idiopathic forms and gallstone are 
contributing factors to the pathology (Witt et al., 2007). It has been reported that CP appears 
to increase the risk of developing PDAC and hereditary pancreatitis has been found to be 





(Whitcomb, 2004). Hereditary pancreatitis has been reported to increase the risk of PDAC 
by 53-fold with a cumulative lifetime risk of approximately 40 % (Lowenfels et al., 1997). 
Nevertheless, the mutations observed in hereditary CP are not the same as those detected 
in PDAC (Whitcomb, 2004). 
 
1.1.9  The cell cycle and pancreatic cancer 
 
In 2000, Hanahan and Weinberg outlined six biological properties acquired during the 
multistep development of human tumours: self-sufficiency in growth signals, insensitivity to 
anti-growth signals, limitless replicative potential, reduced apoptosis, sustained 
angiogenesis, tissue invasion and metastasis (Hanahan and Weinberg, 2000) (Figure 1.11). 
In 2011, conceptual progress has added two more emerging hallmarks: reprogramming of 
energy metabolism and evading immune destruction (Hanahan and Weinberg, 2011) (Figure 
1.11). Deregulated cell proliferation is one of the hallmarks of cancer (Hanahan and 
Weinberg, 2011); PDAC cells display high levels of proliferating activity, indicative of altered 
cell cycle regulation. Tuveson and co-workers were able to show that the proliferation rate in 
early PanIN lesions was 18-fold higher relative to normal pancreatic ducts (Hingorani et al., 
2003). Amongst the plethora of oncogenic events and genetic alterations occurring in PDAC, 
mutations in the K-Ras oncogene are the most frequent. These genetic alterations are 
present in a significant fraction of early precursor lesions suggesting the involvement of K-
Ras in PDAC initiation (Moskaluk et al., 1997). The tumour suppressor p16 is lost in almost 
all PDAC cases (Schutte et al., 1997). Loss of p53 and SMAD4 tumour suppressor proteins 
has also been reported (Sun et al., 2001; Tascilar et al., 2001) (Figure 1.12). This section 






Mutations in the K-RAS oncogene have been reported to occur in approximately 90 % of 
PDAC patients (Zhou et al., 2004). Ras proteins activate signaling downstream effector 
pathways, the best studied of which are Raf-MAPK and PI3 Kinase-Akt (Downward, 2003). 
These signaling cascades are involved in driving proliferation, survival and cell growth; they 
have also been reported to prime the events of cellular transformation and oncogenesis 
(Lewis, 2010). The essential role(s) of various K-Ras-induced signaling pathways in the 
PDAC phenotype is currently unknown. 
 
Figure 1.11 The next generation of the hallmarks of cancer (Hanahan and Weinberg, 2011). 
Taken and reprinted with permission from Elsevier. 
 
 
Figure 1.12 Genetic alterations occurring in pancreatic cancer. A schematic illustration of how 
genes commonly altered in pancreatic cancer affect cell cycle progression. Taken and reprinted with 





The SMAD pathway is the canonical signaling pathway that the transforming growth factor 
(TGF-β) family members signal through (Figure 1.12). This complex signaling network 
regulates cellular proliferation, apoptosis, cell migration and ultimately cell invasion. TGF-β 
ligands bind to type I or II receptors and such interactions induce receptor dimerization, 
activation and subsequent cellular signaling. Activated TGF-β receptors then recruit SMADs 
that bind to SMAD4, which will translocate to the nucleus inducing the regulation of different 
target genes. TGF-β signaling is inactivated in pancreatic cancer, leading to an excessive 
activation of pancreatic cancer cell growth. Nearly 50 % of PDAC have lost the SMAD4 
gene, whereas only a fraction show inactivation of TGF-β receptor (Hahn et al., 1996). 
SMAD4 mutations are not present in early PanIN lesions but do appear in PanIN3, 
suggestive of a role in malignant conversion of precursor lesions into adenocarcinoma 
(Lewis, 2010). 
 
1.1.10  Emerging therapeutic targets for pancreatic cancer and tumour 
microenvironment 
 
Despite numerous efforts, targeted therapies have only provided limited efficacy in treating 
patients suffering from PDAC. More than 80 % of patients are diagnosed in the final and 
advanced metastatic stage, excluding the possibility of a surgical resection (Hotz et al., 
2007). At this stage, PDAC tumours are highly metastatic and show a vigorous stromal 
response, termed desmoplasia, which significantly restricts the successful penetration of 
agents designed to target these tumours.  These tumours are characterized by an increased 
rate of deregulated proliferation, enhanced cell survival, resistance to therapy, evasion from 
immune control, and increased metastasis (Feig et al., 2012) (Figure 1.13 – b). The tumour 
mass that is produced in PDAC commonly consists of a dynamic assortment of cells that 





cells and fibroblasts. This complex cellular environment is dynamic, changing in its 
composition during the progression from early precursor lesions PanIN to invasive PDAC.  
 
In normal pancreas, PSCs are in a relative quiescent state and localize close to the acinar 
cells, capillaries and nerve fibers and can be identified by expression of GFAP (glial fibrillary 
acidic protein) and desmin (Erkan et al., 2013; Omary et al., 2007) (Figure 1.13-a). In normal 
pancreas, PSCs account for 4-7 % of all parenchymal cells, whereas in PDAC they can 
outnumber the cancer cells (Yen et al., 2002). PSCs have been reported to be the major 
source of excessive deposition of extracellular matrix proteins such as collagens, fibronectin 
and proteoglycans in the pancreatic cancer stroma (Bachem et al., 1998). This prominent 
and dense fibrotic stroma impacts on pancreatic cancer aggressiveness, as well as 
providing a physical scaffold with an intensive production of cytokines and growth factors, 
creating a physical barrier to the tumour  (Erkan et al., 2013). The fibrotic stroma causes an 
extremely hypoxic environment leading to distortion and compression of tissue vasculature 
and ultimately prevents efficient drug perfusion (Erkan et al., 2007). PSCs have also been 
shown to actively secrete matrix metalloproteinases (MMP1), which are associated with 
inflammation, fibrosis, cancer invasion and ultimately angiogenesis (Fujisawa et al., 2012). 
Thus, it is possible that therapeutic benefit may be gained through strategies that deplete 
PSCs. 
 
Figure 1.13 Tumour microenvironment in pancreatic cancer. (a) Immunofluorescence analysis of 
cultivated primary pancreatic stellate cell; (b) immunohistochemistry analysis of PDAC biopsy sample, 
hematoxylin-eosyn staining, original magnification: 100x; Taken and reprinted with kind permission 





1.1.11 Targeted therapies in pancreatic cancer 
 
Significant progress has recently been achieved in the treatment of many tumour types such 
as colorectal cancer, lung and melanoma, but a comparable success has not yet been 
achieved for pancreatic cancer (Yauch and Settleman, 2012). Gemcitabine, a commonly 
used chemotherapeutic agent in treating PDAC, produced only a modest increase in patient 
survival rate (Burris et al., 1997). Different approaches for targeted therapies have 
demonstrated huge success in a pre-clinical context; however they have largely failed in the 
clinical setting, suggesting the inability of pancreatic tumour models to recapitulate critical 
aspects and/or barriers associated with the tumour microenvironment in patients.  This 
chapter section will focus on some of the most promising of these therapeutic strategies: 
anti-angiogenic, EGF (epidermal growth factor) inhibition, K-Ras inhibition and MMP1 
inhibition.  
 
TKI258, a tyrosine kinase inhibitor to vascular endothelial growth factor receptor, VEGF-R, 
delayed growth and improved survival in subcutaneously injected tumours and orthotopic 
models (Taeger et al., 2011). Another study reported pre-clinical benefit in using anti-VEGF-
R2 antibodies covalently bound to doxorubicin in depleting VEGF-R2-expressing tumour 
vasculature (Wicki et al., 2012). Another study highlighted the potential benefit of 
gemcitabine given in combination with bevacizumab, a humanized monoclonal antibody that 
blocks specifically vascular endothelial growth factor receptor A, VEGF-RA (Kindler et al., 
2010). Despite the fact that these successful pre-clinical approaches have led to clinical 
trials, there was a great discrepancy between experimental results and clinical reality.  
In terms of EGF inhibition, the EGF receptor (EGFR) tyrosine kinase erlotinib, 
commercialized under the name Tarceva (Genentech), when combined with gemcitabine, 





10 days (Moore et al., 2007). Despite its cost, the overall survival advantage is minimal. 
Additionally, a study has reported that combining gemcitabine with the combination therapy 
known as FOLFIRINOX (composed of the vitamin B derivative folinic acid, the pyrimidine 
analogue 5-fluorouracil (5-FU), the topoisomerase inhibitor irinotecan, and the platinum-
based antineoplastic oxaliplatin) produced a significant survival benefit of 11.1 vs 6.7 
months in patients with metastatic PDAC compared to gemcitabine as a single treatment 
(Conroy et al., 2011b). Still, due to its increased toxicity, FOLFIRINOX is only suitable for 
some patients (Feig et al., 2012). Recently, data published from a phase II trial, in which 
gemcitabine was given in combination with oxaliplatin and cetuximab, lacked significant 
improvements (Merchan et al., 2012). 
 
K-Ras mutations have been reported in 90 % of patients suffering from PDAC (Zhou et al., 
2004). Still, in a study evaluating the efficacy of cetuximab plus gemcitabine/oxaliplatin in 
pancreatic cancer patients with the K-RAS gene mutated, neither monotherapy nor 
combined approaches showed a clinical benefit (Kullmann et al., 2011).  
Given the role of MMPs1 in pancreatic tissue maintenance (Fujisawa et al., 2012), MMP1 
inhibitors have emerged. Ukrain, a potent MMP1 inhibitor, was shown to down-regulate 
MMP1-2 and MMP1-9 in pancreatic cancer cell lines and was also able to decrease invasion 
(Funel et al., 2010). Yet, this approach has also failed in the clinic (Conroy et al., 2011a). 
Since conventional and targeted therapies largely failed in prolonging survival in pancreatic 
cancer patients, new approaches and novel strategies are needed to improve the clinical 








1.1.12  Membrane transports as therapeutic targets in cancer 
 
Nearly 4 % of the genes in the human genome encode for membrane transporters, 
underlying the importance and varied roles played by these proteins (Venter, 2001). 
Membrane transporters function on the selective uptake of nutrients, nucleosides, amino 
acids, inorganic ions and sugars (Venter, 2001). Transporter proteins can be classified into 
two major families, solute carrier (SLC), which comprises both facilitated and secondary 
active transporters and the ATP-binding cassette (ABC) transporters. While the family of 
ABC transporters is very extensive and functionally highly diverse, all members of this family 
utilize the energy generated from ATP hydrolysis.  
 
Various drugs can be substrates for specific membrane transporters, including anti-cancer 
drugs; these interactions can affect absorption, distribution and excretion pathways. Some 
membrane transport proteins, however, might also be capable of internalizing anti-cancer 
drugs in a pro-drug form that emulates an endogenous substrate. Thus the use of specific 
transporters as molecular targets in cancer therapy has been discussed (Cravo and Mrsny, 
2013) (Table 1.2). The remaining portion of this chapter will focus on three of these drug 
transporters: folate, glucose and PepT1 transporter with a special reference to PepT1 as it is 
the drug delivery target subject of this thesis.  
 
The folate receptor (FR) is overexpressed at the cell surface of ovarian cancer cells 
(Weitman et al., 1992), the most lethal gynecologic malignancy (Kim et al., 2012). Based on 
this, FR represents a particularly “smart” approach for targeting chemotherapeutics into 
cancer cells. Another important feature in using FR as a cancer target is the small size of the 
targeting ligand, which allows for repeated administration with a less likely immunogenic 





cytosolic endocytosis (Sudimack and Lee, 2000). Many efforts have been developed 
through the use of liposomes in therapy; nonetheless, major limitations underpin the use of 
immune-liposomes for drug delivery. Apart from the immunogenicity of the targeting ligand, 
the covalent attachment of a protein to a liposome is technically demanding (Sudimack and 
Lee, 2000). Lee and Low entrapped doxorubicin, a cancer drug commonly used to treat 
leukemia as well as cancers of the bladder, breast, stomach, lung and ovaries, in 
folate-PEG-liposomes and were able to show a 45- to 86-fold higher uptake and cytotoxic 
action in cancer cells compared to the free drug (Lee and Low, 1995). However, in cancer, 
the total amount of FR throughout the body is much greater than that expressed in a specific 
tumour; hence drug-folate conjugated therapies have the potential to induce systemic 
toxicity.  
 
As a polar molecule, glucose cannot get into cells via simple diffusion. The GLUT1 glucose 
transporter is responsible for the facilitated transport of glucose into cells (Macheda et al., 
2005). Although constitutively expressed in normal tissues, the GLUT1 transporter has 
attracted some attention as it can be overexpressed in many types of tumours (Brown and 
Wahl, 1993; Yamamoto et al., 1990). Further, cancer cells are typically more dependent 
than non-cancer cells upon glycolysis compared to mitochondrial oxidative phosphorylation 
to produce ATP (Abouzeid et al., 2013). A recent study has reported a dramatic 
improvement in efficacy between the non-targeted and GLUT1-targeted forms of curcumin, 
and doxorubicin-loaded micelles in a model of colorectal carcinoma (Abouzeid et al., 2013). 






Table 1.2 List of some transporter systems able to shuttle specific anti-cancer drugs (Cravo 
and Mrsny, 2013). 
 
 
1.2 The oligopeptide transporter system PepT1  
1.2.1 Structure and function 
 
PepT1, also known as solute carrier family 15 member 1 (SLC15A1) belongs to the 
proton-coupled oligopeptide transporter family, PTR, which also includes PepT2 (SLC15A2), 
peptide histidine transporter 1 (PHT1, SLC15A4) and peptide histidine transporter 2 (PHT2 , 
SLC15A3) (Steiner et al., 1995). From this family, only PepT1 and PepT2 have been shown 
to have transport activity in humans (Liang et al., 1995). 
 
PepT1 uses an electrochemical proton gradient as the driving force (Figure 1.14). The 
optimal extracellular pH for substrate uptake is between 4.5 and 6.5, with compounds that 






Figure 1.14 PepT1 transport. Peptide transport through PepT1 is coupled to an inward proton 
gradient to catalyze electrogenic uptake against a concentration gradient. The sodium anti-porter 
pump, NH3, located at the apical region, exports protons entering the cell through PepT1 in exchange 
for Na
+
 ions. Adapted from Gilbert (Gilbert et al., 2008). 
 
In 1994, Fei and co-workers first cloned and characterized PepT1 by expressing PepT1 
cRNA in Xenopus laevis oocytes (Fei et al., 1994). One year later, PepT1 was isolated from 
humans (Liang et al., 1995). PepT1 consists of 708 amino acids and 12 putative membrane 
domains and has a core molecular mass of 79 kDa (Liang et al., 1995).  
 
PepT2 is composed of 729 amino acids and is located at the luminal membrane of the distal 
part of the proximal tube in the kidney and shares about 50 % amino acid identity with 
PepT1. PepT1 shares a similarity of 83 % between humans (Liang et al., 1995) and mice 
(Fei et al., 2000). The main role of PepT1 is the intestinal absorption of nutrients; conversely 
PepT2 has a role in the reabsorption of peptide associated amino nitrogen from the 
glomerular filtrate (Leibach and Ganapathy, 1996). As a consequence of the distinct 
physiological roles, PepT1 is a low affinity but high capacity transport system whereas 
PepT2 is a high affinity but low capacity transport system (Leibach and Ganapathy, 1996; 







regarding their transport mechanisms, tissue distribution and regulation, substrate specificity 
and structural characteristics.  
 
1.2.2 Substrate conformational and structural requirements 
 
The crystal structure for PepT1 is not yet available due to the technical challenge in 
crystalizing protein membranes; nevertheless site-directed mutagenesis has identified some 
amino acid residues such as Y12, Y56, Y64, Y91, Y167, H57, W294 and E595 to be 
important in modulating substrate binding and transport activity (Brandsch et al., 2008). In 
terms of structural substrate requirements, there is a preference for L- relative to D-  amino 
acids, and for peptides with an acidic or hydrophobic function at the C-terminus and a 
weakly basic group at the N-terminus (Brodin et al., 2002). Nearly all di/tri-peptides can be 
transported by PepT1, although neither free nor tetra-oligopeptides can be transported 
through this system with great efficiency (Chen et al., 2002a). Transport of peptides and 
peptidomimetics occurs in a stereospecific manner and the transporter system discriminates 
substrates by differences in binding affinity that affects the maximal transport rate (Wenzel 
et al., 1995). The minimal substrate requirement involves two oppositely charged head 
groups separated by a carbon spacer, and a peptide bond is not essential in the substrate 
structure (Rubio-Aliaga and Daniel, 2008). 
 
Being a high substrate capacity system capable of shuttling substrate molecules up to 600 
Da, and because of its low affinity (Daniel, 1996; Steiner et al., 1995), PepT1 represents an 
attractive strategy for drug delivery. Many studies have explored the potentialities of PepT1 
as a drug shuttling system. Examples of known substrates for PepT1 include β-lactam 
antibiotics such as cefadroxil (Ganapathy et al., 1995), the anti-herpes virus compound δ-





L-α-methyldopa-L-Phe and L-dopa-L-Phe (Brandsch et al., 2008). More recently, the 
compound JBP485, a dipeptide with anti-hepatitis activity, was also shown to be a substrate 
for PepT1 activity (Liu et al., 2011). 
 
Different methods can be used to screen PepT1 substrates. Through competitive inhibition 
with known PepT1 substrates, polarised monolayers of Caco-2 cells are frequently used as 
an in vitro cell model to assess whether a drug fulfills the requirements of a PepT1 
substrate. Other cell lines besides Caco-2 have also been used to screen for PepT1 
substrates such as HeLa cells, MDCK (Madin-Darby canine kidney cells) or CHO cells 
stably expressing PepT1.  Because of its electrogenic features, the uptake through PepT1 
can also be tested in Xenopus laevis oocytes induced to express PepT1 following the 
injection of cRNA encoding PepT1 (Fei et al., 1994). Genetically modified mice deficient in 
PepT1 are also available, representing a valuable strategy for screening compounds in vivo 
(Hu et al., 2008).  
 
1.2.3 PepT1 regulation  
 
PepT1 expression and function are under tight regulation that is controlled by numerous 
physiological, pharmacological and ultimately pathological factors. PepT1 undergoes diurnal 
regulation and fasting or starvation can up-regulate PepT1 expression both at mRNA and 
protein levels. While there is no known pathology associated with PepT1 malfunction at a 
genomic level, PepT1 up-regulation has been reported in inflammation (Buyse et al., 2002; 
Ingersoll et al., 2012; Vavricka et al., 2006; Wang et al., 2013). Pharmaceutical agents such 
as tacrolimus and cyclosporin (Motohashi et al., 2001), 5-FU (Inoue et al., 2005) as well as 






1.2.4 PepT1 as a drug delivery target 
 
In mammals, PepT1 is predominantly expressed in the small intestine; it localizes at the 
brush border of epithelial cells (Lu and Klaassen, 2006). The concept of targeting intestinal 
PepT1 for improved oral absorption and availability has been well explored (Brandsch, 2009; 
Doring et al., 1998; Ganapathy et al., 1995; Liu et al., 2011). PepT1 expression has been 
reported in cancer tissues fuelling interest in adopting PepT1 as a possible route of drug 
delivery to these types of cancer.  
 
Gonzalez and co-workers reported the surprisingly high expression of PepT1 in two human 
pancreatic cancer cell lines, AsPc-1 and Capan2;  with both cell lines having a ductal origin 
and a mutated K- Ras genotype (Gonzalez et al., 1998). This finding has driven the interest 
in adopting PepT1 as a possible drug delivery strategy to target pancreatic cancer cells 
specifically. Since pancreatic cancer cells overexpress this transporter system relative to 
levels observed in non-cancerous cells, this difference may allow for enhanced drug delivery 
to PDAC. Subsequent to the findings by Gonzalez and co-workers, increased levels of 
peptide transporter activity was reported in gastric cancer, osteosarcoma, bladder cancer 
and cholangiosarcoma (Inoue et al., 2005; Knutter et al., 2002). Additionally, bestatin, an 
anti-cancer drug shown to be a PepT1 substrate (Inui et al., 1992), was reported to have a 
much higher level of intracellular accumulation in a specifically constructed HeLa cell line 







1.3 Cell polarity in cancer 
1.3.1  The main players in the establishment and maintenance of epithelial cell 
polarity 
 
Epithelial tissues are distributed throughout the body to establish a lining that separates the 
external world from the internal surfaces of the body. Each epithelium has specialised 
functions related to its distinct location and physiological role(s). These specialised functions 
are largely dependent upon the structural organization of cells within those tissues 
regulating cell polarity. Epithelial cells exhibit apical-basal polarity defined by two different 
domains: the apical membrane facing the outside surface of the body and basolateral 
membrane oriented away from the lumen. Epithelial cells also display planar cell polarity 
(PCP), referring to the polarization of a field of cells within the lateral plane of a cell sheet 
(Jones and Chen, 2007).  
 
Epithelial cell polarity mechanisms also constitute a barrier to metastasis through a close 
interaction with the apical junctional complex (AJC), which comprises TJ and adherens 
junction (AJ) structures. AJC elements have been shown to be regularly mutated in epithelial 
cancers, which reinforces the role of AJC complex in suppressing cancer malignancy (Royer 
and Lu, 2011). Extensive intracellular signaling networks comprising three protein 
complexes are involved in establishing and maintaining the polarization of an epithelium: 
Par, Crumbs and Scribble (Figure 1.15).  
 
The PAR complex has been extensively studied in Drosophila melanogaster. The core of the 
PAR complex includes the PDZ-domain-containing proteins, PAR3 and PAR6 and an 





the formation and maintenance of apical-basal polarity in cells, however there are multiple 
isoforms of Par6 and aPKC denoting some functional redundancy (Aranda et al., 2008).  
The Crumbs protein complex is a key regulator of epithelial polarity; being initially 
discovered in Drosophila melanogaster as an essential protein for maintaining apico-basal 
polarity and integrity of embryonic epithelia (Bulgakova and Knust, 2009). The core 
components of the Crumbs complex are Crb, Stardust (Sdt), PATJ (protein associated with 
TJ) and Lin-7 (Bulgakova and Knust, 2009). Formation of the Crumbs complex results from 
dynamic interactions with these core components. These elements are scaffolding proteins 
that serve as a platform that recruits other proteins to close proximity thereby facilitating their 
function as a complex. Studies have shown that reducing the expression levels of PATJ1, 
Pals1 or Lin-7 in MDCK cells leads to defects in TJ formation and consequently reduction of 
TER and abnormal cell polarity (Straight et al., 2004; Wang et al., 2007a). 
 
The Scribble complex, including disks large (Dlg) and lethal giant larvae (Lgl), is critical for 
the establishment of the basolateral membrane domain. In contrast to PAR and Crumbs 
complexes, the role of the Scribble polarity complex is less understood. Nevertheless, 
several lines of evidence have demonstrated that mutations in any member of this complex 
results in a pronounced disorganization of epithelial architecture, which is characterized by 






Figure 1.15 Proteins involved in the apical polarity complex (APC). Taken and reprinted with 
permission from Macmillan Publishers Ltd (Iden and Collard, 2008). 
 
1.3.2 TJ and Ocln 
 
Apical-basal polarity has two main fundamental roles in epithelial cells linked to tumour 
suppression:  maintenance of the AJC and regulation of proliferation (Royer and Lu, 2011). 
TJs are the most apical structures and govern the permeability of confluent sheets of 
epithelial cells. TJs participate in many different processes, such as sealing the intercellular 
space, separation of apical and basolateral fluid compartments of epithelia and endothelia, 
barrier to cell migration and participation in cell-cell adhesion. Besides, TJs can also act as 
intermediates and transducers in cell signaling processes involved in polarity, cell 
differentiation, growth and proliferation (Martin and Jiang, 2009). These structures are 
mainly involved in two types of signaling: those that transduce information from the cell 





transmitted to the cell interior to modulate the gene expression involved in proliferation or 
differentiation (Matter and Balda, 2003). The TJ network comprises five families of proteins: 
junctional adhesion molecules (JAMs), claudins, and MARVEL proteins that include occludin 
(Ocln), tricellulin (Tric) and MarvelD3 (Figure 1.16). 
 
Figure 1.16 Schematic diagram showing protein distribution at TJs. (A) Bi-cellular TJ;  
(B) Tri-cellular TJ. Taken and reprinted from The Lancet with permission from Elsevier (Mariano et al., 
2011). 
 
JAMs are a group of proteins with a molecular weight of approximately 40 kDa involved in 
regulating a plethora of cellular adhesive processes including leukocyte migration (Martin-
Padura et al., 1998), cell morphology (Mandell et al., 2005) and intercellular junction 
assembly (Liang et al., 2000). JAMs are subdivided into two subgroups according to their 
structure and sequence. JAM-A, JAM-B, JAM-C, also known as JAM-1, JAM-2, JAM-3 
respectively, have a class II PDZ-binding domain at the C-terminus whereas JAM-4 contains 
a class I PDZ-binding motif at the C-terminus (Ichikawa-Tomikawa et al., 2011). JAM-A 
participates in the formation of TJs and polarity through interaction with Par-3/aPKC/Par-6 
(Suzuki et al., 2002); JAM-B and JAM-C interact with Par-3 through PDZ binding domain 
(Ebnet et al., 2004) and JAM-4 associates with Ligand-of-Numb protein X1 (Kansaku et al., 
2006) and MAGI-1 (Hirabayashi et al., 2003). In contrast to Ocln or claudin, JAM-related 
proteins do not form TJ strands, raising the possibility of having different biological roles 






Claudin belongs to a family comprising 24 distinct members. They are tetra-span proteins 
with a molecular weight of around 18 to 27- kDa (Tsukita et al., 2001). There are many 
isoforms generated by alternative splicing exhibiting different expression patterns and 
physiological functions (Van Itallie et al., 2006). Claudins constitute the TJ backbone, as 
they are able to reconstitute close membrane appositional structures in fibroblasts (Furuse 
et al., 1998). Claudins confer the major and structural features of TJs and their 
phosphorylation is associated with TJ assembly and function in regulating paracellular 
permeability (Ichikawa-Tomikawa et al., 2011). Two classes of claudins with different roles 
have been reported; Isoforms -4,-5,-8 and -11 and -19 have been linked to barrier sealing 
properties, whereas -2,-7,-10 and -15 have been demonstrated to have pore forming 
properties (Krause et al., 2008).  
 
Ocln (~65 kDa) was the first integral membrane protein of TJ to be identified, being shown to 
localize at epithelial and endothelial TJs (Furuse et al., 1993). Ocln exhibits a multi-domain 
tetra-span structure and each individual domain has distinct functions (Figure 1.17). Ocln 
also exhibits a MARVEL (MAL and related proteins for vesicle trafficking and membrane 
link) domain which is a four-transmembrane structural motif involved in membrane 
apposition and fusion events (Cummins, 2012). The extended C-terminus has been shown 
to interact with ZO-1, zona occludens protein-1, mediating its trafficking to the plasma 
membrane. Approximately half of the Ocln amino acid residues localize to the C-terminus 
and increased serine phosphorylation has been shown to correlate with its localisation at 
TJs and paracellular barrier formation (Wong and Gumbiner, 1997). The C-terminus is also 
a target for multiple kinases including c-Yes and c-Src oncogene proteins that when 
activated, cell-cell junctions get dynamically reorganized (Chen et al., 2002b). The 
extracellular Ocln loops have been demonstrated to participate in its localisation and TJ 





A variety of studies have demonstrated Ocln to have a key role in the dynamic regulation of 
TJ permeability. McCarthy and co-authors reported that Ocln overexpression in MDCK cells 
enhanced trans-epithelial electrical resistance (TER) (McCarthy et al., 1996).  Furthermore, 
down-regulation of Ocln via either proteolysis or through growth factors, such as VEGF, or 
phospholipase D2, was directly linked to increased endothelial permeability (Murakami et al., 
2009). Past studies have also suggested the extent of Ocln down-regulation to correlate with 
tumour grade, invasiveness and metastasis (Wang et al., 2007b). Additionally, Li and Mrsny 
also showed the crucial role Ocln plays when TJs are disrupted by oncogenic Raf1 protein. 
Importantly, forced re-expression of Ocln into this system was able to reverse the 
phenotypical changes induced by active Raf1 namely loss of intercellular junctions, loss of 
an epithelial phenotype and ultimately the acquisition of an invasive phenotype (Li and 
Mrsny, 2000).  
 
Tric is also a tetra-span protein that concentrates at tri-cellular contacts of epithelial cells 
(Ikenouchi et al., 2005). Like Ocln, Tric also displays MARVEL domains (Cummins, 2012); 
The MARVEL domain has been found to have a putative role in vesicle transport of proteins 
which is consistent with the observed vesicular trafficking of Ocln (Erickson et al., 2007). 
This group of proteins has been speculated to display a certain degree of redundancy 
contributing uniquely to TJ regulation and epithelial function. Genes encoding for both Ocln 
and Tric are located in chromosome 5 and it has been suggested they may have arisen from 
gene duplication during evolution (Ikenouchi et al., 2005). Tric is related to epithelial barrier 
and organization of both bi- and tri-cellular junctions. Moreover, Tric expression can be 
repressed by SNAI1, a zinc-finger type transcription factor that plays an important role in 
epithelial to mesenchymal transition, EMT (Dorfel et al., 2009).  Recessive mutation of the 






Figure 1.17 Ocln structure with regard to its organization within the plasma membrane. 
 
1.3.3 Cell Polarity and EMT 
 
EMT is an essential process occurring during embryogenesis, growth and wound repair by 
which epithelial cells lose their cell polarity and cell-cell-adhesion properties and gain the 
capacity to migrate and proliferate (Barrallo-Gimeno and Nieto, 2005). Pathological 
activation of EMT events leads to the initiation of uncontrolled growth and metastasis, which 
results in cancer formation and progression (Thiery, 2003). Several lines of evidence have 
suggested that loss of core polarity proteins could induce EMT. Given their potential role as 
tumour suppressors, core polarity proteins are often targeted and disrupted by oncogenic 
signaling (Royer and Lu, 2011). Studies have suggested that the deregulation of polarity 
proteins such as Scrib, Dlg and Lgl, triggers malignant transformation (Huang and 
Muthuswamy, 2010). Recent work suggested that cell polarity may limit growth through 








1.3.4 The Hpo pathway signaling 
 
The Hpo pathway, also known as the Salvador/Warts, is a conserved signaling pathway with 
a crucial role in regulating epithelial tissue growth, alongside cell proliferation, apoptosis and 
other stress responses, events that can be disrupted in epithelial cancers (Badouel et al., 
2009). In contrast to other signaling pathways, such as EGF, TGF- β or WNT signaling 
pathways, the Hpo pathway does not have extracellular growth factor components for 
signaling, instead being regulated by upstream components involved in regulating cell 
adhesion and polarity  (Johnson and Halder, 2014). Epithelial cell shape, adhesion and 
density appear to be directly regulated by the intracellular localisation and phosphorylation 
state of transcriptional regulators of the Hpo pathway known as YAP and TAZ 
(transcriptional co-activator with PDZ-binding motif). The protein kinases MST 1/2 and their 
regulatory protein, SAV1, are at the core of the Hpo signaling cascade and interact together 
to form an activated complex. RASSF family proteins can also activate MST 1/2 which can 
then directly phosphorylate LATS 1/2, large tumour suppressor homolog kinases (Dong et 
al., 2007). At high cell density, the WW-domain containing transcriptional co-activators YAP 
are phosphorylated at Ser127 and TAZ at Ser89; 14-3-3 binds to YAP thereby inhibiting its 
translocation to the nucleus. At low cell density, YAP is mainly nuclear and YAP/TAZ serves 
as a co-activator for the TEA-domain family member (TEAD) group of DNA-binding 
transcription factors, which will then promote survival and proliferation programs (Dong et 






Figure 1.18 The Hpo pathway signaling cascade. Solid lines demonstrate known interactions and 
dashed lines unknown mechanisms. Blunted lines and arrows indicate either activation or inhibition. 
Taken and reprinted from The Lancet, with permission from Elsevier (Ramos and Camargo, 2012). 
 
1.3.5  The Hpo pathway and apico-basal cell polarity 
 
The apical domain and cell-cell junctions play a key role in Hpo pathway regulation. It is not 
yet known, however, what extracellular signals are sensed through cell-cell contacts via the 
Hpo pathway activation (Genevet and Tapon, 2011). Given the role of Hpo pathway in 
contact inhibition (Zhao et al., 2007), a speculative possibility is that TJ/AJs might function 
as a signaling receiving platform to sense through the Hpo pathway signals from neighbor 
cells. Translocation of YAP to the nucleus at high cell density, coincides with the deletion of 
AMOT-like proteins, PALS1 or CRB3 (Crumbs family member 3) (Varelas et al., 2010; Zhao 





with elements of the TJs to sense apical polarity and TJ organization (Schlegelmilch et al., 
2011). While E-cadherin has been identified as a cell-cell contact sensor of AJs, no 
comparable cell-cell contact element for TJs has been identified. 
 
1.3.6 The Hpo pathway and planar cell polarity 
 
PCP represents an essential feature of organs and tissue that regulates their pattern and 
extent of controlled growth. During development, PCP mechanisms control the size and 
shape of cells that can then organize to form organs and tissues of consistent and 
reproducible size. The external epithelia of Drosophila is the tissue commonly used to study 
PCP defects (Simons and Mlodzik, 2008). Here, PCP  appears to be controlled by two 
signaling pathways: Fz/Dsh (Frizzled/Dishevelled) and the Ft pathway (Klein and Mlodzik, 
2005). The study of PCP in vertebrates has been hampered by redundancy as some 
isoforms do not have overlapping expression patterns (Simons and Mlodzik, 2008); double 
and triple knockouts are often the only way to address the study of this mechanism, albeit 
technically demanding. From these studies a concept has emerged.  
 
The Hpo pathway can function as a sensor of epithelial integrity and architecture that can 
override proliferation stimuli involving ligand-receptor pathways. Hpo signaling cascades 
receive information for position inputs, mechanical forces and other stressors that reflect the 
state of the epithelia. These cues ensure a tightly controlled regulation of tissue growth 
during development and a mechanism to maintain tissue homeostasis in adult tissues 







1.3.7 Regulation of cell proliferation and apoptosis by Hpo signaling 
 
Understanding how cell proliferation and cell death are coordinated during tissue growth and 
homeostasis assumes vital importance in preventing diseases such as cancer (Huang et al., 
2005). Deregulated YAP and TAZ can lead to enhanced cell proliferation and survival 
coupled to the acquisition of cancer phenotypes characterized by cancer stem cells 
characteristics, EMT, inhibition of senescence and drug resistance (Johnson and Halder, 
2014).  
 
In mammals, the core kinase components of the Hpo pathway are MST1/2 and LATS 1/2; 
both sets of kinases are regarded as important regulators of apoptosis. Growing evidence 
however, suggests YAP to have a dual role in both inhibiting and inducing apoptosis. As an 
apoptotic inducer, YAP activates p73, a member of the p53 tumour suppressor family, 
promoting the expression of pro-apoptotic elements such as bcl-2 family (Strano et al., 
2005). As an apoptotic inhibitor, studies suggested ASPP (apoptosis-stimulating p53 
protein) to inhibit the interaction of YAP with LATS1, blocking therefore YAP/TAZ 
phosphorylation, which in turn leads to nuclear accumulation of YAP/TAZ promoting cell 
migration and suppression of apoptosis (Vigneron et al., 2010).  
 
Studies have addressed the role of YAP overexpression in stimulating proliferation 
(Camargo et al., 2007; Dong et al., 2007; Zhao et al., 2007). Several transcription factors, 
including Runx2, ErbB4, p73 and TEAD in particular, have been reported to interact with 
YAP (Basu et al., 2003; Vassilev et al., 2001). Zhao and co-workers suggested TEAD to be 
one of the most potent YAP targets from a transcription-activity based screen. In addition, 
connective tissue growth factor (CTGF) was identified as a direct target gene resulting from 





to abrogate YAP-stimulated cell growth reducing significantly YAP-induced colony formation 
(Zhao et al., 2008) .  
 
1.4 The β-adrenergic system 
1.4.1 Physiological and pathophysiological response 
 
Adrenergic receptors, also called adrenoreceptors, are a family within the broad category of 
G-protein coupled receptors (GPCRs). This family of GPCRs is a target of norepinephrine, 
also known as noradrenaline, and epinephrine, also called adrenaline, two well-known 
catecholamines. By definition, a catecholamine is an organic compound that has a catechol 
group and a side-chain amine. In the human body, the most abundant catecholamines are 
epinephrine, norepinephrine and dopamine. The binding of a catecholamine to the receptor 
will stimulate the sympathetic nervous system; various stimulant drugs are catecholamine 
analogues (Rang, 2003). Adrenergic receptors are subdivided into two families, α and β, 
which in turn have several subtypes. α1 receptors couple to Gq alpha subunit that activates 
phospholipase C (PLC) which in turn hydrolyzes PIP2, phosphatidylinositol 4,5-
bisphosphate, to diacyl glycerol (DAG) and inositol triphosphate (IP3); Activation of this 
results in increased cytoplasmic Ca2+. DAG is a second messenger that activates PKC 
(Figure 1.19). Conversely, α2 couples to Gi alpha subunit causing a decrease in cyclic 
adenosine monophosphate, cAMP (Figure 1.19). β receptors couple to Gs alpha subunit, 







Figure 1.19 The mechanism of action of the adrenergic receptors. 
 
1.4.2 β-adrenergic receptors 
 
β-adrenoreceptors are members of the GPCR with seven trans-membrane spanning regions 
and can be subdivided into three families: β1, β2, β3 (Lands et al., 1967). As previously 
mentioned, activation of β-receptors by specific agonists increases cAMP levels via Gs 
which in turn activates cAMP-dependent PKA, leading to the phosphorylation of various 
membrane and/or intracellular proteins. 
  
1.4.3 β-adrenergic agonists and antagonists  
 
β-adrenergic agonists are a class of sympathomimetic agents that act upon 
β-adrenoreceptors, mimicking the actions of adrenaline and noradrenaline signaling. 






β-antagonists, more commonly referred as β-blockers, are a class of drugs that block the 
action of endogenous catecholamines epinephrine (adrenaline) and norepinephrine 
(noradrenaline) (Rang, 2003). Examples of commonly used β-blockers are the non-selective 
agent, propranolol, the β1 selective compound, atenolol, and the β2 selective agent, 
butaxamine. 
 
1.4.4 β-adrenergic receptors in cancer 
 
The role of β-agonists in regulating cell proliferation is still a controversial field as there is a 
lack of consensus in the actions that affect β-adrenoreceptors in controlling cell replication 
and proliferation. Some studies have linked the use of β-adrenergic antagonists, also known 
as β-blockers, with reduced disease progression (Botteri et al., 2013; De Giorgi et al., 2011) 
and other studies reported the effect of agonists in tumour regression (Carie and Sebti, 
2007; Slotkin et al., 2000). 
 
Of particular interest to this work is the β-adrenergic receptor agonist dobutamine (Figure 
1.20), as a possible compound to affect the function of pancreatic cancers. In a cell-based 
screen of 48 drugs aiming at identifying YAP inhibitors, dobutamine was found to be the 
most promising compound in preventing nuclear accumulation of YAP and YAP-mediated 
transcriptional activation (Bao et al., 2011). 
 






1.5 Project aims and objectives  
 
PDAC is one of the most lethal malignancies, having a dismal cure rate. There is an urgent 
need to find better ways to target therapies to or modify the behavior of PDAC. The aim of 
this thesis is to provide insights into functional properties of pancreatic epithelial cells as a 
consequence of de-differentiation and to identify ways to apply this information to improve 
the targeting and/or efficacy of therapies to treat PDAC.  
 
The experimental work in this thesis is divided in three chapters. The first results chapter, 
Chapter 3, explores the expression and distribution of PepT1 in human pancreatic samples 
and investigates how PepT1 could be used to improve the selective targeting of PDAC. The 
following chapter, Chapter 4, examines how cell polarity, disrupted in cancer, can affect the 
efficacy of current chemotherapeutic strategies to treat pancreatic malignancy. Finally, in 
Chapter 5, it is shown how a β-adrenergic agonist might be used to improve the efficacy of a 
currently used chemotherapeutic strategy.  
 
I) PepT1 as a Drug Delivery Target to Treat Chronic Pancreatitis and Pancreatic 
cancer. 
Previous studies have reported the up-regulation of PepT1, an oligopeptide transporter 
system, in pancreatic cancer cells (Gonzalez et al., 1998). Hitherto, there are no studies 
reporting PepT1 distribution in human pancreatic biopsies from inflamed and cancerous 
pancreas. Past research has highlighted the interactions between drug transporters with 
clinically relevant anti-cancer drugs (Inui et al., 1992; Song et al., 2005; Tsume et al., 2008). 
The feasibility of using PepT1 to selectively deliver agents to inflamed or cancerous 





a potential pre-empting or concomitant factor for oncogenesis, will be addressed. The main 
research objectives for this work are as it follows: 
1. To analyze the expression and distribution pattern of PepT1 in pancreatic cancer 
cells and inflamed tissue;  
2. To determine the role of PepT1 in pancreatic cancer cell proliferation; 
3. To investigate the delivery of gemcitabine and ibuprofen into pancreatic cancer 
cells following modification to include a hydrolysis resistant thio-dipeptide, Ala(S)-
-Ser or Ala(S)-Asp as a means to enhance uptake through PepT1. 
 
II) Ocln interactions with Hippo Pathway Signaling. 
Several studies have suggested that the Hippo pathway signaling involved in regulating cell 
proliferation, apoptosis, and apical-basal polarity, could provide an important regulatory 
feedback loop to organize epithelial barriers (Boggiano and Fehon, 2012; Genevet and 
Tapon, 2011). E-cadherin localised at the AJ, has been the only element shown so far that is 
involved in sensing cell-cell contacts and regulates epithelial cell proliferation at high lateral 
cell density (Schlegelmilch et al., 2011). In addition, siRNA-mediated knock-down of 
E-cadherin in MDCK cells leads to disorganized AJs (Qin et al., 2005). There is a rationale 
to speculate that a TJ element would be similarly involved in coordinating the completion of 
apical-basal polarity with the suppression of cell proliferation controlled through the Hippo 
pathway. The research objectives for this chapter are the following: 
1. To characterize potential protein-protein associations between occludin and 
Hippo signaling pathway elements in two pancreatic cancer cell lines with 
different growth characteristics; 
2. To analyze the distribution of Hippo pathway elements in chronic pancreatitis and 





3. To explore if dobutamine treatment, shown to induce YAP translocation from the 
nucleus to the cytoplasm, can affect occludin expression or function in two 
pancreatic cancer cell models; 
 
III) Dobutamine – a potential Adjuvant Molecule in the Treatment of Pancreatic 
Cancer. 
Certain catecholamines appear to be able to control cell division and differentiation (Slotkin 
et al., 2000). Dobutamine, a β-adrenergic agonist, has been reported to reduce the extent of 
nuclear YAP, allowing it to be degraded in the cytoplasm (Bao et al., 2011). Since YAP 
protein down-regulation reduces cell proliferation and clonogenicity of pancreatic cancer 
cells (Diep et al., 2012), the therapeutic potential of dobutamine in pancreatic cancer was 
analysed. The research objectives for this work are as follows: 
1. To examine the cytotoxic actions of dobutamine on pancreatic cancer cell 
viability, proliferation and apoptosis induction; 
2. To explore if dobutamine affects proliferation rates and paracellular permeability 
through occludin expression in pancreatic cancer cells; 
3. To explore if the combined cytotoxic actions of gemcitabine and dobutamine 
would be beneficial as an adjuvant chemotherapeutic approach in pancreatic 
cancer; 
4.  To investigate the potential in maximizing cytotoxicity to pancreatic cancer by 
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2.1 Cell culture  
2.1.1 Methodology 
2.1.1.1 Sub-culturing procedure 
 
All cell lines used were obtained from ATCC© apart from HPDE cells, which were a 
generous gift from Dr. Ming-Sound-Tsao from the University of British Columbia, Toronto.  
HPAFII cells (Figure 2.1, Table 2.1) were grown in Minimum Essential Medium (Fisher©).  
AsPc-1 cells (Figure 2.1, Table 2.1) were cultured in RPMI-1640 (Fisher©), Capan2 (Figure 
2.1, Table 2.1) in McCoy’s (Fisher©) and HPDE in keratinocyte serum free media 
supplemented with L-glutamine, recombinant epidermal growth factor and bovine pituitary 
extract (Fisher©). All cell media except keratinocyte serum free media was supplemented 
with 10 % heat inactivated fetal bovine serum (Fisher©), and 100 units/mL of Penicillin and 
100 μg/mL of Streptomycin (Sigma®). Cells were maintained at 37 °C in a humidified 
atmosphere containing 5 % CO2. For sub-culturing procedures, cells were very briefly 
washed in PBS – Phosphate buffered saline. Following this, 0.25 % trypsin/EDTA (Sigma®) 
was added to the flask, and left for approximately 5 minutes. Afterwards, an equal amount of 
warmed cell medium was added. Cells were centrifuged at 125 x g for 10 minutes. 
Subsequently, cell medium was removed and the cell pellet re-suspended in freshly warmed 
cell media and transferred into one or more culturing flasks depending on the growth 
requirements of the cell line. This procedure was repeated twice a week for all the cell lines 
at a 1:2 split ratio. Due to the extreme grade of HPDE cell line sensitivity, before starting the 
cell culture procedure, a free standing UV lamp (radiation: 253.7 nm; 230 V and 0.5 amps) 
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2.1.2 Freezing and thawing procedure 
 
For thawing purposes, vials were removed from liquid nitrogen and quickly thawed at 37 °C 
in a water bath; warm and complete cell media was added to the cells and centrifuged for 10 
minutes at 125 x g. Pellet was then re-suspended in fresh media and placed in a T25 flask. 
After 2 or 3 days, depending on the cell line, cells were then transferred to a T75 at a 
suitable split ratio. To freeze the cells, the pellet was re-suspended in antibiotic free 
cryopreserving media supplemented with 40 % FBS, fetal bovine serum, and 10 % DMSO; 
after filtering the media, cells were re-suspended at 1 x 106 cells/mL into cryotubes,  placed 
at -80 °C overnight and then stored in liquid nitrogen. 
 
Figure 2.1 Bright field images of three cell lines studied; Scale bar, 50 µm. 
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2.2  Permeability measurements through the paracellular pathway 
2.2.1 Theoretical background 
 
The permeability through the paracellular pathway can be evaluated by different methods: 
measurement of trans-epithelial electrical resistance, TER, and the flux of fluorescent tracer 




TER is a widely used method to determine quantitatively the tight junction dynamics and 
healthy state in cell culture systems (Blume et al., 2010). The traditional method for 
measuring TER values is to use STX2 electrodes that detect how confluent a cell monolayer 
is. Each electrode contains a silver/silver-chloride pellet for measuring voltage and a silver 
electrode for passing current. These electrodes are suitably designed to facilitate its 
placement into a variety of cell culture wells; one set of electrodes is placed in the 
basolateral compartment and the other set at the apical side. TER measurement is based on 
Ohm's law. It is determined by the application of a direct current with a defined voltage 
applied to two electrodes, one on each side of the cell layer (apical and basolateral 
compartments respectively). The generated current is measured, leading to the generation 
of ohmic resistance. Higher resistances between the electrodes will produce a higher level 





Materials and Methods 
51 
 
2.2.3  Fluorescent tracer solutes 
 
Paracellular diffusion of hydrophilic tracers can be measured through the use of 
fluorescently labeled tracers such as dextrans. Dextran is a high molecular weight polymer 
of glucose and, when labelled with fluorescent dyes, allows the study of paracellular barrier 
properties. Fluorescently labelled dextrans, 4 kD FITC and 70 kD Rhodamine dextran are 




2.3.1   Cell seeding 
 
HPAFII cells were seeded onto the apical chamber, a polyester filter with 0.4-μm pore size, 
12 mm Transwell™ filters (Corning®) at a cell density of 7 x 104 per well;  Cells were left in 
complete media (MEM) at the apical chamber, typically for two weeks to reach confluence. 
Media from the two compartments was removed on a daily basis to enable healthy growth. 
For background reading, a well was left only with media without cells. 
 
2.3.2 TER measurements 
 
Pre-warmed media was placed at the apical chamber and incubated at 37 °C for 30 minutes 
to equilibrate. The electrodes were sterilized using 70 % ethanol and placed in PBS in order 
to eliminate ethanol traces and calibrate the equipment. For apical-basal polarity studies, 
TER was determined with a pair of fixed current passing voltage measuring electrodes 
(World Precision Instruments©, UK) as the schematic in Figure 2.2 shows. TER values were 
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obtained by subtracting the contribution of the filter and bathing solution and multiplied by 
the surface area of the well (1.12 cm2). Three measurements were taken per well and 
averaged. Final resistance values were calculated according to the formula shown below. 
Rtrue tissue = RTotal - Rblank 




Rtotal – Resistance measured; 
Rblank – resistance of the control filters 
r –radius of the filters 
 
Figure 2.2 Diagram showing the measurement of TER in HPAF II cell cultures. 
 
2.3.3  FITC Dextran permeability 
 
Cells were plated in 12-well tissue culture inserts (as described in section 2.3.1). Culture 
media was replaced by fresh MEM (Fisher©) without phenol red (1 mL was added to the 
outer chamber and 250 µl to the inner one). Cultures were then left to equilibrate in the 
tissue culture incubator for at least 30 minutes. 50 µL of FITC Dextran (Sigma®) was added 
to the inner chamber bringing the final volume to 300 µL, so that the final concentration was 
1 mg/mL. The cultures were then incubated at 37 °C for 4 h. Filters were removed and the 
diffused tracer measured by the FLUOstar OPTIMA (FITC-DEXTRAN: Exc: 485 nm and 
emission: 544 nm).  
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2.4 Protein extraction and subcellular fractionation 
2.4.1  Methodology 
2.4.1.1  Isolation of whole cell lysates  
 
To collect cytoplasmic fractions, growth media was removed and cells were washed twice in 
ice-cold PBS prior to the addition of lysis buffer (50 mM Tris-HCL, pH 7.5, 150 mM NaCl and 
1% NP-40) containing phosphatase and protease inhibitors. After incubation on ice for five 
minutes, the samples were centrifuged (8000 x g, 10 min, 4°C) to pellet the cell debris and 
the supernatant was carefully removed and placed in another pre-cooled Eppendorf tube. 
Protein concentration was measured through NanoDrop Spectrophotometer 2000 (Thermo 
Scientific) according to the protocol described in section 2.5. 
 
2.4.1.2  Isolation of membrane fractions 
 
For membrane isolation, cells were washed with PBS containing Ca2+ and Mg2+ and lifted in 
50 mM Tris-HCl, pH 7.5 containing protease and phosphatase inhibitors while on ice. 
Collected cells were disrupted by freeze-thaw cycles prior to centrifugation (1000 x g, 10 
min, and 4 ⁰C). Membrane pellets were transferred to a Beckman ultracentrifugation tube 
(Beckman®) and were isolated at 100,000 x g for 1 h at 4 ⁰C. Pellets were then washed 
twice in PBS containing Ca2+ and Mg2+ and then suspended in lysis buffer containing 0.1 % 
Triton-X-100 by leaving it on ice for up to 2 h.  Protein concentration was measured through 
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2.4.1.3 Isolation of nuclear fractions 
 
For nuclear fraction isolation, growth media was removed and cells were washed twice in 
ice-cold PBS prior to the addition of lysis buffer (50 mM Tris-HCL, pH 7.5, 150 mM NaCl and 
1% NP-40) containing phosphatase and protease inhibitors. After incubation on ice for five 
minutes, the samples were centrifuged (8000 x g, 3 min, 4°C) to pellet the cell debris and 
the supernatant was carefully removed and placed in another pre-cooled Eppendorf tube. 
Supernatant was then centrifuged again in order to pellet the nuclear fraction. Protein 
concentration was measured through NanoDrop 2000 according to the protocol described in 
2.5. 
 
2.5 Protein concentration 
2.5.1 Theoretical background 
 
Quantifying protein concentration through absorption spectrophotometry is a fast, 
convenient and reliable technique, in which the protein can be fully recovered at the end of 
the quantification method. This technique is based on the fact that proteins in solution 
absorb UV light between 200 nm and 280 nm. When light of a specific wavelength passes 
through a sample, some of this light is absorbed, decreasing the amount of light that passes 
through the sample - transmitted light. The difference between the original and the 
transmitted light is called absorbance. 
 
The determination of protein concentration through absorbance measurement is based on 
Beer’s law, which states that molar absorptivity is constant and the absorbance is 
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proportional to concentration for a given substance dissolved in a given solute and 
measured at a given wavelength. Beer´s law can be defined as follows: 
A= ε*b*C 
A = absorbance; ε = wavelength-dependent molar absorptivity coefficient m
2
/mol; b = path length in 
centimeters; c = analyte concentration in moles/liter.  
 
Solving the expression of Beer’s law for concentration yields the following equation:  
C = A / ε b 
Unless the ε value is known for a specific protein, this method represents merely a rough 




To ensure an equal sample loading, protein concentration was determined through 
Nanodrop Spectrophotometer 2000 which has a detection limit of 2 ng/µl. Samples were 
blanked first and the sample type option chosen was the default general reference setting in 
which 1 Abs = 1 mg/mL. A sample of 1.5 μL was loaded onto the lower measurement 
pedestal and the sampling arm lowered. Absorbance measurements were taken and 
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2.6 Immunoblotting and immunoprecipitation 
2.6.1 Theoretical background 
2.6.1.1 Immunoblotting 
 
Immunoblotting, also known as Western Blot, is a widely used technique for the detection of 
protein in a cell extract. It is based on gel electrophoresis, whereby denatured proteins are 
separated by the length of polypeptide. The proteins are then transferred to a PVDF or 
nitrocellulose membrane where they are stained through specific antibodies targeting a 
protein of interest. Following incubation, the membrane is exposed to a secondary antibody 
tagged to a HRP (horseradish peroxidase) enzyme; through chemiluminescent agents that 
catalyse the enzymatic action of HRP, light is emitted and then detected on a photosensitive 
film.   
 
2.6.1.2  Immunoprecipitation 
 
Immunoprecipitation is a technique that involves the precipitation of a protein antigen out of 
a cell lysate through a specific antibody, recognizing the protein of interest. This technique 





Cells were lysed and protein quantified as described in sections 2.4 and 2.5; each sample 
was made up approximately to 25 μg of protein in LDS buffer (200 µL of 10x sample 
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reducing agent – Invitrogen™, 500 µL 4x LDS buffer - Invitrogen™, and 400 µL of ddH2O) 
was added per sample and the lysates incubated for 10 minutes at 95 °C, to allow for protein 
denaturation; subsequently, samples were centrifuged at 200 x g and the protein extract was 
then separated in a 12 % acrylamide gel (250 V, 45 min) (Table 2.1 and Table 2.2). After, 
the gel was transferred (XCellTM Blot module; Invitrogen) onto a PVDF membrane (Thermo 
Scientific), previously activated by methanol, using transfer buffer (48 mM Tris-Base, 39 mM 
glycine, 20% methanol) and a voltage of 30 V for 1.5 h was applied. After the transfer was 
complete, membranes were Ponceau stained (Sigma®) to confirm the presence of 
transferred proteins; staining was then washed away with TBS-T (Tris buffer saline - 10 mM 
Tris- HCl, pH 7.5, 150 mM NaCl and 0.1% Tween 20) and then the PVDF membrane was 
blocked in 5 % dried non-fat milk dissolved in TBS-T overnight at 4 °C. After three washes in 
TBS-T at RT, appropriate secondary-HRP antibodies (GE Healthcare) were applied 
generally at a dilution of 1:1000 for 1 h at RT in TBS-T containing 1 % milk. Blots were 
washed in TBS-T with HRP activity being detected by ECL (GE Healthcare©). The film was 
then scanned in order to carry out densitometry measurements through the software 
ImageJ. 
 
2.6.2.2  Immunoprecipitation 
 
Cells were lysed in RIPA buffer for 10 minutes at 4°C and the cell lysate centrifuged (10,000 
x g, 10 min, 4⁰C). Lysates containing 500 μg of protein were incubated with a pull-down 
antibody overnight at 4°C. A/G beads™ (Santa Cruz Biotech) were added and the mixture 
was left in rotation for 2 h at 4 °C. Beads were washed three times in RIPA buffer by 
centrifugation at 4000 x g, 1 minute, RT. Following this, proteins were separated through gel 
electrophoresis and transferred to a PVDF membrane as described in section 2.6.2.1. 
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2.6.2.3  Membrane stripping 
 
The membrane was placed in 1 x stripping buffer (100 mM 2-mercaptoethanol, 2 % SDS, 
sodium dodecyl sulfate, 62.5 mM Tris-HCl, pH 6.7) on a rocking platform in a water bath at 
60 °C during 30 minutes for immunoblotting and for 1 h for immunoprecipitation blots; the 
membrane was then transferred to a TBS-T solution and washed three times (10 minutes 
per wash); After being blocked again, the membrane was incubated with the primary 
antibody of interest. 
 
2.6.3 12% Polyacrylamide gel recipes 
 
Resolving gel: 
Table 2.2 Table showing the volume of each reagent used to make the resolving gel. 
Reagent Volume (mL) 
MQ water 24 
40 % Acrylamide 16.8 
1.5 M Tris pH 8.8 14 
10 % SDS 0.560 
10 % APS 0.560 
TEMED 0.056 
Pour resolving gel into cassette and overlay with Butanol; leave for 45 minutes to 
polymerize. 
Stacking gel: 
Table 2.3 Table showing the volume of each reagent used to make the stacking gel. 
Reagent Volume (mL) 
MQ water 11.6 
40 % Acrylamide 3 
1.5 M Tris pH 8.8 5 
10 % SDS 0.200 
10 % APS 0.200 
TEMED 0.020 
Pour stacking gel over resolving gel and insert combs. 
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2.7  Cell proliferation assay 
2.7.1 Theoretical background 
 
Several assays to determine cell proliferation are widely used, each of which with its own 
limitations. Nucleic acid content is a reliable indicator of cell number since DNA and RNA 
levels are tightly regulated at a cellular level and are generally independent of changes in 
cellular metabolism. In culture, the levels of DNA and RNA vary substantially in a single cell, 
however the net nucleic acid content per an individual cell remains constant over time as the 
culture grows (Jones et al., 2001). Thus, an assay quantifying the nucleic acid content 
should reflect the cell numbers accurately. The CyQUANT® (Life Technologies) assay is a 
rapid and sensitive method for determining the density of cells in culture. It uses a green 
fluorescent cyanine dye characterized by very low intrinsic fluorescence and large 
fluorescence enhancement once it binds to nucleic acids (Jones et al., 2001).  
 
2.7.2 Methodology 
2.7.2.1 Cell seeding and treatment 
 
Cells were plated in white clear bottom 96-well plates (Fisher©), and allowed to attach 
overnight. Test compounds were added in optimal growth media and incubated for a specific 
time interval.  
 
2.7.2.2 Reagent reconstitution 
 
2.2 mL of 5x HBSS (component C) was added to 8.8 mL distilled H2O and 22 µL of 
CyQuant™ dye reagent (component A) was mixed with 11 mL of 1x HBSS buffer. 
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2.7.2.3  Cell proliferation assay 
 
For cell proliferation assays, treatment media was removed and 100 μL of 1 x dye binding 
solution (CyQuant®) was added. After a 30 minute incubation, fluorescent intensity was 
measured at 22 ⁰C using a microplate reader (FLUOstar Omega; BMG Labtech) at 
485/530nm excitation/emission wavelengths.  
 
2.8 Cell viability assay 
2.8.1 Theoretical background 
 
Cell viability is an important determinant in the ability of cells or tissue to recover their 
functional properties after being exposed to an insult, either chemical or physical. Viability 
assays can be classified into 4 different categories: cytolysis or membrane leakage assays 
such as propidium iodide (PI) or trypan blue, mitochondrial activity or caspase assays such 
as formazan (MTT/ XTT), functional assays to assess motility and finally genomic and 
proteomic assays such as DNA microarrays. The cell viability test used for this work was 
formazan, hence a special focus will be placed on this specific assay. It is based on the 
capacity of NAD(P)H-dependent cellular oxidoreductase enzymes to reduce MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) to its 
insoluble formazan in living cells. Therefore reduction of MTS is directly proportional to 
cellular metabolic activity due to elevated NAD(P)H flux (Berridge et al., 2005). The MTS 
assay is a one-step MTT assay and has the convenience of adding the reagent straight to 
the cell culture system without extra steps required for the MTT assay. 
 
Chapter 2 





After determining the ideal seed density for each cell line (data not shown), cells diluted in 
culture medium were plated in 96-well plates, with white clear bottom plates, and allowed to 
attach for 4 h. 5 µl of each stock solution for a specific compound was added to 245 µL of 
cell culture media and mixed well, and 50 µL of the resulting mixture were added to each 
well. Each concentration was repeated four times and control cells received an equal 
amount of cell media alone or supplemented with 1 % DMSO. 50 µL of the cell suspension 
plus 50 µL of the test compound diluted in culture medium, were added to each well (100 µL 
per well).  Plates were incubated for 24 h or 48 h at 37 °C in a humidified atmosphere, 5 % 
CO2; 20 µL of MTS reagent (Promega
©) was then added per well. Plates were returned to 
the incubator for approximately 3 h and absorbance readings were taken at OD 490 nm. 
 
2.9 Immunostaining and Confocal Microscopy 
2.9.1 Theoretical background 
 
Confocal microscopy is an advanced microscopy technique that was patented in 1957 by 
Marvin Minsky whose purpose was to overcome the limitations of the conventional 
fluorescence microscope (Minsky, 1988). This microscopy technique allows for the 
production of exceptional quality and resolution images. It also enables the collection of 
different slices of the same specimen, allowing for the creation of a 3-D representation of the 
sample. The term “confocal” refers to the arrangement of two lenses to focus on the same 
point. There are many aspects that make the confocal microscope a much more versatile 
instrument than the conventional one. The major optical difference between the two is the 
presence of confocal pinholes that allow only light from the plane of focus to reach the 
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detector. In the conventional light microscope, two dimensional images of the specimen are 
formed in X and Y planes, generally parallel to the plane of sectioning (Figure 2.3). The 
same principle applies to confocal microscopy, however the microscope optics only allow 
the light from the plane of focus to reach the detector. The use of suitably positioned 
pinholes allows for the removal of the “out of focus”. The main feature of confocal 
microscopy that poses a major advantage is the fact that only one point in the sample is 
illuminated at a time, allowing for the collection of a series of images (a stack) that 
constitutes a high resolution 3D imaging and the surface profiling of a specimen. 
Conversely, in conventional microscopy, the quality of the image, the resolution and 
magnification rely upon the quality of objective lens used. 
 
Figure 2.3 Diagram representing the main principle of the confocal microscope. 
 
The term fluorescence refers to the emission of light of a specific wavelength which is 
absorbed by the fluorophores at a high-energy state, causing them to emit light of longer 
wavelength in a lower energy state.  The emitted light is of a different color than the 
absorbed light (Figure 2.4).  
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Figure 2.4 Diagram showing the principle of fluorescence imaging and the emitted light colors 
of the three main dyes. 
 
In biology, fluorescence microscopy is a powerful tool that allows examining the distribution 
and localisation of a specific protein within a sample. There is a wide range of techniques 
that allow for the fluorescent analysis of biological samples. Some fluorescent stains are 
specifically designed to bind to an intrinsic target within the sample. An example of this 
biological fluorescent stains is DAPI (4',6-diamidino-2-phenylindole) which binds strongly to 
A-T rich regions in DNA specifically labelling the nucleus.  
 
Immunofluorescence is another technique which uses a highly specific fluorescently labelled 
antibody to its respective antigen, labelling the proteins or other molecules of interest at the 
membrane or inside the cell. 
 
2.9.2  Methodology 
 
Cells were grown on coverslips for the required exposure time. For membrane protein 
detection, cells were washed three times with 10 mM HEPES buffer containing 0.9 % CaCl2, 
and then fixed with 4 % PFA, paraformaldehyde, for 20 min. For cytosolic proteins, cells 
were washed with PBS and then fixed with 4 % PFA. Cells were simultaneously blocked and 
permeabilised for 30 minutes at 4 °C in blocking buffer (PBS containing 2 % BSA - bovine 
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serum albumin and 0.5 % Triton X-100). Cells were then washed, either with 10 mM HEPES 
buffer containing 0.9 % CaCl2 or PBS and incubated for 2 h at 4 °C with a primary antibody 
diluted 1:100 in blocking buffer and then a secondary antibody diluted 1:400 in blocking 
buffer for 30 minutes. 1 µg/mL solution of DAPI was applied on coverslips for 20 minutes 
and cells were mounted on MOWIOL 4-88 (Sigma®), which has the same refractive index as 
immersion oil. Slides were then left to dry overnight and the following day were examined 
through Zeiss Confocal Laser Scanning Microscope using four laser wavelengths: Blue 
diode laser: 405 nm; Argon 488 nm, HeNe 543 nm and HeNe 633 nm (Table 2.3). Controls 
for immunostaining technique are in Figure 8.5, Chapter 8. 
 
Table 2.4 List of the used dyes. 
Name Type Laser Emission 
wavelength 
Application 
DAPI Nuclear dye Blue Diode laser 405 nm Nuclear labelling 
FITC Fluorochrome Argon 488 nm Most widely used green 
dye 
Texas Red Fluorochrome HeNe 595 – 620 nm 
 
Texas Red dye 
Abbreviations – DAPI - 4', 6-diamidino-2-phenylindole; FITC - Fluorescein isothiocyanate; 
HeNe - helium–neon laser; 
 
2.10 Immunohistochemistry – Paraffin staining 
2.10.1  Theoretical background 
 
Immunohistochemistry, or IHC, is a method for the detection and localisation of proteins in 
intact tissue sections. This technique is particularly useful for assessing the progression and 
treatment of cancer and is based on the specificity of antibodies to target the protein of 
interest in the tissue section. The interaction between the antigen and antibody can then be 
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visualized by two different reactions, chromogenic and fluorescence. In chromogenic 
detection, an enzyme conjugated to the antibody, typically peroxidase, is used to cleave a 
substrate producing color at the location of the protein of interest. Fluorescent detection 
involves the conjugation of a fluorophore to the antibody, which then can be visualized 
through fluorescence microscopy. 
 
2.10.2 Methodology 
2.10.2.1 Sample preparation – Dewaxing and rehydration 
 
Tissue sections were dewaxed in Histoclear (Fisher©) for approximately 10 minutes and 
rehydrated through different grades of ethanol (100%, 90%, 70% and 50%) at 10 minutes 
each and then washed in PBS with gentle shaking for 5 minutes.  
 
2.10.2.2 Sample preparation – Antigen retrieval 
 
HIAR (heat induced antigen retrieval) was performed with 10 mM of citrate buffer pH 6.0. 
The buffer was heated up in a pressure cooker (Morphy Richards®) for approximately 10 
minutes, and the de-waxed slides were added to the citrate buffer and heated in a pressure 
cooker for about 15 minutes (Shi et al., 1993). Further to this, sections were heated again 
during 5 minutes at a lower temperature. Tissue sections were allowed to reach RT for 
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2.10.2.3 Antigen detection 
 
Tissue sections were blocked for 30 minutes (HRP detection using Rabbit Elite ABC 
Kit - Vector Labs©). The primary antibody was diluted in 0.1 % BSA in PBS at a 1:100 
dilution, and incubated overnight at 4 °C in a humid chamber. The control antibody used was 
either Rabbit (DA1E, Cell Signaling©) or Mouse (G3A1, Cell Signaling©) depending on the 
immunoglobulin type as the test antibody. After washing the slides in PBS, the biotinylated 
secondary antibody was added for 30 minutes. Following a PBS wash, sections were 
exposed to 30 % (w/w) Hydrogen Peroxide (Sigma©) in order to quench the endogenous 
peroxidase activity. Following a further wash in buffer, the slides were incubated again at RT 
in Avidin:Biotin enzyme complex (Vecstatin Elite ABC kit, Vector laboratories©) for 30 
minutes. The slides were washed and incubated in 3, 3’ – diaminobenzidine (DAB, Vector 
Laboratories©) according to the manufacturer’s instructions and then washed immediately 
with tap water for 5 minutes. Tissue was stained with Meyer´s Haematoxylin (Sigma©) for 2 
minutes and rinsed under the tap water. Finally, the pancreatic biopsies were rehydrated 
through different grades of alcohol (50 %, 70 %, 90 %, 100 %) at 10 minutes each and 
dewaxed in Histoclear for 10 minutes. Further to a final wash in PBS, tissues were mounted 
in DePeX glue (Sigma©) and allowed to dry overnight. 
 
2.10.2.4 Image analysis 
 
Tissue sections were imaged using a DMI 3000B Microscope (Leica Microsystems©), and 
the software used for image analysis was Adobe Photoshop, version 3.0 (Adobe Systems, 
Mountain View©, CA). 
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2.10.2.5 Patient samples and informed consent 
 
Tissue samples were a kind gift from Dr. Mert Erkan, Technical University of Munich, 
Germany; these were collected from patients diagnosed with PDAC following pancreatic 
resection. Normal pancreatic tissue samples were obtained through an organ donor 
procurement program whenever there was no suitable recipient for pancreas 
transplantation. Tissues were fixed in 5 % PFA solution for 12-24 h and then embedded in 
paraffin for histological analysis (Erkan et al., 2005). All patients were informed, written 
consent was obtained, and human protocols were approved by the Ethics Committees of the 
University of Heidelberg (Germany) and the Technical University of Munich (Germany), as 
referred in  Erkan, et al. (Erkan et al., 2005). 
 
2.11  Gene knock-down 
2.11.1 Gene knock-down through RNA interference 
 
Gene knock-down is an experimental technique which aims to reduce the expression of one 
or more genes. This can be achieved through two different ways, either through genetic 
modification or by treatment with a reagent such as short DNA or RNA. 
 
RNAi (RNA interference) was discovered for the first time in Caenorhabditis elegans as a 
gene silencing mechanism in response to an injection of dsRNA (double-stranded RNA) 
(Fire et al., 1998; Hannon, 2002). RNAi interference can be delivered through two different 




Materials and Methods 
68 
 
2.11.2 Stable gene knock-down through lentiviral particles 
 
Stable RNAi cell lines, also known as knock-down stable cell lines, are cells that have 
integrated in their genome shRNA or a plasmid DNA to permanently silence the expression 
of a target gene through mRNA degradation (Paddison et al., 2002). shRNA is an RNA 
sequence that makes a tight hairpin structure which can be used to silence gene expression. 
The introduction of shRNA into mammalian cells is typically achieved through the use of viral 
or bacterial vectors that allow for a stable integration of shRNA and long-term knock-down of 
the targeted gene (Moore et al., 2010). These cell line models provide very valuable 
information on gene functions, long-term silencing effects and pathway signaling; however 
the generation of these biological systems is a very complex and lengthy process. Additional 
biological mechanisms can be used to regulate the gene silencing machinery such as the 
co-transfection of marker genes expressing antibiotic resistance in the presence of an 
antibiotic selecting agent. The cells with the ability to proliferate and divide are then isolated 
and characterized (for example Puromycin-induced stable cell lines).  
 
A variety of viral vectors can be used to successfully obtain shRNA expression in cells such 
as adenoviruses, associated adenoviruses and lentiviruses (Lombardo et al., 2008). The 
lentiviral system is based on the HIV (human immunodeficiency virus) and has the unique 
ability to infect non-dividing cells, which makes this system one of the most efficient methods 
of a gene delivery vector. Structurally, this system uses three plasmids, pREV, pGAG/Pol 
and pVSVG, which are common to all retrovirus and a final plasmid encoding for the vector 
to be inserted into the host cell (Dull et al., 1998). pREV and pGAG/Pol encodes for viral 
proteins required for efficient viral packaging, whereas pVSVG encodes for a protein in the 
viral envelope conferring the viral particle the ability to transduce a broad range of cell types 
(Tiscornia et al., 2006). These plasmids are chemically transfected into a host cell that in 
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turn will release viral particles into the cell culture medium, which can then be used to infect 
the target cells (Figure 2.5). Once the vector has incorporated into the host cell genome, the 
shRNA is transcribed in the nucleus through RNA polymerase III. The transcript is then 
integrated into the host cell genome and it mimics the large RNA precursors designated by 
pri-microRNA, which later is processed by a class 2 RNase III enzyme called Drosha. The 
resulting product is exported from the nucleus by a family that mediates the transport of 
proteins and other cargo between the nuclear and cytoplasmic compartments called 
Exportin 5; the complex is then processed by Dicer (an enzyme with endonuclease activity) 
and loaded into a multi-protein complex that incorporates one strand of siRNA or microRNA 
(miRNA) called RNA-induced silencing complex (RISC); The sense strand is degraded 
whereas the antisense directs the RISC complex to mRNA that has a complementary 
sequence. In case of perfect complementarity, RISC cleaves the mRNA (cleavage 
mechanism). In the situation of imperfect complementarity, RISC represses the translation of 
mRNA (bypass mechanism). In both cases, the shRNA leads to gene silencing (Hannon, 
2002). 
 
2.11.3 Transient gene knock-down 
 
The simplest method for RNAi is the cytosolic delivery of siRNA oligonucleotides, however 
this technique is limited to cells capable of transfection and is primarily used during transient 
in vitro studies. siRNA is a class of double stranded RNA molecules, 20-25 base pairs in 
length with phosphorylated 5` ends and hydroxylated 3` ends; siRNA is able to interfere 
transiently with the expression of specific genes with complementary nucleotide sequences 
(Bernstein et al., 2001). The success of siRNA in gene knock-down largely relies upon its 
binding ability to the RISC complex. Following this, the complex gets cleaved through 
endonucleases. The non-cleaved anti-sense strand-RISC complex can then bind to target 
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mRNAs to initiate transcriptional silencing (Bernstein et al., 2001). siRNA is an important tool 
for validating gene function and drug targeting; any gene can be knocked down by a 
synthetic siRNA with a complementary sequence (Bernstein et al., 2001). 
 
Figure 2.5 Diagram illustrating the process of lentiviral particles production.  
 
2.11.4 Methodology: Stable PepT1 knock-down 
2.11.4.1 Lentiviral generation: bacterial transformation and plasmid preparation 
 
In order to isolate shRNA from E. coli (Sigma Mission® ), agar plates were prepared and a 
final concentration of 100 µg / mL of ampicillin was added per plate. Simultaneously LB 
media solution was made and ampicillin was added at a final concentration of 100 µg / mL. 
After dried, the agar plate was streaked from a glycerol stock and left incubating at 37 °C 
overnight. On the following day, a colony was picked and a start culture inoculated (2-5 mL 
LB media containing the selective antibiotic) and left at 37 °C in an orbital shaker for 
approximately 8 h; after this an overnight culture was prepared (50 µL were taken to 50 mL 
of LB media). The following day, bacterial cells were harvested by centrifugation at 6000 x g 
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for 15 minutes at 4 °C to stop any further bacterial growth; Plasmids were then isolated from 
the bacterial culture using midi prep kits (Qiagen, Manchester, UK) following the 
manufacturer’s instructions. 
 
2.11.4.2 Lentiviral generation: preparation of lentiviral particles 
 
HEK293T were plated and grown overnight to approximately 60-70 % confluence in a T75 
tissue culture flask; 4 h prior to transfection the media was replaced by 10 mL of DMEM 
supplemented with 10 % FBS and 25 mM HEPES (pH 7.4). 7.7 µg of pREV, 7.71 μg 
pGAG/Pol, 3 µg pVSVG and 12.84 μg of shPepT1 were added to 62.52 µL of ddH2O to a 
final DNA concentration of 0.5 µg/μL. Plasmids were added to 90 µL of Mirus LT1 
transfection reagent (Cambridge Bioscience, Cambridge, UK) and then to 750 μL of DMEM 
and left incubating for 45 minutes; subsequently the mixture was added to HEK293T cells 
and left for 48 h at 37 °C in a 5 % CO2 incubator. After this, the supernatant was collected 
and centrifuged at 1000 rpm for 5 minutes to remove any cellular debris and divided into 
aliquot volumes and finally stored at -80 °C until use. 
 
2.11.4.3 Lentiviral infection and cell selection 
 
AsPc-1 cells were grown to 25-30 % confluence prior to infection with viral particles; cell 
culture medium was removed and replaced with fresh RPMI supplemented with 1 mL aliquot 
of viral particles. Following this, fresh cell culture medium containing 10 μg/mL of puromycin 
was added to select infected cells. After a 72 h period of selection, cells were harvested and 
lysed; PepT1 expression was assessed through Western Blotting. 
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2.11.5 Methodology: Transient knock-down through siRNA 
 
A pool of 4 individual siRNA (Accell Human OCLN, siRNA-SMARTpool, Fisher© – Table 2.4) 
targeting different sequences in the Ocln gene was used. For proliferation assays HPAFII 
and AsPc-1 were grown on a 96 well plate until approximately 70% confluent. A transfection 
mixture of 1 μL of HiPerfect, 0.02 μL of siRNA (20 μM stock) or 0.6 μL of scrambled siRNA 
was added to 7.5 μL of serum- and antibiotic-free media and rocked for 15 minutes at RT. 
172 μL of fresh media with or without testing compounds was added to each well in drop-
wise fashion and cells were then incubated at 37 °C in 5 % CO2 for the required exposure 
time.  Knock-down was then confirmed through Western Blot as described in section 2.6.  
 
Table 2.5 Sequences of siRNA used to knock-down human Ocln; Sequences were prepared as 
SMARTpool and used for transfections. 
 





2.12 Cell death: apoptosis and necrosis 
 
Apoptosis and necrosis are two morphologically and biochemically different forms of 
eukaryotic cell death (Stehbens, 2000). The term apoptosis was introduced in 1964 by 
Lockshin and Williams and it was described as a programmed cell death that occurs at 
predictable times and in certain anatomical places during embryogenesis and development 
of the organism (Lockshin and Williams, 1964). Later, Kerr and coauthors described the 
morphological characteristics during cell death and suggested the term apoptosis (Kerr et 
Species Target Sequence 
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al., 1972). Apoptosis is characterized by a sequential set of morphological events such as 
cellular shrinkage with condensation of the cytoplasm, nuclear fragmentation also known as 
karyorrhexis, deposition of chromatin masses in the nuclear membrane and formation of 
apoptotic bodies containing cytoplasmic organelles and nuclear fragments  (Saraste and 
Pulkki, 2000). In apoptosis, mitochondria appear to be normal or shrunken rather than 
dilated or swollen, as happens in necrosis (Krysko et al., 2008). Necrosis is characterized by 
swelling of endoplasmic reticulum and mitochondria followed by collapse of the plasma 
membrane and lysis of the cells. This type of cell death is often considered a passive 
process lacking underlying signaling, as necrotic cells do not follow the apoptotic signal 
transduction pathway that involves different receptors. Identification of necrotic cell death is 
rather challenging, as no surface or biochemical markers have been identified yet and only 
negative markers are available (Krysko et al., 2008); These include the presence of 
differential kinetics of cell death markers such as phosphatidylserine exposure or cell 
membrane permeabilisation and the absence of apoptotic features such as cytochrome c 
release, caspase activation and oligonucleosomal DNA fragmentation (Krysko et al., 2008). 
Annexin V staining has been widely accepted as an apoptotic marker (Schmid et al., 1994); 
this Ca 2+ - dependent phospholipid-binding protein binds strongly to phosphatidylserine 
residues on the cell membrane. In a normal and living cell, these residues are located in the 
inner surface of the membrane thus inaccessible to annexin V, however at the early stages 
of apoptosis, the cell membrane becomes permeable and the phosphatidylserine residues 
translocate to the outside of the cell (Kroemer et al., 1995). Any cell committed to apoptosis 
will have exposed phosphatidylserine residues allowing annexin V binding; if the annexin V 
is labeled with a fluorescein molecule such as FITC, an apoptotic signal will be emitted and 
quantified. Another way of quantifying differentially the percentage of cells that undergo 
apoptosis or necrosis is through FACS (Fluorescence-activated cell sorting – Figure 2.6). 
This technique allows for the detection of morphological changes during apoptosis and 
Chapter 2 
Materials and Methods 
74 
 
necrosis through their light-scattering properties; the forward scatter reflects the cell size, the 
sideward scatter indicates the extension of cell granularity and membrane integrity can be 
assessed through PI uptake. Another method for cell death detection is the quantification of 
nucleosomes in the cytoplasm. As previously mentioned, nuclear condensation and plasma 
membrane blebbing are two morphological characteristics of apoptotic cell death. Activation 
of endonucleases leads to DNA fragmentation and consequently release of 
oligonucleosomes into the cytoplasm (Golstein et al., 1991). The enrichment of mono- and 
oligonucleosomes in the cytoplasm occurs several hours before plasma membrane breaks 
down. Nucleosomes in cytoplasmic lysate can be captured onto ELISA plates coated with 
monoclonal antibodies that recognize histones allowing for the detection of early stage 











Figure 2.6 Diagram showing the principle of FACS; through light scattering and fluorescent 
features, this technique provides a method for sorting a heterogeneous population of cells (A) into two 
or more containers. The cell suspension flows through a stream of liquid specifically arranged to 
enable the separation between cells relative to their specific diameter (B). The flow goes through a 
fluorescence measuring station in which the specific fluorescent pattern emitted by each cell is 
measured (C). Through a vibrational mechanism the streams of cells are separated into individual 
droplets and an electrical charging ring is placed in the region where the stream breaks into droplets 
(D); the opposite charge gets trapped on the droplet as it breaks from the stream. Depending on their 
charge, droplets fall through an electrostatic detection system that separates according to their 
charge (E). Abbreviations: FSC – forward scattered light; SSC – side scattered light. 
 
2.12.1  Methodology 
2.12.1.1 Annexin and Propidium iodide staining 
 
For FACS, approximately 1.0 X 106 cells were washed in PBS and centrifuged at 200 x g for 
5 minutes; cell pellet was then re-suspended in 100 µL of annexin-V-FLUOS labelling 
solution - 20 µL annexin-V-FLUOS labelling reagent and 20 µL Propidium iodide were 
diluted in 1 mL incubation buffer (Roche) and incubated for 15 minutes at 25 ⁰C. Following 
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this, cells were either analysed by fluorescence microscopy, following the protocol described 
in section 2.9, or through FACS (for FITC staining the filter used was BP530/30: 515-545 nm 
and for PI was BP582/42: 561-603 nm).  
 
2.12.1.2 Photometric enzyme immunoassay for the in vitro detection of cytoplasmic 
histone-associated DNA fragments 
 
After inducing cell death, cells were trypsinized and centrifuged at 125 x g for 10 minutes 
following the protocol described in section 2.1.1.1.  Supernatant was pre-diluted 1 in 10 with 
incubation buffer (1 x 104 cells/mL); 100 µL of coating solution was pipetted into each well of 
the plate modules and covered with adhesive cover foil. After 1 h incubation at 20 ⁰C, 
coating solution was removed; 200 µL of incubation buffer was pipetted into each well and 
plate was incubated for 30 minutes at 20 ⁰C; after rinsing the wells three times with washing 
solution, 100 µL of sample solution was sampled (sample diluted in incubation buffer 1 in 10) 
into each module; after a 90 minute incubation at 20 ⁰C, 100 µL of substrate solution was 
pipetted into each well; plate was then incubated on a plate shaker at 250 rpm for 10 
minutes until color development was sufficient for photometric analysis. Finally, absorbance 
readings were taken at 450 nm through FLUOstar Omega; BMG Labtech. 
 
2.13 Statistical analysis 
 
Data are represented as the mean of 3 independent experiments ± SEM. Statistical analysis 
was performed using GraphPad Prism 5 software. Significant differences between 
experimental and control groups were determined by one-way ANOVA followed by Dunnet’s 
post hoc test for experiments in which three or more groups were compared. A paired t-test 
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was also used when comparing only two groups. A statistically difference was accepted if 
the p values were less than 0.05. Significance is indicated on the graphs as it follows: * 
p<0.05, ** p<0.01, *** p<0.001. 
 
2.14 List of materials and reagents used 
 
Table 2.6 List of reagents and materials. 
Reagent / Material Company / catalogue number Application 
12 well plates Fisher
©
 / 07-200-82 In vitro assays 
2-mercaptoethanol Sigma
® 
/ M3148 Membrane stripping 
30 % Acrylamide/Bis Bio-rad / 161-0154 Gel electrophoresis 
30 % Hydrogen peroxyde Sigma
® 
/ H1009 Immunohistochemistry 
6 well plates Fisher
©
 / CLS3335-50EA In vitro assays 
96 well plates Fisher
©
 / 10212811 In vitro assays 
A/G beads Santa Cruz Biotech /  sc-2003 Immunoprecipitation 




 / E-187897-00-0005 Transient knock-down 
Ammonium Persulphate (AMPS) Fisher
© 
/ A/P470/46 Gel electrophoresis 
Ampicilin Sigma
® 
/ A9393 Stable knock-down 
Annexin-V-FLUOS staining kit Roche / 11858777001 In vitro apoptotic / 
necrotic staining 
AsPc-1 Cell line ATCC
©
 / CRL-1682 In vitro cell experiments 
Atenolol Sigma
®
 / A7655 β-adrenergic mediation 
BCH Sigma
® 








 / A7906 Blocking buffer 
Butan-1-ol Fisher
©
 / 11413543 Resolving gel 
Capan2 Cell line ATCC
©
 / HTB-80 In vitro cell experiments 
Cell death detection ELISA Roche / 11544675001 In vitro apoptotic  
quantification 
Cell scraper 30 mm blade length  Fisher
©
 / 10370881 Cell lysis 
Centrifuge tubes conical, 15 mL Stores / TES-136-110R Cell culture 
Chemically modified  
Gemcitabine 
Gift from Prof. Patrick Bailey  
and Gayle Wilson, 
University of Keele 
In vitro cell experiments 
Chemically modified Ibuprofen Gift from Prof. Patrick Bailey  
and Gayle Wilson, 
University of Keele 
In vitro cell experiments 
CyQuant™ Fisher
©
 / 10709253 Cell proliferation assay 
DAB Vector labs
 
Ltd /  SK-4100 Immunohistochemistry 
DAPI Sigma
®
 / 32670 Immunostaining 
DePex mounting media Fisher
©
 / 10050080 Immunohistochemistry 
DMEM Fisher
©
 / 51445C Cell culture 
DMSO Sigma
®
 / D8418 Solvent 
Dobutamine Hydrochloride Sigma
®
 / D0676 In vitro cell experiments 
Dymethyl sulphoxide Fisher
© 
/ BP231-100 Solvent 
ECL GE Healthcare
©
 / RPN2232 Western Blot 
         Epithelial voltmeter World Precision Instruments
© 
 
          TER measurement 
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Extra thick blot paper – 
absorbent filter paper 
Bio-Rad / 170-3966 Western Blot 
FACS tubes Scientific lab. supplies / PK1000 FACS 
FBS Invitrogen / 10500064 Cell culture 
FITC-Dextran 4 KDa Sigma
® 
/ 46944 Paracellular studies 
Gel cassettes 1.0 mm Fisher
©
 / VXNC 2010 Gel electrophoresis 
Gel loading tips Sigma
®
 / CLS4853-400EA Sample loading 
Gemcitabine hydrochloride Sigma
®
 / G6423 In vitro cell experiments 
Glass coverslips  Fisher
© 
/ MNJ-150020A Immunostaining 
GlySar Sigma
®




 / H9627 Immunohistochemistry 




 / 10082139 Cell culture 
Hepes Sigma
® 
/ H3784 Wash buffer 
HiPerfect Qiagen / 301802 Transient knock-down 
Histoclear Fisher
©
 / HIS-010-010S Immunohistochemistry 
HPAFII Cell line ATCC
© 
/ CRL-1997 In vitro cell experiments 
HPDE Cell line Gift from Dr. Ming-Sound Tsao, 
Toronto 
In vitro cell experiments 
Human recombinant epidermal 




 / 37000-015 Cell culture 
Hydrophobic pen  Vector / H-4000 Immunohistochemistry 
Ibuprofen Sigma
® 
/ I4883 In vitro cell experiments 
IFN γ Miltenyi Biotec / 130-097-068 Cell inflammation 
ImmEdge Hydrophobic Barrier  
Pen 
Vector labs Ltd / H-4000 Immunohistochemistry 





 / 17005-034 Cell culture 
LB media Fisher
©
 / BP9723-500 Stable knock-down 
LDS buffer 4x Invitrogen™ // NP0008 Western Blot  
LT1 Mirus / MIR2300 Stable knock-down 
McCoy’s Fisher
©
 / 11511861 Cell culture 
MEM Fisher
© 
/ 11514426 Cell culture 
MEM  without phenol red Fisher
©
 / 51200-038 Paracellular permeability 
Micro dishes high glass bottom Thistle Scientific Ltd. Live cell staining 
Microscope slide superfrost Fisher
©
 / 12372098 Immunostaining 
Microscope slide superfrost Fisher
© 
/ MNJ 750-010B Immunostaining  
Milk powder Marvel Western blot 
Mowiol 4-88 Sigma
®
 / 81381 Mounting media 
MTT Promega
®
 / G3582 Cell viability assay 
MYR-PKCζ Fisher
©
 / 10717873 Cell polarity disruption 
NanoDrop 2000 Thermo Scientific Protein quantification 
Nonidet P-40 Fisher
® 
/ PI85124 Cell lysis 
Pancreatic Stellate Cells Gift from Dr. Mert Erkan, 
Technical University of Munich 
Immunohistochemistry 
Pancreatic tissue biopsies Gift from Dr. Mert Erkan, 




 / P4417 Immunohistochemistry,  
cell lysis, cell culture. 
Penicillin/Streptomycin Sigma
®
 / P4333 Cell culture 
PFA Sigma
® 
/ 158127 Immunostaining 
Phosphatase Inhibitors cocktail Fisher
©
 / 12851650 Cell lysis 
Pipette Pasteur Fisher
©
 / 11566963 In vitro cell experiments 
Ponceau staining Sigma
®
 /  P7170 Western Blot 
Pressure Cooker Morphy Richards Immunohistochemistry 
Propranolol Sigma
® 
/ P8688 β-adrenergic mediation 
Protease Inhibitors cocktail Fisher
©
 / 12841640 Cell lysis 
Protein ladder Fisher
®
 / BP3603500 Gel electrophoresis 
Protein ladder 10-170 KDa Fisher
©
 / 11478503 Western Blot 
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PSC cell lysates Gift from Dr. Mert Erkan, 




 / P9620 Cell selection 
PVDF membrane Thermo Scientific / 10617354 Western Blot 
Qiagen midi prep kit Qiagen / 12143  Plasmid isolation 
RIPA buffer Fisher
©
 / 10017003 Cell lysis 
RNAse free water Fisher
©
 / BPE561-1 Plasmid isolation 
RPMI-1640 Fisher
©
 / 10418243 Cell culture 
Sample reducing agent 10x Invitrogen™ / NP0004 Western Blot 
SDS Fisher
©
 / S/5200153 Gel electrophoresis 
Serological pipettes 25 mL Fisher
©
 / 11517752 Sample measurement 
siRNA - scrambled Fisher
©
 / 11841984 Transient protein  
knock-down 
shRNA PepT1 Sigma Mission
®
 / SHCLNG Stable gene knock-down 
Slide box storage for slides Fisher
©
 / 11730594 Slides storage 
Sodium citrate Sigma
®
 / W302600 Immunohistochemistry 
Staining dish set Fisher
©
 / MNK-710-010T Immunohistochemistry  
Staurosporine  Sigma
®
 / S4400 Induction of  
cell apoptosis 
T 25 flasks Fisher
©
 / 156367 Cell culture 
T 75 flasks Fisher
© 
/ TKT-130-210T Cell culture 
TEMED Fisher
© 
/ T/P190104 Gel electrophoresis 
TGF-β Miltenyi Biotec / 130-095-067  Cell inflammation 
TNFα Miltenyi Biotec / 130-094-014   Cell inflammation 




 / CLS3460 Cell polarity assays 
Triton X-100 Sigma
©
 / T8787 Detergent  
Trizma base (Tris) Sigma
®
 / T1503 Buffer 
Tween 20 Fisher
© 
/ P1379 Cell lysis;  
immunohistochemistry 
VECTASTAIN Elite ABC Kit 
(Rabbit IgG) 
Vector labs Ltd / PK-6101 Immunohistochemistry 
X Cell Blot Module Fisher
©
 / 10073582 Western Blot 
Y-27632 Sigma
©
 /  Y0503 Cell polarity disruption 
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Table 2.7 Table showing the antibodies used for each technique 
 Western Blotting Immunofluorescence Immunohistochemistry 





Catalogue no / Company / 
















HPA018119 / Sigma / 100 µg / mL 
    
0.1 % BSA in 1X 
PBS 
1 in 100 
E-cadherin Rabbit 
 
3195 / Cell Signalling / 0.1 mg / mL 
  




SAB1408190 / Sigma / 0.5 mg / mL 
  
0.2 % BSA and 0.5 % Triton-X in 1X PBS 1 in 100 
  
Tricellulin Rabbit 65 kDa 700191 / Invitrogen / 0.5 mg / mL 5% Milk in TBS-T 1 in 1000 
    
TEAD Rabbit 50 kDa 8526 / Cell Signalling / 0.1 mg / mL 5% Milk in TBS-T 1 in 1000 0.2 % BSA and 0.5 % Triton-X in 1X PBS 1 in 100 
0.1 % BSA in 1X 
PBS 
1 in 100 
c-Yes Mouse 62 kDa sc-8403 / Santa Cruz / 200 µg / mL 5% Milk in TBS-T 1 in 1000 
  
0.1 % BSA in 1X 
PBS 
1 in 100 
HDAC Mouse 60 kDa sc-7872 / Santa Cruz / 200 µg / mL 5% Milk in TBS-T 1 in 1000 
    
c-Yes Rabbit 
 
sc-14 / Santa Cruz / 200 µg / mL 
    
0.1 % BSA in 1X 
PBS 
1 in 100 
PepT1 Rabbit 79 kDa 
Custom made Peptide synthesis-
Innovagen / 0.5 mg / mL 
5% Milk in TBS-T 1 in 1000 
    
PepT1 Rabbit 
 
HPA002827 / Sigma / 0.2 mg / mL 
    
0.1 % BSA in 1X 
PBS 
1 in 100 
YAP Rabbit 
 
4912 / Cell Signalling / 0.1 mg/ mL 
  
0.2 % BSA and 0.5 % Triton-X in 1X PBS 1 in 100 
0.1 % BSA in 1X 
PBS 
1 in 100 
Occludin Rabbit 65 kDa 33-1500 / Invitrogen / 0.5 mg / mL 5% BSA in TBS-T 1 in 1000 0.2 % BSA and 0.5 % Triton-X in 1X PBS 1 in 100 
  
Occludin Mouse 65 kDa 71-1500 / Invitrogen / 0.25 mg / mL 5% BSA in TBS-T 1 in 1000 
  
0.1 % BSA in 1X 
PBS 
1 in 100 
PepT1 Goat 
 
sc-19917 / Santa Cruz / 200 μg / mL 
  
0.2 % BSA and 0.5 % Triton-X in 1X PBS 1 in 100 
  
ERK Rabbit 44 kDa sc-93 / Santa Cruz / 200 μg / mL 5% Milk in TBS-T 1 in 1000 






Mouse 31 kDa 
H00000483-B01P 
Novis Biologicals / 0.5 mg / mL 
5% Milk in TBS-T 1 in 500 
    




3900 / Cell Signalling / 2.5 mg / mL 
    
0.1 % BSA in 1X 
PBS 






5415 / Cell Signalling / 2.5 mg / mL 
    
0.1 % BSA in 1X 
PBS 
1 in 100 
Beta Actin Rabbit 45 kDa 4967 / Cell Signalling / 0.2 mg / mL 5% Milk in TBS-T 1 in 500 
    
YAP Rabbit 65 kDa sc-15407 / Santa Cruz / 200 μg / mL 5% Milk in TBS-T 1 in 1000 







FI-1000 / Vector / 1.5 mg / mL 
  






FI-5000 / Vector / 1.5 mg / mL 
  







TI-2000 / Vector / 1.5 mg / mL 
  
0.2 % BSA and 0.5 % Triton-X in 1X PBS 1 in 400 
  




NA934 / GE Healthcare / 200 μg / 0.5 mL TBS-T 1 in 1000 





NXA931 / GE Healthcare / 200 μg / 0.5 mL TBS-T 1 in 1000 
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Most cells in the body express transporter systems capable of selectively shuttling 
molecules that otherwise would be impermeable to the plasma membrane. Since the 
majority of these materials brought into cells via specialised transporter systems are 
nutrients, many of these integral membrane proteins are constitutively expressed at the cell 
surface of these cells. Nonetheless, the expression profile of a few transporters can be 
restricted to specific conditions or are cell type dependent (Cravo and Mrsny, 2013). 
Carrier-mediated transport, either Na+- or H+- coupled, can play an active role in the 
transport of drugs (Tsuji and Tamai, 1996). PepT1 in particular, represents an attractive 
strategy for pro-drug design as it opens up the possibility of chemically coupling a drug with 
a nutrient moiety, which could increase the efficacy of its uptake in cells that express that 
transporter (Lee, 2000).  
 
As previously mentioned, Gonzalez and co-workers reported high expression of the 
oligopeptide transporter PepT1 in two human PDAC cell lines, AsPc-1 and Capan2 with a 
ductal origin and a K- Ras genotype (Gonzalez et al., 1998). This finding has fuelled interest 
in adopting PepT1 as a possible drug delivery strategy to target PDAC. Since PDAC cells 
may overexpress this transporter system in tumours and non-cancerous pancreatic cells do 
not, this occurrence may provide a novelty in tumour targeting strategy. Enhanced peptide 
transporter activity has also been reported in gastric cancer, osteosarcoma, bladder cancer 
and cholangiosarcoma (Inoue et al., 2005; Knutter et al., 2002). In addition, Mitsuoka and 
co-workers used a radiolabelled peptide PET tracer 11C-Gly-Sar, an well-established PepT1 
substrate, as a tool for cancer detection in vivo (Mitsuoka et al., 2008). The approach of 
using Gly-Sar to reveal cancer cells that over-express PepT1 provides an exciting 
opportunity to identify tumours (Mitsuoka et al., 2008). Gly-Sar, as a well characterised 
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dipeptide substrate for PepT1 (Brandsch, 2009; Hu et al., 2008; Ocheltree et al., 2005; 
Thwaites et al., 1993), is peptidase and hydrolysis resistant as it contains a N-methyl amide 
isostere (Mitsuoka et al., 2010).  
 
Through the adoption of rational drug design, a therapeutic compound could be masked with 
a nutrient moiety; in the case of PepT1 this is an amino acid that is used to generate a pro-
drug. Being a low affinity and high substrate capacity system (Daniel, 1996; Steiner et al., 
1995), specific molecules with very unique characteristics can be coupled to drugs in order 
to increase the specificity of the complex for PepT1 which would increase the efficiency of 
drug permeation through the biological barrier. Other advantages in designing drugs 
according to a specific drug transport pathway include not only the specific uptake, but also 
specialised drug delivery systems that target to specific drug transporters.  
 
Previous studies have demonstrated that single amino acid pro-drugs of non-PepT1 
substrates could potentially use this transporter system to enter the cell (Cao et al., 2012). 
Tsume and co-workers reported that amino acid ester pro-drugs of the anti-cancer agent 
floxuridine had enhanced cellular uptake and cytotoxic activity in PDAC cells; this approach 
also enabled a striking prolonged systemic circulation and consequently a more efficient 
therapeutic action (Tsume et al., 2008). Floxuridine however, is most often used in colorectal 
cancer treatment (Hohn et al., 1989). In what might be more directly relevant to PDAC, 
amino acid ester conjugates of gemcitabine have been evaluated for uptake by peptide 
transporters using HeLa cells stably expressing PepT1 as an in vitro model; this approach 
resulted in an improved drug delivery to cancer cells or tissues overexpressing PepT1 (Song 
et al., 2005).  
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The aims of this chapter were initially to validate the expression of PepT1 in pancreatic cell 
lines from normal and cancerous origin and to evaluate, for the first time, the distribution of 
PepT1 in human pancreatic biopsies from normal, inflamed (CP) and cancerous tissues 
(PDAC). Secondly, this work also aimed to explore the role of PepT1 in pancreatic cancer 
cell proliferation. Finally, this study assessed the feasibility in using this transporter system 
as a drug delivery strategy by comparing the uptake of chemically modified anti-cancer and 
anti-inflammatory agents in a novel system: AsPc-1 PepT1 expressing and AsPc-1 PepT1-/- 
cell line. 
 
3.2 Materials and methods 
3.2.1 Cell culture and immunostaining 
 
AsPc-1 (passage 12), Capan2 (passage 12), HPAFII (passage 8) and HPDE - human 
pancreatic ductal epithelial cell line - (passage 3) were grown on coverslips reaching up to 
50 % confluency (generally 2 days for AsPc-1 and Capan2 and 5 days for HPAFII and 
HPDE cells). After cells were fixed and permeabilised as described in section 2.9, Chapter 
2, they were subjected to a 1 h incubation with a primary antibody, PepT1 (custom made 
antibody - Innovagen) at  4 °C. A polyclonal antisera raised against PepT1 was affinity 
purified and prepared by Innovagen from rabbits injected with a peptide corresponding to the 
last 18 amino acid residues of the human protein PepT1 (LEKSNPYFMSGANSQKQM) 
(Gonzalez et al., 1998).  Afterwards, cells were washed and incubated with the secondary 
antibody (Table 2.6, Chapter 2). Subsequently, slides were mounted as described in section 
2.9, Chapter 2 and then taken to confocal microscopy. PSC lysates were a kind gift from Dr. 
Mert Erkan from the Technical University of Munich; stellate cells were cultured and isolated 
by individuals in Dr. Erkan´s laboratory as previously described (Erkan et al., 2010). 
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3.2.2 Immunoprecipitation and Western Blot 
 
For immunoprecipitation assay, Capan2, HPAFII and HPDE were used at passages 12, 8 
and 4, respectively. Cells were lysed as mentioned in section 2.4. Whole cell lysates 
containing approximately 500 μg of protein were incubated with a pull-down antibody, PepT1 
(Innovagen - Table 2.6, Chapter 2) overnight at 4 °C. Proteins were then isolated as 
described in section 2.6.2.2, Chapter 2. Isolates were analysed through Western Blot as 
outlined in 2.6.2.1, Chapter 2. For Cox-2 experiments, cells were exposed to the compounds 
100 μM Ala(S)Asp-IB and 100 μM control ibuprofen (IB) for 24 h and then lysed for protein 
expression as described in section 2.4, Chapter 2. 
 
3.2.3  Immunohistochemistry 
 
Fifteen human biopsies from five different patients (five normal, five CP and five PDAC) 
were obtained as described in Erkan, et al. (Erkan et al., 2010). PepT1 tissue distribution 
levels were assessed. Paraffin tissue sections were prepared according to section 2.10 
Chapter 2, using VECTASTAIN Elite ABC Kit (Rabbit IgG). For antigen detection, slides 
were subject to an overnight incubation in a humid chamber at 4 °C with the polyclonal 
antisera recognizing PepT1 or control antisera from a control Rabbit (Table 2.6, Chapter 2). 
After, slides were mounted on DePex, they were allowed approximately 12 h to dry; 
subsequently slides were examined as described in section 2.9, Chapter 2. 
 
3.2.4 Generation of stable PepT1 knock-down cell line: AsPc-1 PepT1-/-  
 
AsPc-1 cells, passage 8, were infected with lentiviral particles (shPepT1- 
GCGGCTCATCTCCCAAATT) as outlined in section 2.11, Chapter 2. After selecting the 
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colonies of interest, cells were passaged and trypsinized according to section 2.1, Chapter 
2. To confirm the down-regulation of PepT1 signal at the membrane (PepT1-/-), cell 
fractionation of AsPc-1 lysates was performed according to section 2.4, Chapter 2. Lysates 
were then subject to Western Blot (Section 2.6, Chapter 2). For immunostaining analysis, 
AsPc-1 WT, wild type, (passage 14) and AsPc-1 PepT1-/- (passage 2) were grown on 
coverslips for approximately two days to reach approximately 70 % confluence. Cells were 
then fixed and permeabilised as described in section 2.9, Chapter 2. For co-localisation 
purposes, cells were simultaneously incubated with the membrane marker E-cadherin and 
the antibody PepT1 (Table 2.6, Chapter 2) at 1:100 dilution for 1 h at RT. Subsequently cells 
were exposed to rabbit secondary antibody for 1 h and then to DAPI for 20 minutes, as 
described in section 2.9, Chapter 2. After being mounted in mowiol, slides were examined 
through confocal microscopy and the image analysed through the software Start LSM 5 
Image Browser. 
 
3.2.5 Cell treatment with different compounds and cell viability/proliferation assays 
 
AsPc-1 WT and AsPc-1 PepT1 -/- were plated in 96 well plates at a cell density of 500 cells 
per well. Six different testing concentrations of BCH (2-Amino-2-norbornanecarboxylic acid),  
reported to be an L-system amino acid transporter inhibitor (Kim et al., 2008; Mitsuoka et al., 
2010), were used: 0.3 mM, 1 mM, 3 mM, 10 mM, 20 mM and 50 mM. Test compound was 
applied to the cells as described in section 2.8, Chapter 2 and left incubating for 24 h and 48 
h. Subsequently, 20 µL of MTS reagent was added per well and the plate returned to the 
incubator. After 3 h, absorbance readings were taken at 490 nm. Data was plotted using the 
software Graphpad Prism 5 software.  
Gemcitabine and ibuprofen chimeras were obtained from Prof. Patrick Bailey and Gayle 
Wilson, University of Keele, UK. Compounds were dissolved in DMSO to a final 
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concentration of 50 mM. Eight different testing concentrations were further prepared: 500 
µM, 200 µM, 100 µM, 50 µM, 20 µM, 10 µM, 5 µM and 1 µM. After incubating the cells with 
the compounds for the chosen exposure time, cell viability and cell proliferation was 
assessed using either the MTS or CyQuant reagent, as described in section 2.8 and 2.7 
respectively, Chapter 2. To evaluate the involvement of PepT1 in mediating the uptake of 
chemically modified gemcitabine and ibuprofen, cell culture media was either supplemented 
with PepT1 substrate, 50 mM Gly-Sar (Brandsch, 2009; Hu et al., 2008; Ocheltree et al., 
2005; Thwaites et al., 1993) or with the L-system amino acid transporter inhibitor, 10 mM 
BCH (Mitsuoka et al., 2010). 
 
3.2.6 HPAF II and Caco 2 treatment with TNF α and IFN γ; 
 
HPAFII and Caco 2 were grown on trans-wells for 14 days. TERs were checked on a daily 
basis and on day 14, HPAFII and Caco 2 acquired a TER value of typically 600 Ω.cm2 and 
300 Ω.cm2, respectively.  On day 10, the FBS was increased to 30 % (vol/vol) to induce 
apical Na+/H+ exchange activity as described in Vavricka´s study (Vavricka et al., 2006). 50 
ng/mL of interferon γ (IFN γ) or tumour necrosis factor α (TNFα), were added to the 
basolateral compartment and left incubating for 2, 24 and 48 h. The apical compartment was 
acidified with a specific buffer in order to increase the activity of PepT1 due to additional 
protons, which are co-transported with PepT1 substrates. The acidified apical flux buffer 
contained 15 mM MES, pH 6.5, 140 mM NaCl, 1 mM MgCl2, 2 mM CaCl2 and 5 mM KCl. 
The basolateral side buffer consisted of 130 mM choline chloride, 5 mM KCl, 1 mM MgCl2, 2 
mM CaCl2, 15 mM HEPES, pH 7.4 and 20 mM NaCl (Vavricka et al., 2006). PepT1 protein 
levels were determined through Western Blot as described in section 2.6, Chapter 2. 
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3.3.1 Validation of PepT1 expression and localisation in human PDAC cell lines 
compared to a normal ductal cell line 
 
For the validation of PepT1 expression in PDAC, three different cell lines were used. 
Capan2 cell line is derived from a 56-year old male Caucasian and is from pancreatic ductal 
origin. These cells grow in adherent tissue culture and display epithelial features        
(Kyriazis et al., 1986). AsPc-1 cells were initially isolated from ascites fluid and demonstrate 
aggressive growth characteristics and metastatic behavior; these cells fail to differentiate 
(apical-basal polarization) when grown in vitro (Tan and Chu, 1985). HPAFII cell line, 
established from a human pancreatic adenocarcinoma, can differentiate in vitro to form 
polarised monolayers on permeable supports (Kim et al., 1989). For localisation studies, we 
have also used HPDE cells isolated from primary and immortalized epithelial cell lines of 
human pancreatic ducts (Furukawa et al., 1996). Firstly, PepT1 was precipitated out of 
whole cell lysates from Capan2, HPAFII and AsPc-1 (Figure 3.1-A). PepT1 signal was 
detected in the three cell lines tested consistent with previous findings                     
(Gonzalez et al., 1998). Subsequently, PepT1 localisation was assessed in HPDE, AsPc-1 
and Capan2 cell lines through confocal microscopy (Figure 3.1-B). In HPDE cells, PepT1 
was predominantly detected in the cytoplasm and a similar pattern was observed for HPAFII 
cells (data not shown). In AsPc-1, a clear ring shape could be observed suggesting that 
PepT1 was distributed mainly at the cell surface of these cells. In Capan2 cells, PepT1 
localised at the cytoplasm and more predominantly at the cell membrane. HPAFII cell line 
expressed the highest level of PepT1 whereas HPDE cell line showed the lowest level 
(Figure 3.1-C). Since AsPc-1 cells expressed PepT1 at a significant higher level compared 
to HPDE and the oligopeptide appeared to be distributed exclusively at the cell membrane, 
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in contrast to Capan2, AsPc-1 cells were selected for the in vitro model to carry out 
functional studies.  
 
Figure 3.1 PepT1 is expressed in PDAC derived cell lines and localizes at the cell surface; (A) 
Immunoprecipitation of PepT1 in whole cell lysates from three cell lines derived from PDAC patients; 
(B) Confocal microscopy images showing PepT1 distribution in HPDE cells (top panel) in AsPc-1 cells 
(middle panel) and in Capan2 cells (bottom panel); Scale bar, 20 µm. Magnified micrographs of  
FITC-PepT1 on the right hand side of the panel; (C) Immunoblot comparing PepT1 expression levels 
in whole cell lysates from three different pancreatic cell lines. Data is presented as the mean of 3 
independent experiments ± SEM; *p < 0.05 compared to HPDE cell line. 
 
PDAC is often accompanied by a vigorous stromal response, termed desmoplasia          
(Feig et al., 2012). From a drug delivery perspective, this fibrotic component assumes great 
importance as the microenvironment established around the organ works as a physical 
barrier to chemotherapeutic events, preventing efficient pancreatic drug perfusion        
(Jaffee et al., 2002). As previously mentioned, PSCs play a major role in the pathobiology of 
CP and PDAC contributing to the remarkable fibrosis observed in the exocrine pancreas 
(Omary et al., 2007). We sought to analyse PepT1 expression levels in PSCs lysates from 
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three patients with PDAC and two with CP. PepT1 signal was detected in the five samples 
analysed, regardless the pathological condition (Figure 3.2).  
 
Figure 3.2 PepT1 is expressed in PSC from patients diagnosed with PDAC and CP. Immunoblot 
showing PepT1 expression in pancreatic stellate cell lysates from three patients diagnosed with 
PDAC and two with CP and in whole cell lysates from Caco 2 cells used as a control.  Data presented 
as n=1 due to limited sample volume. 
 
3.3.2 Assessment of PepT1 distribution in normal, inflamed and cancerous human 
pancreatic tissue 
 
While PepT1 expression and localisation has been described in pancreatic cancer cells  
(Gonzalez et al., 1998), no studies have previously reported PepT1 distribution in pancreatic 
tissue. Through a collaboration established with Dr. Mert Erkan, pancreatic biopsies were 
obtained from healthy individuals and patients that had been diagnosed either with CP or 
PDAC. 
 
Each slide contained two paraffin embedded tissue sections. One section was exposed to 
the antisera raised against a human PepT1 peptide while the other section was exposed to 
control antisera (Table 2.6, Chapter 2) to estimate the extent of non-specific antibody 
binding due to Fc (fragment crystallisable of the antibody) receptor binding or other 
protein-protein interactions that could compromise labelling specificity. Because no staining 
was obtained for the tissue sections treated with the control antisera, as shown by the 
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insets, PepT1 staining was positively validated (Figure 3.3); (Figure 8.4, Chapter 8). PepT1 
distributed at the cell surface of inflamed and cancerous pancreatic ducts (Figure 3.3) and 
the staining intensity obtained was comparable across the different stages of cancer cell 
differentiation or TNM (tumour, nodes and metastasis) staging (Table 3.1).  
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Figure 3.3 PepT1 distributes at the cell surface of morphologically inflamed and cancerous pancreatic ducts. PepT1 expression in five 
different patients diagnosed with CP and PDAC compared to normal pancreas. Scale bar, 50 µm. 
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Table 3.1 Table showing the medical information concerning the nature and aggressiveness of 




PDAC develops through a multistep progression model; the ducts are the first structures to 
become morphologically altered which are subject to non-invasive intra-ductal lesions 
culminating in invasive adenocarcinoma (Basturk et al., 2010). Being the structures more 
prone to malignancy, PepT1 distribution was closely examined in altered ductal structures 
and compared to normal pancreatic ducts from different patients.  
 
PepT1 localised essentially at the cytoplasm of normal acinar cells and negligible staining 
was observed in ductal structures from normal pancreas. In cancer, however, PepT1 was 
distributed primarily at the apical surface of poorly- and well-differentiated pancreatic ducts 
(as indicated by the black arrows in Figure 3.4). This finding provides support to the strategy 
of directing the uptake of chemically modified compounds into PepT1 substrates to tumour 
cells. Moreover, the differential distribution between normal and cancerous ductal structures 
should not only allow for an efficient drug delivery but would also confer a certain degree of 
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selectivity. Yet, it is rather premature to make definite assumptions given the small sample 
size analysed as only six patients were studied in this work. 
 
Figure 3.4 PepT1 signal at the cell surface of malignant transformed pancreatic ducts is 
stronger compared to morphologically normal ducts. PepT1 distribution levels in normal (top 
panel) and cancerous pancreatic ducts (bottom panel) from six different patients.Scale bar, 50 µm 
 
3.3.3 Generation of a knockout PepT1 cell line through lentiviral particles  
 
PepT1 deficient mice have already been generated and were found to be viable, fertile, grew 
to normal size and weight, and showed no obvious abnormalities (Hu et al., 2008). In order 
to assess the functionality of PepT1 in cancerous cells, a control cell line stably expressing 
reduced or absent levels of PepT1 had to be generated. This was achieved through 
targeting shRNA against a specific region in the PepT1 gene 
(GCGGCTCATCTCCCAAATT). This approach was repeated for two other PDAC derived 
cell lines expressing PepT1, namely Capan2 and HPAFII, but without success. To confirm 
PepT1 knock-down in the AsPc-1 cell line, localisation and expression assays were carried 
out (Figure 3.5). Confocal microscopy demonstrated some co-localisation between PepT1 
and E-cadherin, an epithelial membrane marker of AJs, in AsPc-1 WT cells                
(Nelson et al., 1990). Conversely, no co-localization was obtained between the two proteins 
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in the AsPc-1 PepT1-/- cell line, validating the successful knock-down of PepT1. To further 
confirm the confocal microscopy data, PepT1 levels were analysed in membrane fractions 
from both cell lines. When compared to the wild type cell line, PepT1 was not detected at the 
membrane of cell lysates from PepT1-/- cells. Interestingly, a weak signal for nuclear 
expression and slightly more pronounced labelling in the cytosolic fraction was observed in 
the knock-down cell line. This occurrence is not particularly relevant, as this study focuses 
on the transport of PepT1 substrates across the plasma membrane, where the loss of 
expression of this transporter was primarily observed.  
 
Figure 3.5 PepT1 knock-down in AsPc-1 cell line. (A) Confocal microscopy showing co-localisation 
of PepT1 and E-cadherin at the cell membrane of AsPc-1 WT; Scale bar, 20 µm; (B) Immunoblot 
analysis showing PepT1 expression levels at the cell membrane of AsPc-1 PepT1
-/- 
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3.3.4  Inhibition of PepT1 function decreased cell viability 
 
Amino acids are organic compounds essential for protein synthesis which are critical for cell 
growth and proliferation in normal and transformed cells (Christensen, 1990). Amino acid 
transport across the plasma membrane is mediated by specialised amino acid transporter 
systems. Among these, are the  system L amino acid transporters (LATs) responsible for 
Na+ independent transport of neutral, branched or aromatic amino acids to the cells 
(Christensen, 1990).  
BCH is a model compound for the study of amino acid transporters as it is a specific inhibitor 
for  LAT; BCH has been shown to be cytotoxic due to its ability to deplete ATP (Babu et al., 
2003; Kim et al., 2008). Several studies have reported the anti-cancer potential achieved by 
inhibition of LATs and an enhancement in the cytotoxic activity of several chemotherapeutic 
agents (Haining et al., 2012; Kim et al., 2008). Importantly, inhibition of LATs results in 
reduced nutrient supply leading to cell growth suppression (Kim et al., 2008). Inhibition of 
oligopeptide transporter activity has been shown to suppress the growth of   AsPc-1 cells 
known to express PepT1 (Gonzalez et al., 1998; Mitsuoka et al., 2010). Hence, the 
functional role of the oligopeptide transporter in AsPc-1 cells was examined.  
WT and PepT1-/- cell lines were exposed to different concentrations of BCH over 24 and     
48 h.  At 24 h, cell viability did not differ considerably between cells expressing WT and 
PepT1-/- cell lines. However, after 48 h, PepT1-/- cell line exhibited less of an effect of BCH 
on cell viability compared to WT cells (Figure 3.6). Reduction in cell proliferation resulting 
from BCH exposure has been previously reported (Kim et al., 2008). We now show that 
even though BCH inhibits Na+ - independent transport of amino acids, it can also affect the 
cell viability of PepT1 expressing cells. These results are consistent with other studies, 
however it appears that BCH not only inhibits the transport of amino acids into the cancer 
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cells but it can also affect the transport of oligopeptides (Kim et al., 2008; Mitsuoka et al., 
2010). Manipulation of system L activity has been suggested to have anti-cancer 
implications; the inhibition of LAT1 activity in tumour cells was proposed to be effective in 
suppressing tumour cell growth through essential amino acid deprivation in tumour cells  
(Kanai and Endou, 2001; Kim et al., 2002). Our data suggests that PepT1 might be a new 
target for suppression of pancreatic cancer cell growth.  
 
Figure 3.6 BCH decreases cell viability in PepT1 expressing cell lines in a more pronounced 
manner compared to the knock-down cell line. MTT assay in PepT1 expressing (AsPc-1 WT) and 
knock-down cell lines (AsPc-1 PepT1
-/-
) after being exposed to different concentrations of BCH during 
a 24 h and 48 h time-course. Data is presented as the mean of 3 independent experiments ± SEM; 
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3.3.5 Targeting PDAC through chemically modified PepT1 substrates 
 
Gemcitabine, through its ability to incorporate into the genome and block DNA 
synthesis(Plunkett et al., 1995) , is a current front line treatment for pancreatic cancer                  
(Burris et al., 1997). Despite being clinically effective, the drug has many side effects. 
Hence, conjugation of an amino acid moiety to gemcitabine structure could increase the 
selectivity of delivering this cytotoxic agent into the cytoplasm of cells overexpressing 
PepT1, such as those derived from PDAC patients. Despite the fact that the crystal structure 
of PepT1 is not yet available, PepT1 seems to be a more robust target to the cytotoxicity of 
chemotherapeutic agents than other membrane bound proteins (Lee, 2000).  
Designing drugs in a way that favours their cellular uptake via membrane transporters 
provides an attractive approach to selectively targeting cancer cells. Such an approach has 
several advantages to the parent drug, including improved specificity of drug uptake and 
retention in the cytoplasm of cells that over-express a particular membrane transporter    
(Lee, 2000). Understanding the physical and chemical properties of the PepT1 transporter 
may improve the delivery of drugs via this route.  
Despite the wealth of information regarding the prediction of a compound´s affinity for 
PepT1, little is known about its transport capacity. Meredith and co-workers, reported the 
ability of PepT1 in transporting thio-dipeptides pro-drugs of ibuprofen (Foley et al., 2009). 
Through a collaboration with the Bayley group at the University of Keele, the anti-cancer 
drug gemcitabine was chemically modified and linked to a hydrolysis resistant thio-dipeptide 
that is recognized as a potential substrate for PepT1. The carrier Ala(S)Asp- 
(Figure 3.7 - compound A) was attached to gemcitabine through the primary alcohol via an 
ester linkage. Gemcitabine is set slightly away from the carrier in the chimera that it could be 
placed, a feature identified to improve transport efficacy by Bayley´s group (data not 
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published). An important factor determining the sensitivity of a particular cell line to 
gemcitabine treatment is the intracellular retention of dFdCTP (Huang et al., 1991). 
Gemcitabine can be deaminated to form 2,2-difluorodeoxyuridine. The efficacy of formulated 
gemcitabine pro-drugs and consequently their transport across cells partially relies on the 
resistance to such enzymatic degradation at the cell surface (Song et al., 2005; Tsume et 
al., 2014). To overcome this, gemcitabine was attached to two carriers: 5-hydroxymethyl-
ala(S)7-asp-gemcitabine (compound B) and 4-hydroxy-ala(S)asp-5-hydroxymethyl-ala(S)7-   
-asp-gemcitabine (compound C). 
 
Figure 3.7 Gemcitabine modified chimeras as PepT1 substrates. Courtesy of Prof. Bailey and 
Gayle Wilson (University of Keele). 
 
Firstly, we wished to characterise the cell viability response by directing the uptake of the 
three chimeras through the transporter system using as an in vitro model a PepT1 
expressing and a PepT1-/- cell line. Unexpectedly, compound C was the most effective at 
decreasing AsPc-1 cell viability. Despite the fact that compound C had the highest molecular 
weight and according to the oocyte data showed the least efficacy in getting transported 
through PepT1 (data not shown), it was the most efficient chimera at reducing cell viability in 
PepT1 expressing compared to PepT1-/- cells (Figure 3.8). 
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Figure 3.8 Compound C was the most effective gemcitabine modified chimera in decreasing 
cell viability mediated through PepT1 uptake. Concentration-response of modified gemcitabine 
compounds exposed to WT and PepT1 knock-down AsPc-1 cells. Data presented as mean of 3 
independent experiments ± SEM; * p < 0.05; *** p < 0.001. 
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Cell viability was assessed after PepT1 expressing and PepT1-/- cell lines were exposed to 
compound C (Figure 3.9). The calculated EC50 in the cell line expressing PepT1 was nearly 
fivefold lower (~11 μM) than in the PepT1-/- cell line (~54 μM) suggesting the gemcitabine 
chimera was more efficient at reducing cell viability in the cell line expressing PepT1. 
 
Figure 3.9 Compound C has a higher EC50 in the PepT1
-/-
 cell line compared to the WT. 
Exposure of PepT1 expressing cell line and PepT1
-/-
 to compound C over a 48 h period. Data 
presented as mean of 3 independent experiments.  
 
Cell proliferation was assessed in PepT1 expressing and PepT1-/- cell line after exposure to 
compound C (Figure 3.10). There was a statistically significant decrease in cell proliferation 
in AsPc-1 cells when compared to cells with reduced levels of PepT1 expression         
(Figure 3.10). The selective growth inhibition of PepT1 expressing cells over PepT1-/- cells 
after exposure to the chemically modified gemcitabine compound suggests that it is 
mediated through PepT1.  
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Figure 3.10 Compound C reduced cell proliferation in PepT1 expressing cells much more 
efficiently compared to the knock-down cell line. Cell proliferation rate of PepT1 expressing cells 
and knock-down cells after being exposed to compound C over a 48 h period. Data are presented as 
the mean of 3 independent experiments ± SEM; *** p < 0.001. 
 
The cytotoxic potential of compound C was compared to gemcitabine. As it can be seen 
from Figure 3.11, cells treated with compound C had lower cell viability compared to the 
parent gemcitabine compound. Amino acids and mono-acid ester pro-drugs have been 
shown to be substrates for PepT1 (Landowski et al., 2005). The current results show that 









Figure 3.11 Compound C decreased cell viability more efficiently than its parent compound. 
AsPc-1 cells were exposed to compound C and to the parent compound over a 48 h period. Data 
presented as mean of 3 independent experiments ± SEM; *p < 0.05; ** p < 0.01; *** < 0.001. 
 
Next, the specificity of PepT1-mediated transport involved in the uptake of compound C was 
investigated. To check this, PepT1 function was competed with using the specific substrate 
Gly-Sar (Brandsch, 2009; Hu et al., 2008; Ocheltree et al., 2005; Thwaites et al., 1993). 
Cells treated with normal media supplemented with compound C and 50 mM Gly-Sar 
showed a higher degree of cell viability compared to cells that were cultured in normal media 
with compound C only (Figure 3.12). Even though a statistically significant reduction in cell 
viability was only obtained for one specific concentration (1 μM), there was a trend 
suggesting that the improved cellular uptake of the gemcitabine chimera can be attributed to 








Figure 3.12 Cell viability showed a more pronounced decrease in cells treated with compound 
C compared to cells treated with compound C in a Gly-Sar enriched medium. AsPc-1 cells 
exposure to compound C in normal or Gly-Sar enriched medium over a 48 h period.  Data presented 
as mean of 3 independent experiments ± SEM; ** p < 0.01. 
 
After showing the potential effect of BCH in reducing AsPc-1 cell viability (Figure 3.6), it was 
investigated if by inhibiting amino acid transport there would be a difference in the uptake of 
compound C at different concentrations. Cell viability response did not differ greatly in 
response to compound C between the two cell lines when treated with 10 mM BCH, 
suggesting that PepT1, rather than LATs, is likely to be involved in compound C uptake 
(Figure 3.13).  
 
Figure 3.13 Similar cell viability response between PepT1 expressing and PepT1-/- AsPc-1 cells 
treated with compound C in cell media enriched with BCH. PepT1 expressing cell line and 
PepT1
-/-
 were exposed to 10 mM BCH and different concentrations of compound C over a 48 h 
period. Data presented as mean of 3 independent experiments ± SEM. 
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3.3.6  Redistribution of PepT1 in CP biopsies 
 
CP has been suggested to be a pre-empting factor contributing to the development of PDAC 
(Howes and Neoptolemos, 2002). Given this, we sought to investigate if there was a 
continuum in PepT1 expression levels resulting from the progression of normal to inflamed 
pancreas culminating in cancer. As previously shown (Figure 3.3), PepT1 was detected at 
the cell surface of inflamed ducts in five patients. As shown by Figure 3.14, a schematic 
representation of PepT1 expression throughout normal, inflamed and cancerous pancreas, 
suggests that there is a continuum in PepT1 expression consistent with the representative 
pancreatic biopsies collected from different patients. These data are in line with other 
studies reporting the involvement of PepT1 in inflammatory processes (Ingersoll et al., 2012; 
Nguyen et al., 2009). Merlin and co-workers also suggested that PepT1 was expressed in 
inflamed colonic tissues, while Buyse and colleagues reported PepT1 capacity in 
transporting formyl-Met-Leu-Phe (fMLP), a known neutrophil attractant peptide of bacterial 
origin (Buyse et al., 2002; Merlin et al., 2001).  
 
Representative pictures of different areas of pancreatic tissue were taken from normal, 
inflamed and cancerous pancreatic tissue (Figure 3.14). The cellular distribution of PepT1 in 
biopsies obtained from patients diagnosed with CP was altered from that observed in       
non-inflamed samples (Figure 3.15). In normal pancreas, PepT1 labelling was not as strong 
as it was observed in CP or PDAC samples. At the early stages of CP (PanIN-1A,        
PanIN-1B), as pointed by the black arrows, PepT1 distributed at the apical side of inflamed 
pancreatic ducts; at later stages of inflammation (PanIN-3), the oligopeptide transporter was 
no longer located selectively at the apical surface of cells, as in a normal polarizing cell 
condition, but instead it relocated around the entire cell membrane.  Finally in cancer, PepT1 
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labelling was markedly strong in malignant transformed ducts and a visible stromal 
distribution could also be observed. 
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Figure 3.14 PepT1 expression in tissues from inflamed and cancerous pancreas compared to normal tissue. Diagram representing the 
changes in PepT1 expression levels in six different patient biopsies from normal, CP and PDAC tissue (scale bar, 50 µm).
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Figure 3.15 PepT1 redistributes at the cell surface of inflamed pancreatic cells. Biopsy sample 
collected from a patient diagnosed with CP and immunostained for PepT1. 
 
3.3.7  The creation of an in vitro model of CP 
 
Given the observed alteration of PepT1 distribution in CP, an in vitro model recapitulating 
the molecular biology of pancreatic inflammation would be very valuable, yet there are 
limited studies in this field. The up-regulation of PepT1 in intestine in response to cytokine 
exposure has been well documented (Buyse et al., 2003; Ingersoll et al., 2012; Vavricka et 
al., 2006; Wang et al., 2011). Moreover, a study reported that TNF α and IFN γ increased 
the activity, total and apical PepT1 expression in a concentration and time-dependent 
fashion in Caco 2 cells (Vavricka et al., 2006). However, the experimental setup referred in 
this study was not reproducible in the cell lines used for this study: HPAFII and Caco 2. 
Since both cell lines are able to polarise in vitro (Kim et al., 1989; Yee, 1997), an increase in 
PepT1 expression levels after cytokine induction would be expected; instead, PepT1 levels 
decreased after   24 h of cytokine treatment in HPAFII cells and in Caco 2 cells. Even 
though an increase was observed after 2 h of treatment, this cytokine treatment was unable 
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to sustain an increase in PepT1 expression levels after 24 and 48 h, so the experiment 
could not be validated   (Figure 3.16).  
 
Figure 3.16 Change in PepT1 expression following cytokine treatment in HPAF and Caco-2 
treatment. 50 ng/mL of IFN γ and 50 ng/mL of TNFα were added to the basolateral compartment and 
left incubating for 2, 24 and 48 h. Cells were then lysed for PepT1 expression levels. Data presented 
as mean (± SEM) of 3 independent experiments. 
  
3.3.8 Cell viability and proliferation response after treatment with Ala(S)Asp-IB 
 
Foley demonstrated the capacity of PepT1 to mediate the transport of thio-dipeptides and 
the use of this carrier transporter as a delivery approach of rationally designed drugs      
(Foley et al., 2009). Through an established collaboration with the Bailey Group at the 
University of Keele, we obtained a chimera compound composed of a peptide analogue 
Chapter 3 
PepT1 as a Drug Delivery Target to Treat Chronic Pancreatitis and Pancreatic cancer 
110 
 
chemically coupled to the anti-inflammatory chimera compound, ibuprofen (Ala(S)Asp-IB). 
This material was tested for uptake into AsPc-1, as they express the oligopeptide 
transporter. PepT1 binding affinity for Ala(S)Asp-IB (Figure 3.17) has been confirmed 
through binding studies measuring the concentration at which this compound inhibited the 
uptake of radiolabelled D-Phe-L-Gln in Xenopus laevis oocytes expressing rabbit PepT1 
(Foley et al., 2009). 
 
Figure 3.17 Ibuprofen modified chimera as a PepT1 substrate (Ala(S)Asp-IB). 
 
NSAIDs, non-steroidal anti-inflammatory agents, have been previously reported to inhibit 
cancer cell proliferation (Hixson et al., 1994). To investigate if Ala(S)Asp-IB would affect cell 
proliferation through a PepT1-specific mechanism uptake, we assessed the actions of this 
chimera in PepT1 expressing and PepT1-/- cells (the same model as described in          
Figure 3.5). PepT1 expressing cells were found to be more susceptible to the anti-
proliferative actions of Ala(S)-Asp-IB compared to PepT1-/- cells (Figure 3.18). At high 
concentrations (~200 and 500 μM) cell proliferation decreased in a comparable manner in 
both cell lines tested, possibly as a result of a toxicity threshold.  
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Figure 3.18 Ala(S)-Asp-IB affected differently cell proliferation rates observed in PepT1 
expressing and PepT1
-/- 
cells. AsPc-1 and AsPc-1 PepT1
-/-
 cells were exposed to different 
concentrations of     Ala(S)-Asp-IB during a 24 h period. Values are expressed as mean ± SEM from 
3 independent experiments; **p< 0.01; ***p< 0.001. 
 
Following this, we wanted to confirm the involvement of PepT1 in the uptake of chemically 
modified ibuprofen molecule achieved using the Ala(S)Asp-IB chimera. For this, PepT1 
function was blocked through a specific substrate: Gly-Sar (Brandsch, 2009; Hu et al., 2008; 
Ocheltree et al., 2005; Thwaites et al., 1993). The rate of cell proliferation induced by 
Ala(S)Asp-IB was significantly decreased when compared to AsPc-1 cells cultured in media 
supplemented with Gly-Sar, suggesting the involvement of PepT1 in the uptake of        








Figure 3.19 Blocking PepT1 function in AsPc-1 cells resulted in an increased proliferation level 
when compared to cells with normal PepT1 function after exposure to Ala(S)-Asp-IB.  
Proliferation rate of AsPc-1 cultured in normal media compared to AsPc-1 cells cultured in media 
supplemented with Gly-Sar after being exposed to Ala(S)-Asp-IB. Values are expressed as mean ± 
SEM from 3 independent experiments; * p< 0.05; *** p< 0.001. 
 
Finally, to assess the actions of Ala(S)Asp-IB on cell viability, an MTT assay was carried out. 
Cell viability decreased significantly in WT AsPc-1 cells compared to PepT1-/- cells 
suggesting that the compound Ala(S)-Asp-IB could be taken up by the oligopeptide 
transporter, PepT1 (Figure 3.20-A).  
 
The best characterized intracellular targets for anti-inflammatory drugs (NSAIDs) are 
inhibitors of the cyclooxygenase enzymes, Cox-1 and Cox-2 (Vane et al., 1998). Cox-1 is 
constitutively expressed in the majority of tissues and has a role in normal tissue 
homeostasis whereas Cox-2 is up-regulated as a stress response induced by inflammatory 
cytokines, growth factors and oncogenes (de Groot et al., 2007; Vane et al., 1998). 
Therefore, we investigated Cox-2 levels after cells were exposed to the PepT1 specific 
anti-inflammatory compound (Figure 3.20-B). No signal for Cox-2 expression was detected 
in PepT1 expressing cells followed by exposure to Ala(S)Asp-IB whereas in PepT1-/- a signal 
could be observed. This data suggested that the chemically modified ibuprofen was more 
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effective at reducing Cox-2 levels in PepT1 expressing cells compared to cells in which 
PepT1 expression was reduced. 
 
Figure 3.20 Cell viability response decreased in PepT1 expressing cells compared to PepT
-/- 
cells; Cox-2 levels were absent in PepT1 expressing cells after Ala(S)-Asp-IB treatment. (A) 
Cell viability assay after AsPc-1 and AsPc-1 PepT1
-/-
 cells were exposed to Ala(S)-Asp-IB during a  
24 h period. Values are expressed as mean ± SEM from 3 independent experiments;                                
* p<0.05; ** p< 0.01; *** p<0.001; (B) Cox-2 expression levels after AsPc-1 and AsPc-1 PepT1
-/-
 cells 
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3.4 Summary of results 
 
 PepT1 is expressed at the cell surface of PDAC derived cell lines, whereas in       
non-cancerous pancreatic cell lines it localised predominantly at the cytosol and cell 
nuclei; 
 PepT1 is expressed in PSC lysates from patients diagnosed with CP and PDAC; 
 PepT1 immuno-labelling at the cell surface of malignant transformed pancreatic 
ducts is more prominent compared to morphologically normal ducts; 
 PepT1 is expressed in tissue biopsies from patients diagnosed with CP and PDAC; 
 BCH treatment decreases AsPc-1 cell viability through PepT1; 
 Chemical coupling of gemcitabine to an hydrolysis resistant thio-dipeptide increases 
the specificity of the complex being taken by PepT1 as cell viability and proliferation 
decreases faster; 
 Chemical coupling of gemcitabine to an hydrolysis resistant thio-dipeptide decreases 
cell viability more efficiently than the parent compound;  
 PepT1 redistributes at the cell surface of inflamed pancreatic cells in later stages of 
CP; 
 Chemical coupling of ibuprofen to an hydrolysis resistant thio-dipeptide decreases 












The use of specific drug transporters as molecular targets in cancer therapy has been 
considered for targeting tissues selectively as a means to reduce systemic toxicity. Amongst 
the wide range of membrane transporters, PepT1 is perhaps the drug transporter in the 
mucosal drug delivery field that has caught the most attention recently. As well as nutrients, 
some of these transporters are also capable of transporting anti-cancer drugs or anti-cancer 
agents in a pro-drug form. The robustness of PepT1 to adverse environmental conditions 
such as to the cytotoxic effects of conventional chemotherapy raises the possibility that 
PepT1 might pose as a good and robust target for drug delivery.  
 
PepT1, normally restricted to the apical surface of small intestine where it functions to 
absorb di- and tri-peptides (Fei et al., 1994), has been reported to be expressed in cells 
derived from gastric cancer, osteosarcoma, bladder cancer, cholangiosarcoma and in PDAC 
(Gonzalez et al., 1998; Inoue et al., 2005; Knutter et al., 2002). In particular, Gonzalez´s 
work highlighted the overexpression of PepT1 in two PDAC cell line models with a ductal 
origin and a K-Ras genotype: AsPc-1 and Capan2 (Gonzalez et al., 1998). This work has 
reproduced those findings; PepT1 expression was confirmed in three PDAC derived cell 
lines, Capan2, HPAF II and AsPc-1 (Figure 3.1 - A). For localisation studies, cells were 
labelled with a polyclonal antibody raised against a peptide mapping near the C –terminus of 
PepT1 from human origin (Figure 3.1-B). Both PDAC cells showed a similar labelling pattern 
suggestive of both plasma membrane and intracellular vesicle distribution, whereas in the 
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Being a transporter system that works through a proton gradient, it was not unexpected to 
find PepT1 localised in intracellular vesicles. Nevertheless, these findings are consistent 
with Bockman´s observations proposing there is a considerable amount of PepT1 present in 
intracellular vesicles in a steady-state (Bockman et al., 1997). This could be down to the 
presence of small peptides resulting from incomplete protein breakdown that are then co-
transferred from the lysosomes using the H+ transport through the membrane (Bockman et 
al., 1997). Knowing that one of the main functions of lysosomes is to maintain a low internal 
physiological pH, such localisation could be facilitating the transport of oligopeptides present 
within these vesicles into the cytoplasm. In the same study, the authors co-localised PepT1 
and Lamp-1, a lysosomal marker, in Caco 2 cells suggesting that at steady state PepT1 
localizes in lysosomes. From the data obtained, it cannot be concluded exactly where these 
vesicles localised as a specific marker for lysosomal identification was not used. However, 
assuming that such vesicles were lysosomes, a possible physiological function for the 
localisation of PepT1 inside the lysosomes would be down to PepT1 function through an 
endocytic pathway, as suggested by Gonzalez (Gonzalez et al., 1998).  
 
Next, we compared the expression levels between two cancer cell line models and the 
pancreatic ductal cell line derived from normal pancreatic ducts, HPDE.  Both cancer cell 
lines, HPAFII and AsPc-1, showed significantly higher PepT1 expression levels compared to 
HPDE (Figure 3.1-C). As the challenge in the treatment of various epithelial cancers 
including PDAC, an intense desmoplastic reaction surrounding the organ contributes to limit 
access of drugs to these tumours, resulting in increased non-selective actions and off-           
-target toxicity (Erkan et al., 2013; Feig et al., 2012). In PDAC, the intense stromal reaction 
is composed of PSCs, lymphatic and vascular endothelial cells, immune cells and fibroblasts 
(Bachem et al., 1998). All these elements create a complex microenvironment around the 
organ, promoting tumour growth, invasion, metastasis and ultimately resistance to 
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chemotherapy. PepT1 expression was examined in PSCs lysates from three patients 
diagnosed with PDAC and two with CP (Figure 3.2). A signal for PepT1 expression was 
confirmed in the five patients analysed. As PSCs are not from an epithelial origin, it was 
unexpected that PepT1 was expressed in myofibroblast-like cells. Thus, it remains to be 
confirmed if the oligopeptide transporter is functional or not in these particular stellate cells 
or if it serves a cellular function distinct from its ability to internalize small peptides. 
Nonetheless, this finding is consistent with the work carried out by Nakanishi, in which the 
fibroblastic cancer cell line HT1080 was reported to express the oligopeptide transporter at 
considerable levels (Nakanishi et al., 1997).  
 
Established proton gradients at the cell surface of epithelial cells facilitate the uptake of 
substrates across oligopeptide transporters and through the polarised nature of cells, an 
acidic pH is maintained at the membrane surface (Mrsny, 1998). Mesenchymal cells, like 
PSCs, typically lose this polarised status, and cannot maintain a specific trans-epithelial pH 
gradient required to facilitate the uptake through oligopeptide transporters. A local injection 
of an anti-cancer agent capable of entering cells through an oligopetide transporter would 
circumvent unwanted uptake by PepT1 expressed in other organs, potentially improving its 
delivery to cancer cells. Additionally, the tumour microenvironment is known to be very 
acidic when compared to the normal tissue; such acidic conditions might favour the function 
of PepT1 which is activated by an inward proton gradient and require an acidic pH for 
optimal substrate uptake conditions (Figure 1.14). Supporting this, some PepT1 labelling 
was observed in the stroma of biopsy samples collected from cancer patients (Figure 3.3). 
Most, if not all, of the chemotherapeutic strategies to target PDAC are directed at the cancer 
and not the microenvironment. These findings have potentially highlighted a novel strategy 
of targeting the tumour stroma through the oligopeptide transporter in a way to increase the 
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tumour uptake. This idea is based upon a very limited patient sample size. Thus additional 
studies would be required to adequately test this possibility.  
The majority of pancreatic carcinomas have a ductal origin (Von Hoff et al., 2005) and derive 
from the same gut tube that originates the small intestinal epithelia in which PepT1 is 
expressed as an important component of dietary nutrient absorption (Fei et al., 1994; Liang 
et al., 1995). It is possible to postulate that the gene expression imprinted in a specific 
cancer cell type, in this case from pancreatic origin, may be related to its embryological 
derivation. Cancer cells derived from tissue sharing an embryological origin in the primitive 
gut tube, such as the exocrine pancreas, may overexpress PepT1 preferentially over other 
transporter systems (Mrsny, 1998). After confirming PepT1 expression and localisation in 
cancer cell lines from PDAC origin (Figure 3.1), PepT1 distribution was also confirmed for 
the first time in pancreatic tissue biopsies derived from patients diagnosed with CP and 
PDAC (Figure 3.3). In particular, an increase in PepT1 localisation at the cell surface of 
cancerous pancreatic ducts could be observed compared to what was observed in 
non-cancerous biopsies (Figure 3.4). Despite the fact that the adult pancreas is a relatively 
quiescent organ, pancreatic ducts are structures with a very active role in the neogenesis of 
the pancreas (Bardeesy and DePinho, 2002). Since PepT1 was observed to be distributed 
at the basal and lateral surfaces of cells present in morphologically altered pancreatic ducts, 
it would be likely that the chances of targeting the organ more selectively through the blood 
stream would be considerably higher. 
 
Cancer cells are metabolically more active than non-cancer cells and the high expression of 
PepT1 in some cancers has been shown to be related to an increased demand in nutrients 
required by fast growing cancer cells. Thus, inhibition of PepT1 might result in a novel 
strategy to delay or stop tumour growth. Manipulation of LATs activity has been speculated 
to have anti-cancer implications. Besides, due to the inhibition of LAT1 activity in tumour 
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cells was suggested to be effective in supressing tumour cell growth through essential 
amino acid deprivation in tumour cells (Kanai and Endou, 2001; Kim et al., 2002). Mitsuoka 
and co-workers synthesized a dipeptide, 4-(4-methoxyphenyl)-L-phenylalanyl sarcosine, 
able to inhibit PepT1 function; this resulted in the complete suppression of a xenograft 
model of human pancreatic AsPc-1 cells reported to express high levels of PepT1   
(Gonzalez et al., 1998; Mitsuoka et al., 2010).  
BCH has been described to inhibit LATs (Kim et al., 2008; Nawashiro et al., 2006). Mitsuoka 
observed the capacity of this inhibitor in inducing cell death by decreasing ATP content in 
AsPc-1 cells expressing PepT1 but failed to compare the outcome to a cell line with reduced 
or absent levels of PepT1 (Mitsuoka et al., 2010). To circumvent this, a cell line stably 
expressing reduced levels of PepT1 was created (Figure 3.5). Subsequently, differences in 
cell viability response to BCH between cells expressing PepT1 and PepT1-/- cells were 
investigated. After 48 h, PepT1 expressing cells presented a significant decrease in cell 
viability compared to PepT1-/- cells. These observations were consistent with the study 
carried out by Mitsuoka and suggested that inhibition of PepT1 might hinder AsPc-1 cell 
growth (Mitsuoka et al., 2010). Our data suggests that PepT1 might be a new target for 
suppression of pancreatic cancer cell growth (Figure 3.6). 
 
The use of specific transporters as molecular targets in cancer therapy has revealed to be a 
promising strategy for tissue-selective drug delivery, while minimizing off-targeted toxicity. 
Pro-drugs can be designed to target specific antigens, enzymes or even peptide 
transporters. This can be achieved through conjugation of a specific tumour ligand to the 
chemotherapeutic drug via a cleavable linker (Han and Amidon, 2000). Coupling amino 
acids to anti-cancer agents to make them into PepT1 substrates represents an attractive 
method for targeted drug delivery. Through expression of mammalian PepT1 in Xenopus 
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laevis oocytes as a model system, essential residues in the functioning of PepT1 have been 
identified and a substrate template model has been established (Bailey et al., 2005; Bailey 
et al., 2006; Foley et al., 2009; Foley et al., 2010; Meredith, 2009). Through a collaboration 
established with the Bailey and Meredith group from the University of Keele, it was possible 
to chemically test PepT1 substrates generated from the chemical coupling of gemcitabine 
with a specific peptide in our in vitro model for PDAC (Figure 3.7).  
 
Out of three possible chimeras, the most promising one in eliciting a reduction in cell 
proliferation and viability response was chosen and further characterised (Figure 3.8). The 
role of PepT1 involved in the uptake of gemcitabine chimera was assessed in PepT1-/- and 
PepT1 expressing cell lines. Chemically modified gemcitabine was revealed to have an 
enhanced cytotoxic effect in PepT1 expressing cell lines compared to cells in which the 
expression of the oligopeptide transporter was reduced. The calculated EC50 in the cell line 
expressing PepT1 was nearly fivefold lower (~11 μM) than in the PepT1-/- cell line (~54 μM) 
(Figure 3.9). In terms of proliferation, compound C decreased cell proliferation in a more 
pronounced manner in AsPc-1 cells when compared to cells with reduced levels of PepT1 
expression (Figure 3.10).  
 
After confirming that compound C decreased cell viability more efficiently than gemcitabine 
(Figure 3.11), competitive assays were used to examine the role of PepT1 in this outcome; 
cells treated simultaneously with compound C and a substrate for PepT1 (Gly-Sar) had 
greater level of viability compared to cells treated with compound C only. This suggested the 
potential involvement of Gly-Sar in blocking partially PepT1 uptake (Figure 3.12). Finally, the 
involvement of PepT1 in the uptake of gemcitabine chimeras was evaluated. Cell viability did 
not differ between PepT1 expressing and PepT1-/- cells after treatment with 10 mM BCH, 
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previously shown to affect cell viability through PepT1 inhibition. This data reinforced the 
role of PepT1 in the uptake of the gemcitabine chimera (Figure 3.13).  
 
The correlation between the presence of inflammation and the development of 
pre-cancerous lesions at various anatomic sites is well established (Mantovani et al., 2008).  
Accumulating evidence has defined pre-existing and longstanding CP as a pre-empting 
factor for PDAC (Howes and Neoptolemos, 2002). CP and PDAC share some similarities 
and the most striking one is the abundant desmoplastic response (Logsdon et al., 2010).  
Several studies have reported PepT1 expression in inflamed cells (Buyse et al., 2002; 
Ingersoll et al., 2012; Vavricka et al., 2006; Wang et al., 2013; Wang et al., 2011), yet there 
are no reports about PepT1 distribution in inflamed pancreatic tissue. To address this, 
PepT1 distribution was assessed in five different patients diagnosed with CP (Figure 3.3 and 
Figure 3.14). PepT1 was observed to localize at the cell surface of inflamed ducts. Despite 
the controversy, for some, CP is still one of the biggest risk factors for PDAC (Howes and 
Neoptolemos, 2002); the detection of PepT1 in inflamed biopsy samples may provide both a 
diagnostic tool and a novel way to target inflamed pancreas prior to malignant 
transformation.  
 
These findings support the idea that PepT1 might be used as a strategy to target anti-cancer 
agents as a way to increase selectivity and to minimize toxicity. In an attempt to develop an 
in vitro model of CP, epithelial-like HPAFII cells were allowed to polarise and then were 
exposed to two different cytokines (Figure 3.16). Due to lack of reproducibility, it was not 
possible to create an inflamed cell line model derived from pancreatic cancer (Figure 3.16).  
Cyclooxygenase is an enzyme responsible for mediating the conversion of arachidonic acid 
to prostanoids, including prostaglandins, prostacyclin and thromboxane, which are 
mediators of acute and chronic inflammation (Vane et al., 1998). Cox-2 plays an important 
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role in inflammation and the increased production of prostaglandins has been associated 
with tumourigenesis (Dang et al., 2002). Some studies have demonstrated that NSAIDs had 
a beneficial effect in the prevention and treatment of colon cancer and ovarian cancer  
(Kune et al., 2007; Rodriguez-Burford et al., 2002). Andrews and co-workers reported that 
ibuprofen was able to significantly supress cell proliferation in a prostate cancer cell line at 
clinically relevant concentrations (Andrews et al., 2002). So far, the use of NSAIDs for 
cancer prevention and therapy remains controversial as many clinical studies have reported 
the long-term side effects ranging from GI toxicity to cardiotoxicity; as a result many Cox-2 
specific agents have been withdrawn from the market (Rayburn et al., 2009).  
 
Through collaborative work, ibuprofen was chemically modified and attached to a thio-
dipeptide pro-drug and shown to be stable and resistant to hydrolysis                             
(Foley et al., 2009)(Figure 3.17). Firstly, the impact of Ala(S)Asp-IB in reducing cell 
proliferation was assessed in PepT1 expressing and in PepT1-/- cells. Chemically modified 
ibuprofen into PepT1 substrates had a more pronounced effect on cell proliferation and 
viability in PepT1 expressing cells compared to control cells (Figure 3.18 and Figure 3.20-A). 
These findings are consistent with the recent study carried out by Lichtenberger, in which 
ibuprofen demonstrated a direct inhibitory effect on the growth of colon cancer cells 
(Lichtenberger et al., 2014). Likewise, our findings are in line with the effect reported by 
other NSAIDs drugs in reducing cancer cell proliferation                                                    
(Hanif et al., 1996; Rodriguez-Burford et al., 2002). To assess the involvement of PepT1 in 
the uptake of Ala(S)Asp-IB, cells that were cultured in media supplemented with Gly-Sar 
showed a much higher proliferative rate compared to cells cultured in normal media; This 
suggests a blocking effect by Gly-Sar in preventing the compound uptake (Figure 3.19).  
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Cox-2 was reported to be expressed in patients with CP and PDAC and its pharmacological 
inhibition has been associated with an increased apoptotic rate in PDAC cells (Schlosser et 
al., 2002). This prompted us to differentiate Cox-2 levels in PepT1 expressing and PepT1-/- 
cells after exposure to Ala(S)-Asp-IB. A signal for Cox-2 expression was not detected in 
PepT1 expressing cells treated with Ala(S)-Asp-IB, suggesting the specific uptake and 
targeting of the chemically modified chimera. Cox-2 levels were diminished compared to the 
control, ibuprofen, in PepT1 expressing cells but not in PepT1-/- cells (Figure 3.20). 
 
Targeting cancer cells  with novel pro-drug chemotherapeutics functionally directed to 
nutrient uptake pathways has shown some promise in reducing side effects and increasing 
clinical efficiency (Cravo and Mrsny, 2013; Nakanishi, 2007) (Figure 3.21). Nonetheless, 
there are some pitfalls that need to be taken into account. Firstly, there are challenges in 
relying on membrane transporters as drug delivery targets; susceptibility to drug-drug and 
drug-endogenous ligand interaction, as well as sensitivity to changes in the 
microenvironment of the transporter as it is likely to occur in inflammation or infection, are 
two important hurdles that need to be considered (Lee, 2000).  
 
It is becoming clearer that even though some cancer cells overexpress certain cellular 
markers, it is still not known if these receptors are functional or not. PepT1 up-regulation 
could be the result of a clonal expansion from the cell line when cultured in vitro, instead of 
representing the original tumour conditions (Mrsny, 1998). Secondly, the RNA message for 
PepT1 has been reported in the small intestine, liver and kidneys, albeit the primary site for 
PepT1 expression is the intestine (Fei et al., 1994; Liang et al., 1995). The uptake of 
anti-cancer compounds using PepT1 could therefore have the potential for secondary 
toxicity in other organs where the protein is expressed. With this is mind, it could be useful to 
understand what factors drive such up regulation in cancer cells. Finally, because there are 
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specific transcription factors that induce the expression of these transporter systems in 
cancer cells, it is not known if the same drivers are also up-regulating efflux pathways, such 
as P-gp (P-glycoprotein). Needless to say, an up-regulated efflux system could limit the 
effectiveness of anti-cancer compounds delivered to these cancer cells. 
 
Important to this discussion are potential differences concerning the gene expression profile 
between cells cultured in vitro and the in vivo condition.  Many of these differences may be 
the consequence of either tumour microenvironment or stromal gene expression that well 
characterizes PDAC. As future work, to confirm the specificity of PepT1 in taking up peptide 
modified chimeras such as gemcitabine and ibuprofen, the use of PepT1 null mice would be 
a very valuable tool to prove the concept of specific drug delivery through PepT1.  
 
The importance of drug transporters in cancer biology and chemotherapy highlights the 
pivotal role of these molecules in the redesign of modern and targeted therapies. It could 
even be said that an exciting era to use these proteins as a cancer therapy tool has already 
begun. A more rational and sensible use of these molecules with unique patterns of 
expression will certainly underline the optimization of individualized cancer medicines. A 
rational drug design in combination with a rational drug delivery are factors that assume 
utmost importance and need to be integrated as major pillars sustaining an effective and 
promising cancer therapy. Until now, there is no known human pathology associated with 
the abnormal function of peptide transporters and no polymorphisms in human peptide 
transporters have been shown either. Understanding the mechanisms underlying the 
regulation of PepT1 will certainly be a key factor for the prediction of intra and inter individual 
variability of the compounds bioavailability, maximizing their efficacy ultimately. 
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Here, it was demonstrated that PepT1 is up-regulated in cancer cell lines compared to 
normal cells and in inflamed and malignant pancreatic human biopsies compared to normal 
tissue. This work suggested that a differential expression of transporters in cancers can be 
exploited for drug delivery or even used as diagnostic markers in the treatment or prevention 
of PDAC. In order to optimize efficacy versus safety outcomes, further work will need to be 
carried out to fully address this concept.  
 
 
Figure 3.21 Diagram representing the pro-drug uptake model through PepT1 transporter 







































As part of their differentiation, epithelial cells polarise into apical and basal domains 
following their adjacent cell-cell contact. This differentiated organization functions to restrict 
lateral expansion, which is reflected in cell size, shape and proliferative properties. 
Differentiated cells have an apical-basal polarity defined by the apical membrane facing the 
outside surface of the body, or the lumen of internal cavities, and the basolateral membrane 
oriented away from the lumen (St Johnston and Ahringer, 2010). Lateral membrane 
interactions formed by AJs and the generation of apical-basal polarity appear to precede the 
initiation of TJ formation (Sawada, 2013). TJ complexes are composed of a branching 
network of independent sealing strands (Gonzalez-Mariscal et al., 2003). Each strand is 
formed by transmembrane proteins embedded in both plasma membranes and the 
extracellular domains interacting in homotypic and heterotypic contacts with TJ proteins of 
the adjacent cell (Tsukita et al., 2001). The establishment of TJ at the uppermost portion of 
the plasma membrane is the result of a polarised insertion of proteins; apical to basolateral 
polarity is required for restriction of plasma membrane components and for limiting the 
solute flux between adjacent cells. Three main conserved protein complexes are involved in 
the maintenance and establishment of the apical-basal polarity: Crumbs, PAR and Scribble 
(Benton and St Johnston, 2003; Bilder and Perrimon, 2000; Ebnet et al., 2001).  
Fence and barrier function are two well-established properties of TJ (Rescigno et al., 2001); 
the other concerns the involvement of TJ molecules in the regulation of signaling 
transduction pathways (Balda and Matter, 2009). Of particular interest to this work is the 
possible TJ role as a platform that integrates Hpo pathway phosphorylation events. YAP and 
TAZ gene mutations have been demonstrated in several human epithelial cancers and 
YAP/TAZ over-expression in mammalian cells can trigger a plethora of oncogenic events 
(Sudol et al., 2012). Disrupted regulation of Hpo pathway elements, in particular YAP, 
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correlates with loss of epithelial cell crowding control leading to deregulated proliferation, a 
hallmark of epithelial cancers (Pan, 2010; Poon et al., 2011). Mutation at the 
phosphorylation site Ser127 in the YAP gene serves as a signal for the translocation of YAP 
to the nucleus where it binds to a transcription factor element, TEAD, which is responsible to 
drive the transcription of genes involved in promoting growth promoting and anti-apoptotic 
programs (Zhao et al., 2008). Thus, YAP/TAZ actions provide a means for individual cells 
within an epithelial sheet to monitor their cell density and polarity status.  
A critical aspect of assuring reproducible cell density and polarity conditions requires 
mechanisms to sense the status of individual cells in the context of the epithelial sheet. 
Interactions between Hpo pathway elements and components of the APC and the AJ have 
been reported (Rajasekaran et al., 2004). Yet, E-cadherin localised at the AJ has been the 
only cell-cell contact sensor shown to be involved in the regulation of YAP and suppressing 
epithelial cell proliferation at high lateral cell density (Schlegelmilch et al., 2011). Therefore, 
it is reasonable to hypothesise that a TJ element would be involved in a feedback sensor 
mechanism to coordinate the completion of apical-basal polarity program with the 
suppression of cell proliferation coordinated by Hpo signaling. Indeed, it has already been 
hypothesised as an extracellular sensor able to detect competent TJs (Nusrat et al., 2005).  
The aim of this chapter is to examine a possible link between the TJ protein Ocln and 
elements of the Hpo pathway that could provide a novel mechanism to control epithelial cell 
polarization in pancreatic cancer cells. Besides, this chapter also aims at analyzing the 
distribution of Hpo pathway elements in CP and PDAC. Finally, this work also explored if 
dobutamine, previously shown to induce YAP nuclear translocation, can affect Ocln 
expression and function (Cravo, et al., 2014, submitted).  To address this, an epithelial cell 
line able to undergo apical-basal polarization (HPAFII) and another cell line that cannot 
(AsPc-1) were studied.  
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4.2 Materials and methods 
4.2.1 Immunohistochemistry 
 
Histological slides from fifteen human biopsies from five different patients (five from normal 
tissue, five from patients with CP and five from patients diagnosed with PDAC) were 
analysed for Ocln, YAP, TEAD and c-Yes distribution levels. Paraffin tissue sections were 
prepared according to section 2.10, Chapter 2. For antigen detection, slides were subjected 
to an overnight incubation in a humid chamber at 4 °C with antibodies recognizing Ocln, 
YAP, TEAD and c-Yes (Table 2.6 , Chapter 2) diluted 1:100. The control antibody used was 
rabbit antisera (Table 2.6, Chapter 2). After slides were mounted on DePex, they were 
allowed approximately 12 h to dry out; subsequently slides were examined as described in 




AsPc-1 (passage 14), and HPAFII  (passage 10) cells were grown on coverslips reaching up 
to 50 % confluency (generally 2 days for AsPc-1 and 5 days for HPAFII cells). For 
co-localisation experiments, after cells were fixed and permeabilised as described in section 
2.9, Chapter 2, they were subjected to 1 h incubation exposed to simultaneously YAP and       
c-Yes, Ocln and c-Yes, Ocln and YAP and finally Ocln and TEAD (Table 2.6, Chapter 2) at   
4 °C. Afterwards cells were washed and incubated with the appropriate secondary antibody 
at a 1:400 dilution (Table 2.6, Chapter 2). Subsequently, slides were mounted and analysed 
through confocal microscopy as described in section 2.9, Chapter 2. 
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4.2.3 Immunoprecipitation and Western Blot 
 
 For immunoprecipitation assay, AsPc-1 and HPAFII, passages 17 and 14 respectively, 
were lysed as described in section 2.4, Chapter 2. Whole cell lysates containing 
approximately 500 μg of protein were incubated with a pull-down antibody, YAP, (Table 2.6, 
Chapter 2) overnight at 4°C. Proteins were then isolated and analysed through Western Blot 
as outlined in section 2.6, Chapter 2. Five PSC lysates, obtained from Dr. Mert Erkan from 
The Technical University of Munich, were collected for YAP protein expression levels (three 
samples were isolated from patients diagnosed with PDAC and two from patients with CP).  
Lysates were then subject to Western Blot following the protocol outlined in section 5.1, 
Chapter 2.  
 
4.2.4 Cell culture, and TER measurements 
 
AsPc-1 (passage 9) and HPAF II (passage 8) cell lines were obtained from ATCC© and 
cultured as described in section 2.1, Chapter 2. TER measurements were carried out daily 
and performed as mentioned in section 2, Chapter 2. 
 
4.3 Results 
4.3.1 Ocln expression decreases and YAP expression increases with pancreatic 
cancer progression 
 
TJs provide a coherent cell-cell adhesion structure acting as a barrier to the initiation and 
progression of cancer (Brennan et al., 2010). A hallmark of aggressive epithelial cancers, 
such as those derived from pancreatic acini and ducts, is loss of functional cell-cell contacts 
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(Hezel et al., 2006). The distribution of the TJ marker, Ocln, was assessed in inflammation 
and pancreatic cancer (Figure 4.1 – top panel and Figure 4.2). Ocln expression in 
non-inflamed and in non-cancerous pancreatic tissue, localised essentially at the cytoplasm 
and at the apical surface of ducts. In PDAC tissue, however, Ocln staining appeared to be 
substantial but did not distribute at the plasma membrane (Figure 4.2). 
 
Figure 4.1 Ocln distribution in five histologically defined tissues representing the various 
stages of progression from normal pancreas through CP and PDAC. Weak to moderate Ocln 
staining intensity and moderate to strong YAP staining intensity was observed in PDAC biopsies. 
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Figure 4.2 Ocln distribution decreases progressively in human pancreatic inflammation and 
cancer; Immunohistochemistry analysis of 15 human pancreatic biopsies (5 patients with normal 
pancreas, 5 patients with CP and 5 patients with PDAC) immunostained for Ocln; Insets with higher 
magnification of specific tissue regions are presented and black arrows are pointing at specific 
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The Hpo tumour suppressor pathway regulates cell proliferation and apoptosis in the context 
of establishing and maintaining proper lateral (planar) cell polarity that defines cell density 
within an epithelium (Martin-Belmonte and Perez-Moreno, 2012). YAP interacts with specific 
transcription factors to promote cell proliferation, organ growth and survival                    
(Shao et al., 2014a). Disrupted regulation of Hpo pathway elements, in particular YAP, 
correlates with epithelial cell transformation (Pan, 2010; Poon et al., 2011). Since YAP was 
observed to be continuously overexpressed in inflammation (Figure 4.1 – bottom panel) and 
also in PDAC biopsy samples, YAP distribution from five different patients was analysed 
(Figure 4.3). YAP expression in normal pancreatic epithelial cells was detected mostly in the 
cytoplasm of acinar and ductal cells with minimal nuclear staining observed whereas in 
inflammation and more markedly in cancer, a strong nuclear signal could be observed. In 
cancer biopsies, strong YAP staining was detected in PanIN lesions; YAP was 
predominantly distributed in the nucleus, however some cytoplasmic expression could be 
observed in both inflamed and cancerous conditions.  
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Figure 4.3 YAP distribution increases progressively from human pancreatic inflammation to 
pancreatic cancer; Immunohistochemistry analysis of 15 human pancreatic biopsies (5 patients with 
normal pancreas, 5 patients with CP and 5 patients with PDAC) immunostained for YAP; Insets with 
higher magnification of specific tissue regions are presented and black arrows are pointing at specific 
immuno-labelling; scale bar, 50 µm. 
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PSC take an important role in controlling the tumour microenvironment in pancreatic cancer 
(Omary et al., 2007), yet there are no studies reporting YAP activity in these cells. We 
sought to analyze YAP expression levels and correlated it with data obtained from the 
biopsy samples. YAP was detected in at least two patients diagnosed with PDAC and 
absent levels were observed in pancreatic inflammation (Figure 4.4). The results obtained 
from patients diagnosed with CP were not consistent with the biopsy samples analysed as a 
weak to moderate staining was obtained for the five patients diagnosed with CP. However, 
due to this limited set of patients, no further conclusions can be drawn. 
 
 
Figure 4.4 YAP expression was detected in PSC lysates from two patients diagnosed with 
PDAC but not in patients with CP. Immunoblot showing YAP levels in PSC lysates collected from 
patients diagnosed with either PDAC or CP. 
 
4.3.2 Nuclear TEAD expression increases in PDAC 
 
The Hpo signaling cascade regulates planar cell polarity and, in turn, controls cell 
proliferation and survival pathways (Pan, 2010). Translocation of YAP from the nucleus to 
the cytoplasm with its subsequent phosphorylation and degradation is correlated with 
suppression of cell proliferation (Pan, 2010). YAP does not contain an intrinsic DNA-binding 
domain but instead regulates target genes by interacting with DNA-binding transcription 
factors in the nucleus (Yu and Guan, 2013). One of these transcription factors is the 
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TEA-domain family member TEAD, regarded as the most potent targets of YAP, which 
functions to activate cell proliferation processes (Bao et al., 2011; Vassilev et al., 2001). To 
investigate TEAD tissue distribution and localisation, human pancreatic biopsies from five 
different patients diagnosed with either CP or PDAC were analysed and compared to normal 
tissue. TEAD labelling in normal pancreas was restricted to the cytoplasm and very minor 
amounts could be observed in the nucleus. In CP, TEAD signal was stronger compared to 
non-inflamed and non-cancerous biopsies. PDAC tissue showed some cytoplasmic staining 
but more strikingly an extensive nuclear localisation (Figure 4.5). 
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Figure 4.5 Nuclear TEAD distribution increases progressively in human pancreatic 
inflammation and cancer; Immunohistochemistry analysis of 15 human pancreatic biopsies (5 
patients with normal pancreas, 5 patients with CP and 5 patients with PDAC) immunostained for 
TEAD; Insets with higher magnification of specific tissue regions are presented and black arrows are 
pointing at specific immuno-labelling; scale bar, 50 µm. 
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4.3.3 Ocln co-localises with Hpo pathway elements in HPAFII and AsPc-1 cells 
grown at low density  
 
Despite the fact that Ocln was the first integral membrane protein identified                  
(Furuse et al., 1993) acting in the organization and dynamic function of the tight junction, 
recent studies have been showing that it does not have a critical role in barrier function; 
mice lacking Ocln can produce an efficient barrier function through claudin-based TJs. Still, 
the Ocln knockout mice have a peculiar phenotype characterized by bone thinning, brain 
calcifications, stunted growth, and others (Saitou et al., 2000). Past studies have shown that 
down-regulation and epigenetic silencing of Ocln correlates with cancer progression   
(Osanai et al., 2006; Tobioka et al., 2004a; Tobioka et al., 2004b). In addition, loss of Ocln 
expression or disruption has been observed to correlate with epithelial cell transformation 
(Sawada, 2013). The coiled coil domain of Ocln interacts selectively with c-Yes and 
interactions between c-Yes and Ocln appear essential for TJ formation (Chen et al., 2002b; 
Nusrat et al., 2000). As c-Yes is a bona fide binding partner of YAP which in turn plays a 
critical role in Hpo signaling and associates with the cytoskeleton organized at TJ structures 
(Aragona et al., 2013), we conjectured that this integral plasma membrane protein involved 
in cell-cell contacts could function as a potential sensor to coordinate lateral (planar) and 
apical-basal epithelial cell polarity with proliferation control through the Hpo pathway.  
In humans, the phenotype for mutations in Ocln is restricted to the brain, again suggesting 
some functional redundancy for Ocln. Thus, essential Ocln function(s) imparting these 
phenotypes would seem to involve cell processes beyond the establishment of the epithelial 
barrier. Important to this discussion is the fact that Ocln-/- mice exhibit chronic inflammation 
and hyperplasia of their gastric epithelium, indicating that Ocln is involved in epithelial 
differentiation (Furuse, 2009). Epithelial inflammation is associated with reduced barrier 
function and the internalization of TJ proteins, such as Ocln, although it has minimal effects 
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on the cytoplasmic plaque proteins and cytoskeleton associated with TJ structures   
(Bruewer et al., 2003). Importantly, YAP-mediated Hpo signaling can occur through the 
cytoskeleton (Aragona et al., 2013) and epithelial cancers involving dysfunctional Hpo 
pathway elements have been identified (Pan, 2010).  
While the location of polarity elements and many of their interactions have been established 
for polarised epithelia, the identification of Ocln as a sensor for Hpo pathway signaling 
provides an important link for TJ signaling to control the balance between epithelial cell 
proliferation versus polarization. We first characterized potential protein-protein associations 
in HPAFII, capable of undergoing apical-basal polarization, grown on plastic as small 
clusters where nascent and lateral cell-cell contacts had been established. Through confocal 
analysis and specialised co-localisation software, we examined the interactions between 
YAP and c-Yes, Ocln and c-Yes, Ocln and YAP and finally Ocln and TEAD in HPAFII and 
AsPc-1. YAP and c-Yes, previously shown to interact (Sudol, 1994), were observed to 
co-localise extensively at the cell membrane and cytoplasm but not in the nucleus of    
HPAFII cells (Figure 4.6 - A1). Ocln and c-Yes co-localised in large aggregates at the cell 
membrane and in regions adjacent to the nucleus but these occurred to a lesser extent than 
c-Yes and YAP and showed similarities to the Ocln and YAP distribution: mostly cytoplasmic 
interactions (Figure 4.6 – A2). Ocln and YAP co-localised essentially at the external facing 
surfaces of these cell aggregates, although less striking relative to Ocln/c-Yes and 
c-Yes/YAP interactions. Interestingly, higher magnification analysis showed TEAD/Ocln 
co-localisations to be diffusely distributed throughout the cytoplasm and many of these 
interactions were incomplete in their overlap (Figure 4.6 - A4), unlike the more complete 
overlay observed for c-Yes/Ocln, c-Yes/YAP, and YAP/Ocln co-localisations 
(Figure 4.6 - A1-A3). There was also a similar cytoplasmic and possibly some nuclear 
co-localisation observed for Ocln and TEAD, with limited interactions at the cell surface 
(Figure 4.6 - A4). Following this, the interactions between Ocln and Hpo pathway elements 
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were examined in the AsPc-1 cell line, known for its aggressive growth and inability to form 
functional TJ (Tan and Chu, 1985). When grown at low cell density as previously described 
for HPAFII cells (Figure 4.6), AsPc-1 cells expressed Ocln at levels comparable to or even 
greater than those observed in HPAFII cells with some immunofluorescence being 
associated with the plasma membrane (Figure 4.7-A1). Previously shown to be associated 
with carcinogenesis (Barraclough et al., 2007), the interactions between YAP and the    
proto-oncogene c-Yes appeared to occur mostly in the cytoplasm and not in the nucleus. 
Ocln and c-Yes co-localised predominantly at the membrane similarly to that observed in 
HPAFII cells (Figure 4.7 - A2). YAP and Ocln interactions occurred almost exclusively in 
large aggregates at the plasma membrane and in the nucleus of AsPc-1 cells, different from 
that observed for HPAFII cells (Figure 4.7 - A3). This was further confirmed by an 
immunoprecipitation assay that showed an interaction between YAP and Ocln at the cell 
membrane of aggressively growing AsPc-1 cells but not in HPAFII cells (Figure 4.8). 
Furthermore, another striking difference between HPAFII and AsPc-1 cells was primarily 
related to YAP and TEAD distribution with a much greater relative expression in the nucleus 
of the aggressively growing AsPc-1 cells (Figure 4.7 - A4). TEAD/Ocln interaction was 
almost non-existent and failed to show cytoplasmic co-localisations as observed in HPAFII 
cells.   
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Figure 4.6 Distribution and Co-localisation of YAP, c-Yes, Ocln, and TEAD in HPAFII cells in 
vitro. (A) Immunofluorescent distribution and confocal co-localisation of YAP and c-Yes (A1), Ocln 
and c-Yes (A2), Ocln and YAP (A3), and Ocln and TEAD (A4). Higher magnifications of                   
co-localisations are presented (A1-4). Graphs showing overlapping fluorescence intensity are 
presented below with the associated micrograph with red line denoting path of analysis; scale bar,    
20 μm. 
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Figure 4.7 Distribution and Co-localisation of YAP, c-Yes, Ocln, and TEAD in AsPc-1 cells in 
vitro. (A) Immunofluorescent distribution and confocal co-localisation of YAP and c-Yes (A1), Ocln 
and c-Yes (A2), Ocln and YAP (A3), and Ocln and TEAD (A4). Higher magnifications of co-
localisations are presented (A1-4). Graphs showing overlapping fluorescence intensity are presented 
below with the associated micrograph with red line denoting path of analysis; scale bar, 20 μm. 
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Figure 4.8 Co-localisation of Ocln and YAP at the cell membrane of aggressive growing    
AsPc-1 cells. Immunoprecipitation of YAP followed by an immunoblot analysis for Ocln in 
cytoplasmic and membrane fractions of AsPc-1 and HPAFII cells. Abbreviations: Cyt (Cytosolic 
fraction); Memb (Membrane fraction). 
 
4.3.4 Dobutamine treatment induced the redistribution of functional Ocln in HPAFII 
cells 
 
Subcellular localisation of YAP is critical for Hpo pathway regulation (Boggiano and Fehon, 
2012; Zhao et al., 2007). The Hpo pathway responds to cell density and regulates YAP 
phosphorylation, preventing its translocation into the nucleus where it functions as a 
transcriptional co-activator (Zhao et al., 2007). As previously mentioned, Bao and               
co-workers suggested that dobutamine was able to induce YAP phosphorylation at Ser127 
inhibiting YAP-mediated gene transcription in osteoblastoma cells (Bao et al., 2011). Since 
the Hpo pathway is activated by different upstream molecular signals including cell-cell 
contact and cell polarity molecules (Yu et al., 2012), we asked whether dobutamine 
treatment could affect the cellular distribution or function of the TJ marker Ocln based upon 
the observed YAP/Ocln interactions and as a consequence of shifting YAP cell distribution. 
To test this, HPAFII cells were subjected to 10 and 20 μM dobutamine as a single treatment 
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during 24 h. HPAFII cells grown at high cell density on plastic to provide extensive cell-cell 
contacts and treated with dobutamine resulted in a dose-dependent shift of YAP 
immunofluorescence from the nucleus to the cytoplasm relative to controls. This event was 
associated with Ocln stabilization at the plasma membrane (Figure 4.9 – A). Western Blot 
analysis of isolated cytoplasm and nuclear fractions (Figure 4.9 - B) demonstrated a striking 
reduction in nuclear YAP content following dobutamine treatment, presumably through its 
redistribution to the cytoplasm where it is phosphorylated and degraded (Chan et al., 2011). 
Dobutamine treatment in this cell system also produced a dramatic loss of nuclear TEAD 
with the remaining TEAD being notable for its apparent co-localisations with Ocln at the 
plasma membrane in a punctate pattern (Figure 4.10 – A, white arrows pointing at              
co-localisation regions and Figure 4.10-B).  
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Figure 4.9 Dobutamine induces YAP translocation from the nucleus and stabilization of Ocln 
at the cell membrane of HPAFII cells. (A) Confocal immunofluorescence microscopy showing YAP 
and Ocln distribution in HPAFII cells. Cells treated with 10 or 20 µM dobutamine for 24 h were 
similarly analysed for YAP and Ocln cell distribution. Scale bar, 20 μm; (B) Immunoblot analysis of 
total YAP in nuclear and cytoplasmic fractions of HPAF II cells as a consequence of 10 or 20 μM 
dobutamine (Dob) exposure. HDAC (histone deacetylase) and β-actin were used as loading controls 
for nuclear and cytoplasmic fractions, respectively. Abbreviations: Dob. - Dobutamine; 
Cyt - Cytoplasm; Nucl. - Nucleus. 
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Figure 4.10 Dobutamine induces TEAD translocation from the nucleus and stabilisation of 
Ocln at the cell membrane of HPAFII cells. (A) Confocal immunofluorescence showing TEAD and 
Ocln distribution in HPAFII cells with control buffer addition versus 20 µM dobutamine for 24 h; scale 
bar, 20 μm. (B) Immunoblot analysis of TEAD in the nuclear fractions of HPAFII cells as a 
consequence of 10 or 20 μM dobutamine exposure. Quantification of TEAD expression values are 
mean of 3 independent experiments ± SEM; *p < 0.05. Abbreviations: Dob. – Dobutamine. 
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4.3.5 Dobutamine-induced redistribution of Ocln has functional consequences 
 
Past studies showed that Ocln immunoprecipitates and co-localises with non-receptor 
tyrosine kinase c-Yes (Chen and Lu, 2003). Further to this, the same study showed that 
treatment of MDCK cells with a c-Yes inhibitor disrupted the Ocln/c-Yes complex inhibiting 
the phosphorylation of Ocln required for TJ formation (Chen et al., 2002b). Initially, we 
sought to analyze c-Yes distribution in pancreatic tissue biopsies from patients diagnosed 
with CP and PDAC compared to normal pancreatic tissue sections. In normal 
(non-cancerous, non-inflamed) pancreas, c-Yes was distributed in the cytoplasm and in 
small amounts at the apical plasma membrane of ducts as pointed by the black arrows 
(Figure 4.11). A moderate to strong nuclear c-Yes staining was observed in pancreatic 
cancer tissue biopsies and a strong signal was also detected at the apical surface of 
epithelial cells as indicated by the black arrows (Figure 4.11), which agrees with the 
distribution of this non-receptor tyrosine kinase in AsPc-1 cells (Figure 4.7 - A1, A2).   
 
Next, it was investigated whether dobutamine could affect c-Yes cellular distribution to align 
it with Ocln expression at these external faces; c-Yes distribution was monitored after 
exposing cells to 10 and 20 µM dobutamine during 24 h. Treatment of HPAFII cells grown at 
low cell density caused a dose-dependent shift of c-Yes from the cytoplasm to the plasma 
membrane. Concomitant with this shift, there was an increase in co-localisation and 
association between c-Yes and Ocln at the plasma membrane (Figure 4.12 - A, B). 
Presumably this phenomenon happened through translocation of YAP from the nucleus to 
the cytosol. These results are consistent with previous findings suggesting that c-Yes is 
associated with Ocln at assembling TJ structures but is dissociated from Ocln at times when 
TJ structures are disassembling  (Chen et al., 2002b). Thus, suppression of YAP 
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translocation to the nucleus appears to allow for more c-Yes-Ocln associations in HPAFII 
cells that are able to polarise.  
 
Figure 4.11 Nuclear c-Yes distribution increases progressively in CP and in PDAC human; 
Immunohistochemistry analysis of 15 human pancreatic biopsies (5 patients with normal pancreas, 5 
patients with CP and 5 patients with PDAC) immunostained for c-Yes; Insets with higher 
magnification of specific tissue regions are presented and black arrows are pointing at specific 
immunolabelling; scale bar, 50 µm. 
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Figure 4.12 Redistribution of Ocln and c-Yes in HPAFII cells following dobutamine treatment.  
(A) Confocal microscopy showing c-Yes and Ocln distribution in HPAFII cells. Cells were treated with 
10 or 20 µM dobutamine for 24 h period prior to c-Yes and Ocln cell distribution analysis.              
Scale bar, 20 μm. (B) Immunoprecipitation of Ocln followed by an immunoblot analysis for c-Yes in 
nuclear, cytoplasmic, nuclear and membrane fractions of non -treated HPAFII cells (top panel) and 
after 20 μM dobutamine exposure (bottom panel). Abbreviations: Nucl (Nuclear fraction); Cyt 
(Cytosolic fraction); Memb (Membrane fraction); WCL (Whole cell lysate).  
 
Besides Ocln, two other MARVEL family proteins localize to TJ structures: MARVELD2 
(Tric) and MARVELD3 (Md3) (Mariano et al., 2011). As previously mentioned, 
Raf1-mediated induction EMT was associated with the loss of functional TJ structures and 
EMT could be reversed by the re-introduction of Ocln (Li and Mrsny, 2000). Similar to Ocln, 
down-regulation of Md3 is associated with EMT in pancreatic cancer cells; Ocln and Md3 
strongly co-localise at bi-cellular contacts (Kojima et al., 2011). Knock-down studies of Tric, 
localised to tri-cellular contacts, suggest it to have a more directed role at the size-selective 
property of TJ barriers rather than EMT events (Mariano et al., 2011).  
 
As Tric is involved in the establishment of functional TJs, the impact of dobutamine on Tric 
organization in HPAFII cells that had begun forming cell-cell contacts was examined. 
Untreated HPAFII cells demonstrated co-localised Ocln-Tric that was predominantly 
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distributed at both internal cell-cell contact sites and at cell surfaces of the external face of 
these cell colonies (Figure 4.13 – A). Dobutamine treatment resulted in the exclusion of Tric 
from bi-cellular contact faces that were not dominated by Ocln. Interestingly, Ocln-Tric was 
still observed to co-localise at the externally directed cell surfaces of these cell colonies. 
Immunoprecipitation studies confirmed that following dobutamine treatment, Tric 
associations with Ocln at the cell membrane were diminished compared to non-treated cells 
(Figure 4.13 –B). Our data shows that Tric expression shifts from bi-cellular to tri-cellular 
contacts after treatment with dobutamine results in the enhanced expression of Ocln. The 
lack of Tric restriction at externally directed cell surfaces suggests that cell-cell contacts are 
required in these HPAFII cells to allow Ocln to affect Tric localisation at the plasma 
membrane. Our data is consistent with that of others who have described the ability for Ocln 
to drive Tric from bi-cellular to tri-cellular contact sites (Ikenouchi et al., 2005). What is novel 
about this finding is that suppression of Hpo pathway signaling allowed for this segregation 
of Tric localisation. Here, it is important to note that c-Yes was also observed to localize 
more predominantly with Ocln at bi-cellular contacts than with this kinase at externally 
directed cell surfaces of these cell colonies.  
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Figure 4.13 Restriction of Tric to tri-cellular contacts after dobutamine treatment. (A) Confocal 
images showing distribution of Ocln and Tric in HPAFII cells treated with 20 μM dobutamine for         
24 h. Scale bar, 20 μm. (B) Immunoprecipitation of Ocln followed by an immunoblot analysis for Tric 
in nuclear, cytoplasmic and membrane fractions of HPAFII cells following 20 μM dobutamine 
exposure. Abbreviations: Nucl (Nuclear fraction); Cyt (Cytosolic fraction); Memb (Membrane 
fraction). 
 
4.3.6 Dobutamine accelerates and enhances epithelial cell apical-basal polarization 
 
We next asked if the translocation of Ocln from the cytoplasm to the plasma membrane as a 
result of dobutamine treatment could be associated with functional TJ structures          
(Figure 4.9). Confluent cultures of HPAFII cells grown on plastic and treated with 
dobutamine demonstrated subtle changes in phenotype consistent with an increasing extent 
of cell-cell contacts without striking differences in cell number, size, or shape                
(Figure 4.14 - A-C). HPAFII cells were then grown as confluent monolayers on permeable 
supports to allow their complete apical-basal polarization; this resulted in the establishment 
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of polarised sheets with TER values of ~300-500 Ώ.cm2 by day 8 of culture (Figure 4.14-D). 
Addition of dobutamine accelerated and enhanced the TER values of HPAFII cell sheets in a 
dose-dependent manner with TER values increasing to as high as ~4,000 Ώ.cm2              
(Figure 4.14 - D) but plateauing at ~1,700 Ώ.cm2 (Figure 4.14 - E). Ocln protein distribution 
in polarised sheets of HPAFII cells, assessed by confocal immunofluorescence, 
demonstrated the localisation of this protein across the apical surface and at TJs located at 
the apical neck of adjacent cells; dobutamine treatment resulted in an apparent increase in 
total Olcn levels and a consolidation of this protein at TJs relative to its expression across 
the apical surface (Figure 4.14 - F).  Immunoblot analysis verified that dobutamine treatment 
increased total cellular Ocln levels (Figure 4.14 – G and H).  
 
Further to this, the condition of Ocln redistribution as a consequence of dobutamine 
treatment was also investigated. Immunoblot analysis showed that Ocln associated with the 
membrane fraction of polarised HPAFII cells treated with dobutamine had an increased 
relative molecular weight (Figure 4.14 - I), consistent with an increased phosphorylation 










Figure 4.14 Dobutamine treatment of polarised cell sheets of HPAFII cells. Bright field light 
micrograph of confluent HPAFII cells grown on plastic without treatment (A), or after 24 h exposure to 
10 μM dobutamine (B) or 20 μM dobutamine (C); scale bar, 50 μm. TER values of HPAFII cell sheets 
cultured on permeable supports in the absence or presence of dobutamine (D); TER values acquired 
on day 10 – note this is a separate study from data shown in (E).  Z-stacks of non-treated polarised 
HPAF II cells (top panel) or HPAFII monolayers exposed to 10 μM or 20 μM of dobutamine (middle 
and bottom panel respectively) red (Ocln), blue (cell nuclei) (F); Immunoblot for total Ocln in HPAFII 
cell monolayers at day 10 (G); Quantification of total Ocln in HPAFII cells at day 10 culture comparing 
non-treated with cells exposed to dobutamine; values are mean of 3 independent experiments ± 
SEM; * p<0.05 (H) Immunoblot for Ocln in HPAFII cells present in isolated fractions before and after 
treatment with dobutamine (I). Abbreviations: Nucl (Nuclear fraction); Cyt (Cytosolic fraction); 
Memb (Membrane fraction). 
 
Subsequently, the enhanced level of Ocln at the plasma membrane was also observed to be 
associated with the formation of rosettes that resemble primitive lumen organizations in 
HPAFII cells cultured in a 2-D cell model (Figure 4.15). 
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Figure 4.15 Formation of “luminal-like” structures after HPAFII cells were treated with 
dobutamine for a 24 h period; Confocal images showing a progressive decrease in YAP nuclear 
signal and the formation of “rosette” structures (pointed by the white arrows) after HPAFII cells were 
treated with dobutamine; scale bar, 20 μm. 
 
4.3.7 Dobutamine affects cellular distribution of YAP, Ocln, c-Yes and TEAD in 
AsPc-1 cells 
 
Dobutamine actions were then examined in an epithelial pancreatic cancer cell line that 
does not demonstrate apical-basal polarization in vitro: AsPc-1. Treatment of AsPc-1 cells 
with dobutamine increased Ocln expression and directed its distribution to the plasma 
membrane, similar to that observed in HPAFII cells (Figure 4.16).  An increase in the extent 
of c-Yes-Ocln interactions in large structures could also be observed at or near the plasma 
membrane, similar to HPAFII cells (Figure 4.17). Western Blot also confirmed increased 
Ocln and c-Yes interactions at the cell membrane after dobutamine treatment. As expected, 
dobutamine caused a loss of nuclear YAP and TEAD in AsPc-1 cells as seen with HPAFII 
cells (Figure 4.18), but in these cases there were no observed YAP-Ocln or TEAD-Ocln 
co-localisations at the cell surface as detected in HPAFII cells (Figure 4.10-A).  
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Figure 4.16 YAP trans-locates to the cytoplasm and Ocln formation gets stabilized at the cell 
membrane of AsPc-1 cells; Confocal images showing YAP trans-location from the nucleus to the 
cytoplasm and Ocln formation at the cell membrane after cells were treated with 10 and 20 μM 
dobutamine for a 24 h period compared to non-treated cells. Scale bar, 20 μm. 
 
 
Figure 4.17 c-Yes trans-locates from the cytosol to the cell membrane of AsPc-1 cells. (A) 
Confocal images showing co-localisation of Ocln and c-Yes as cells are treated with 10 and 20 μM 
dobutamine for a 24 h period. Scale bar, 20 μm; (B) Immunoprecipitation of Ocln followed by an 
immunoblot analysis for c-Yes in nuclear, cytoplasmic, and membrane fractions of non-treated    
AsPc-1 cells (top panel) and 20 μM dobutamine treated (bottom panel). Abbreviations: Nucl. – 
Nuclear fraction; Cyt. – Cytosolic fraction; Memb. – Membrane fraction; WCL – Whole cell 
lysate input. 
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Figure 4.18 Nuclear TEAD signal gets reduced after dobutamine treatment in AsPc-1 cells; 
Confocal images showing a progressively weaker nuclear TEAD labelling as cells are treated with 10 
and 20 μM dobutamine for a 24 h period. Scale bar, 20 μm. 
 
4.3.8 Dobutamine treatment affected differently CRB3 cell distribution and the extent 
to which it co-localised with Ocln in HPAFII and AsPc-1 cell lines 
 
The Crumbs Polarity Complex (CPC) is involved in the monitoring of apical to basolateral 
polarity of an epithelial cell (Tepass, 1996), however this complex is not known to establish 
robust cell-cell contacts that could provide the basis for monitoring lateral cell density that 
precedes the formation of TJ structures. CRB3 functions as a membrane element that 
participates in the polarity complex through interactions with PAR-6 via TJ-associated 
PALS1 and is associated with TJs at the apical surface of epithelial cells                  
(Lemmers et al., 2004). Thus, CRB3 would be a likely candidate to function as an external 
sensor for cell-cell contact events associated with apical-basal polarity events. We asked the 
question of whether the potential interaction of Ocln with polarity complexes might be 
integrated into the way this MARVEL protein interacts with YAP. Immunofluorescence 
studies demonstrated CRB3 and Ocln to be separately dispersed through the cytoplasm and 
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at the plasma membrane of non-polarised HPAFII cells. Some co-localisation between 
CRB3 and Ocln labelling was observed in the nucleus of these cells. Most strikingly, CRB3 
distribution and interactions with Ocln differed between HPAFII and AsPc-1 cells. In HPAFII, 
CRB3-Ocln co-localisations were limited to some overlapping fractions of small vesicles and 
were not affected substantially by dobutamine treatment (Figure 4.19-A). Oppositely,    
CRB3-Ocln interactions were extensive in AsPc-1 cells, which shifted from large aggregates 
near the plasma membrane to a more uniform distribution across the plasma membrane 
following dobutamine treatment (Figure 4.19-B). These results suggested that CRB3 
redistribution followed that of Ocln changes induced by dobutamine in AsPc-1 cells but not 
in HPAFII cells. 
 
Figure 4.19 CRB 3 does not co-localise with Ocln at the cell membrane of HPAFII cells. 
Confocal images showing different cell distribution of CRB3 and Ocln in HPAFII (A) and in AsPc-1 
(B). Scale bar, 20 μm. 
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4.4 Summary of results 
 
 Ocln tissue staining decreases and YAP tissue staining increases with pancreatic 
cancer progression; 
 Nuclear TEAD tissue expression increases in PDAC; 
 Ocln co-localises with Hpo pathway elements in HPAFII and AsPc-1 cells grown at 
low density;  
 Dobutamine treatment induced the redistribution of functional Ocln in HPAFII cells; 
 Dobutamine affects cellular distribution of YAP, Ocln, c-Yes and TEAD in AsPc-1 
cells; 
 Dobutamine treatment differently affected CRB3 cell distribution and the extent to 




The Hpo pathway provides important growth regulation of polarizing epithelia through an 
interaction between the Crumbs complex and YAP (Varelas et al., 2010). These studies 
were a landmark in that they set YAP at the location of apical neck of polarizing epithelial 
cells where interactions with proteins such as PALS1, PATJ, MUPP1, LIN7C, and AMOT 
could couple cell density regulation with the establishment of TJs. The Crumbs complex, 
however, does not affect cell-cell junction formation (Varelas et al., 2008). Despite the fact of 
interacting at the cytoplasmic surface of TJ structures (Tepass, 1996), Crumbs complex 
elements do not contain a component that directly establishes extracellular protein-protein 
interactions that might sense polarity status with an adjacent epithelial cell .  
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These observations have naturally raised the question about the physiological function of 
Ocln, suggesting it not to play an essential role in epithelial barrier function in vivo. Recent 
studies, however, support the potential for another TJ-associated MARVEL protein member 
normally restricted to tri-cellular interaction sites, Tric, to replace absent Ocln at bi-cellular 
contacts (Takasawa et al., 2013). This replacement does not provide an equivalent 
correction, however, might provide an explanation for the Ocln knockout mice. While Ocln-/- 
mice demonstrate morphologically and functionally normal TJs, reach adulthood and are 
born with no abnormal phenotype in the expected Mendelian rations, they exhibit a complex 
phenotype that includes reduced growth rates, brain calcifications, testicular atrophy, loss of 
cytoplasmic granules in salivary gland, striated duct epithelial cells, and thinning of compact 
bone (Saitou et al., 2000).  
 
Despite the controversy, there is a relationship between CP and PDAC                    
(Logsdon et al., 2010). Thus, our comparisons between pancreatic epithelial cell lines 
capable of polarizing in vitro (HPAFII to emulate a non-cancerous format) or being incapable 
of this process (AsPc-1 to emulate a cancerous format) were used to examine potential 
differences that might be relevant to pathological states. 
 
The data presented in this chapter initially described Ocln and YAP distribution in CP and 
PDAC biopsy samples obtained from a limited set of patients. In normal tissue, Ocln 
localised primarily at the cytoplasm and at the apical surface of ducts. In PDAC tissue, Ocln 
staining appeared to be substantial but did not distribute at the plasma membrane, 
consistent with past studies reporting a correlation between the loss of Ocln and pancreatic 
cancer progression (Tan et al., 2004) (Figure 4.1-top panel, Figure 4.2). Loss of Ocln 
expression or disruption of its normal cellular organization was found to be associated with 
epithelial cell transformation (Figure. 4.1-top panel), consistent with several studies reporting 
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the down-regulation of Ocln and its correlation with cancer progression (Martin et al., 2010; 
Osanai et al., 2007; Tobioka et al., 2004a).  
 
In this limited set of biopsies, YAP was mostly detected in the cytoplasm of normal acinar 
and ductal cells with minimal nuclear staining observed. In CP samples and more markedly 
in cancer, a strong nuclear signal could be observed. In cancer biopsies, strong YAP 
staining was detected in PanIN lesions (Figure 4.1 – bottom panel, Figure 4.3); nuclear 
expression of YAP was found to be associated with cytoplasmic expression (Figure 4.3).  
This might indicate a possible mechanism involved in the alteration and enhancement of 
YAP activity observed in some epithelial cancers. Malignant cells might produce an excess 
of YAP during genomic amplification overwhelming the stable environment essential for 
normal cell function. Hence, this leads to an abnormal cytoplasmic accumulation of YAP 
establishing a dynamic equilibrium between the two pools of proteins for nuclear 
translocation. Also, another possibility is the fact that in cancer, the stability of YAP protein 
might be altered as a consequence of an anabolic state that generates an imbalance 
between protein synthesis and protein degradation. Overall, YAP was predominantly 
distributed in the nucleus however some cytoplasmic expression could be observed in both 
inflamed and cancerous conditions. These findings are supported by past studies reporting 
YAP to be amplified in a variety of human cancers such as oral cancer (Baldwin et al., 2005) 
and oral squamous cell carcinoma (Snijders et al., 2005), hedgehog-associated 
medulloblastomas (Fernandez-L et al., 2009), colon, lung and ovarian serous 
cystadenocarcinoma (Steinhardt et al., 2008), hepatocellular carcinomas and breast cancers 
(Overholtzer et al., 2006; Zender et al., 2006).  
 
High levels of nuclear YAP has been associated with a worse overall survival and shorter 
disease-free progression particularly in human esophageal squamous cell carcinoma 
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(ESCC) and in adenocarcinoma of the cervix (Imoto et al., 2001; Tang, 2002). This is 
consistent with the known cellular function of YAP protein: YAP is localised in cytoplasm 
when it is inactivated and it gets trans-located into the nucleus when gets activated (Zhao et 
al., 2007). Even though the immunohistochemistry staining was not quantified by an 
experienced pathologist, it was quite clear overall YAP labelling appeared to be stronger in 
CP relative to normal tissue particularly the nuclear staining. Cancerous tissue had a 
considerably greater amount of YAP labelling compared to normal or inflamed pancreas 
biopsies (Figure 4.3).   
 
Given the role of PSCs in modulating pancreatic tumour microenvironment                   
(Omary et al., 2007), YAP expression levels were analysed in PSCs lysates collected from 
three PDAC patients and two CP patients (Figure 4.4). Absent YAP levels were observed in 
CP samples whereas in PDAC samples, at least two patients showed a positive signal. 
These results did not fully match early observations reporting a weak to moderate YAP 
staining intensity in inflamed tissue. However, due to the limited sample size and also the 
technical difficulties in obtaining PSC aspirates from patients, no further conclusions can be 
taken on this experiment.  
 
Studies have addressed the role of YAP overexpression in stimulating proliferation 
(Camargo et al., 2007; Dong et al., 2007; Zhao et al., 2007). Several transcription factors, 
including Runx2, ErbB4, p73 and TEAD in particular, have been reported to interact with 
YAP (Basu et al., 2003; Vassilev et al., 2001). TEAD distribution levels were analysed in 
normal, inflamed and cancerous pancreatic biopsies. PDAC tissue showed some 
cytoplasmic staining but more strikingly an extensive nuclear localisation in comparison to 
normal or inflamed pancreas (Figure 4.5). Zhao and co-workers suggested TEAD to be one 
of the most potent YAP targets from a transcription-activity based screen. In addition, CTGF 
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was identified as a direct target gene resulting from the interaction between nuclear YAP 
and TEAD. Moreover, knock-down of CTGF was found to abrogate YAP-stimulated cell 
growth reducing significantly YAP-induced colony formation (Zhao et al., 2008). 
 
Sensing the extent of mature cell-cell contacts at the time of polarity induction is critical for 
the establishment and maintenance of epithelial sheet composition and characteristics. The 
interactions between Hpo signaling pathway and Ocln would provide a mechanism to 
measure the extent of lateral membrane interactions and the organization of cell surface 
polarity complexes that appear to precede the initiation of TJ formation. We hypothesised 
that such an interaction would be important to coordinate the establishment of apical-basal 
polarity with cell proliferation through Hpo pathway regulation of cell density. Several 
interactions between Ocln and Hpo pathway were analysed in two cell line models with 
different growth characteristics, AsPc-1 and HPAFII (Figure 4.6, Figure 4.7). 
 
In HPAFII cells, YAP and c-Yes co-localised extensively at the cell membrane and 
cytoplasm but not in the nucleus of HPAFII cells. Ocln and c-Yes co-localised at the cell 
membrane but these occurred to a lesser extent than c-Yes and YAP; Like Ocln and YAP 
distribution, these interactions were mostly confined to the cytoplasmic region. Ocln and 
YAP co-localised essentially at the external facing surfaces of these cell aggregates and 
Ocln and TEAD co-localisations appeared to be diffusely distributed throughout the 
cytoplasm. These results are consistent with previous demonstrations that c-Yes/Ocln and 
c-Yes/YAP interactions occur in epithelial cells (Chen et al., 2002b; Sudol, 1994) but 
demonstrate for the first time, potential interactions between Ocln and the Hpo signaling 
elements YAP and TEAD.  
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In AsPc-1 cells, the interactions between YAP and c-Yes occurred mostly in the cytoplasm 
and not so much in the nucleus whereas Ocln and c-Yes co-localised predominantly at the 
membrane similarly to that observed in HPAFII cells (Figure 4.7). YAP and Ocln interactions 
occurred predominantly at the plasma membrane and in the nucleus of AsPc-1 cells, 
different from that observed for HPAFII cells. Besides, as opposed to HPAFII cells, TEAD 
and Ocln interaction was almost non-existent and failed to show cytoplasmic co-localisations 
(Figure 4.7). Co-localisation of Ocln and YAP at the cell membrane of aggressive growing 
AsPc-1 cells was further confirmed through immunoprecipitation assay (Figure 4.8). Our 
search for such a sensor uncovered an interaction between YAP and Ocln, an integral 
membrane protein of the TJ complex that forms homotypic extracellular contacts          
(Furuse et al., 1993).  
 
Pharmacological shifting of YAP from the nucleus to the cytoplasm, using the β-adrenergic 
receptor agonist dobutamine, increased the extent of Ocln expression at the cell surface in 
bi-cellular contact surfaces in both HPAFII and AsPc-1 cell lines (Figure 4.9 and Figure 
4.16). Dobutamine also induced TEAD translocation from the nucleus and stabilisation of 
Ocln at the cell membrane of HPAFII cells (Figure 4.10). In AsPc-1, nuclear TEAD levels 
were reduced after dobutamine treatment (Figure 4.18). Liu-Chittenden, showed that 
disruption of the interaction between YAP and TEAD could block YAP transforming activity 
in HEK293 cells and out of a small molecule library screen were able to find three 
compounds able to inhibit YAP transcription (Liu-Chittenden et al., 2012); the compounds 
identified, all from the porphyrin family, were protoporphyrin IX, hematoporphyrin and 
verteporfin. Particularly, the compound Verteporfin (Visudyne®) is already used in the clinic 
and it was shown to inhibit the interaction between YAP and TEAD in vitro                               
(Liu-Chittenden et al., 2012).  
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Nuclear c-Yes distribution increased progressively in CP and in PDAC tissue samples. This 
increase in c-Yes expression is consistent with previously observed changes in pancreatic 
cancer (Kubo et al., 2009) (Figure 4.11). Subsequently, Ocln and c-Yes interactions were 
monitored after dobutamine treatment. Dobutamine enhanced the distribution of Ocln at the 
plasma membrane in both cell types where increased interactions with c-Yes (Figure 4.12 
and Figure 4.17) and decreased interactions with YAP in AsPc-1 cells (Figure 4.16) could be 
observed, consistent with early observations in HPAFII cells (Figure 4.9 and Figure 4.12). 
Ocln regulated in this way was observed to be functional at cell-cell contacts as 
demonstrated by its ability to restrict Tric from bi-cellular contacts and by increasing 
epithelial barrier properties (Figure 4.13), findings consistent with previous studies 
examining Ocln function (Ikenouchi et al., 2005; Ikenouchi et al., 2008). Two striking 
differences between AsPc-1 and HPAFII cells were nuclear YAP and TEAD content (Figure 
4.10 and Figure 4.18) along with altered CRB3-Ocln co-localisations (Figure 4.19). While 
dobutamine treatment failed to dramatically alter the CRB3-Ocln co-localisation observed in 
HPAFII cells, it did affect YAP and TEAD distribution (Figure 4.19 and Figure 4.10).   
 
Dobutamine treatment also accelerated and enhanced epithelial cell apical-basal 
polarization (Figure 4.14). Particularly, dobutamine appeared to induce the formation of 
“rosette” structures indicative of luminal-like organization in HPAFII cells cultured in a 2-D 
system (Figure 4.15). Despite the fact that a luminal marker to confirm the formation of a 
single hollow lumen was not used in this study, this observation opens up the possibility of 
using this in vitro system as a powerful tool to study epithelial architecture and 
morphogenesis of the pancreas under close to physiological conditions. Culturing HPAFII 
cells in extracellular matrixes such as collagen I or matrigel, could potentially create a 3-D 
culture system in which a spherical epithelial monolayer with a central single hollow lumen 
would be formed. In essence, such specialised systems constitute a powerful tool that can 
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shed light on how cell polarity is regulated and how does it interact with the extracellular 
matrix. Additionally, 3-D culture of tumour cells recapitulates pancreatic cancer physiology 
and tumour microenvironment providing a more reliable and high-throughput screening 
platform for chemotherapeutic drugs.  
 
The role of YAP in malignancy still remains controversial and accumulating evidence 
suggests that the dual roles as an oncogene and tumour suppressor gene in human 
oncogenesis appear to be tissue and cell context specific. It has become clear that the 
interplay between YAP binding to transcriptional factors and its interaction with different 
signaling pathways as well as the specific stimuli acting on a particular cell or tumour type, 
determine the dual function of YAP as an oncogene or as tumour suppressor gene. Several 
studies have linked several proliferation markers to YAP, yet it is still not clear if the 
expression of YAP in epithelial cancers induces tumourigenesis or if it contributes to a more 
favorable cellular environment for the development of tumours                                      
(Camargo et al., 2007; Zhao et al., 2007). Under normal conditions, YAP functions to 
maintain tissue homeostasis, however once it becomes deregulated it can contribute 
towards a malignant phenotype. Being a nuclear effector, YAP might cause genomic 
instability sustaining an environment that promotes cell proliferation and inhibits apoptosis.  
 
Most epithelial cancers, including pancreatic cancer, that contain mutant K-Ras (Kanda et 
al., 2012; Morris et al., 2010) and have somatic mutations in the small K-RAS gene are 
generally associated with poor response to standard therapies (Ostrem et al., 2013). Despite 
the efforts in developing targeting therapies directed to oncogene-addicted tumour, nearly all 
tumour remissions are followed by tumour relapse and acquired resistance (Greten, 2014). 
PDAC cells have been reported to be able to survive in the absence of oncogenic K-Ras 
signaling and acquiring alternative mechanisms of resistance that sustain their continuous 
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growth (Greten, 2014). Recent studies reported that YAP can substitute for loss of K-Ras 
and YAP and the transcriptional factor TEAD-2 was suggested to be responsible to drive     
K-RasG12D – independent tumour maintenance in a mouse model of PDAC (Kapoor et al., 
2014). YAP has also been shown to be able to rescue cell viability in K-Ras-dependent cells 
upon suppression of K-Ras (Shao et al., 2014b). These studies have highlighted a novel 
mechanism of resistance to K-Ras inhibition through Ras signaling replacement by YAP 
(Kapoor et al., 2014). These findings have paved the way to identify small-molecule 
modulators of Hpo signaling as novel and exciting approaches for cancer therapy.  
 
Identification of pathways or molecules that are required for tumour growth provides a new 
strategy that would overcome the drawbacks of conventional cancer treatments. The Hpo 
signaling pathway is an emerging growth control and tumour suppressor pathway portending 
the need for YAP inhibitors (Genevet and Tapon, 2011; Halder and Johnson, 2011; Stanger, 
2012). The fact that altered Hpo signaling cascade appears to be tightly linked to tumour 
initiation and/or progression makes this pathway an attractive target for therapy. 
Nevertheless, part of the downstream effectors of the Hpo pathway are kinases that function 
as negative regulators by inhibiting YAP function, so targeting inhibitors to these 
constituents might result in YAP activation and consequently induction of cell proliferation 
(Stanger, 2012).  
 
In particular, in this study, YAP seemed to act as an oncogene and dobutamine was 
introduced as a promising strategy to target pancreatic cancer more effectively. Dobutamine 
treatment was shown to lead to suppression of YAP localisation to the nucleus and 
hypothesised that Ocln re-expression in cancer cells functions in a fail-safe mechanism to 
induce cell death, which will be further discussed into more detail in the following chapter 
(Figure 4.19). It has been shown by different studies that re-expression of Ocln in cancer 
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rescues the malignant phenotype back to normal and these cells are then able to polarise 
again (Li and Mrsny, 2000). Thus strategies that re-express endogenous Ocln in cancer 
might open up new therapeutic modalities. However, since these results have been obtained 
in an in vitro system, conclusions for clinical application should be drawn prudently. In vivo 
studies were able to show that knock-down of YAP affects pancreatic cancer cell growth and 
YAP expression enables tumour growth even in the absence of K-Ras (Greten, 2014). Given 
the potential interest in targeting the Hpo pathway to allow for a redesign of novel pancreatic 
cancer therapies, there is a considerable value in testing dobutamine in a YAP knock-down 
mice model. 
 
These findings have linked Hpo pathway to the actin cytoskeleton, cell junctions and cell 
polarity. Our studies have now addressed the identification of a potential extracellular cell 
density sensor that can fine-tune the suppression of cell proliferation. Ocln, the first integral 
membrane protein found to be associated with TJ structures, has the characteristics that 
suggest it to fulfill this cell density sensor role through a mechanism that involves its removal 
from the plasma membrane in the absence of cell-cell interactions. 
 
Overall, our data suggest that Ocln is uniquely positioned at TJ structures to register the 
extent of a functional barrier for the coordination of cell density and apical-basal polarity 
(Figure 4.20). Importantly, this work suggested that Ocln is able to directly interact with 
YAP’s co-activator, TEAD, in a manner that could suppress cell proliferation (discussed in 
more detail in Chapter 5).  These studies also showed that treatment with dobutamine, 
currently approved to treat acute heart failure, can reactivate Ocln expression and cell 
surface distribution. Finally, the in vitro findings were correlated with the expression pattern 
of Ocln and Hpo signaling elements in human pancreas biopsies obtained from healthy 
individuals or individuals diagnosed with CP and PDAC (Cravo, et al., 2014, submitted).  A 
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role for Ocln as a sensor for planar cell polarity that intersects with the Hpo pathway 
provides some potential explanations for the complex and poorly understood function(s) of 
this TJ protein. Previous studies have shown the TJ protein AMOT and Crumbs complex 
components to help sequester YAP to the TJ (Zhao et al., 2011). Our data now shows that 
Ocln, a TJ protein that is rapidly regulated at bi-cellular TJ structures (Furuse, 2010), is 
capable of relaying information relevant to the extent apical-basal polarization through YAP 
and TEAD to provide a potential sensor function for Hpo pathway regulation (Figure 4.20). In 
this way, Ocln interactions with YAP and TEAD could couple apical-basal polarity with lateral 
cell density to allow epithelial cells to calibrate their bias towards proliferation versus 
polarization (Figure 4.20). 
 
Chapter 4 




Figure 4.20 Schematic representation of dobutamine molecular actions in cancer cells 
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The Hpo pathway is activated by different upstream molecular signals including cell-cell 
contact and cell polarity molecules, adhesion and junction proteins and also GPCRs          
(Yu et al., 2012). In mammals, adrenergic activity modulates the rate of cell replication and 
differentiation (Slotkin et al., 1988); Catecholamines, activators of GPCRs, play a role in 
controlling cell replication and differentiation (Slotkin et al., 2000). Adrenergic gene 
knockouts have lethal effects (Zhou et al., 1995) and β-adrenergic signalling can regulate 
the function of several epithelial cancer cell types (Baker et al., 2011; Daly and McGrath, 
2011). In adulthood adrenergic control terminates as cells exit mitosis and transition to the 
terminal differentiation stage. Some epithelial cancers and cancers of secretory cells, 
however, can re-express β-adrenergic receptors (MacEwan and Milligan, 1996; Mitra and 
Carraway, 1999). Epidemiologic studies associating stress levels with accelerated tumour 
progression have prompted studies involving β-adrenergic regulation in tumour biology 
(Antoni et al., 2006; Chida et al., 2008).   
 
A hallmark of epithelial cancers is the loss of functional cell-cell contacts involving AJs and 
TJs (Martin et al., 2010).  In this regard, stable TJ structures have a crucial role in 
suppressing cell proliferation and in priming cells for apoptotic induction in epithelial cells 
(Balda and Matter, 2009). The function of Ocln has been poorly understood since its 
identification as the first integral membrane protein of the TJ (Furuse et al., 1993). 
Subsequently, it was demonstrated that TJ structures could form in the absence of Ocln 
(Saitou et al., 2000), but studies have shown that its presence can modulate certain aspects 
of epithelial barrier function (Yu et al., 2005).  The cytoplasmic C-terminal tail of Ocln has 
been shown to bind directly to PKCζ (Nusrat et al., 2005). This serine/threonine kinase also 
functions as a cell polarity regulator through its interactions with PAR3 and PAR6              
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(Liu et al., 2004). Additionally, PKCζ can associate with KIBRA, an upstream regulator of the 
Hpo pathway (Yoshihama et al., 2012). Since the TGF-β-SMAD pathway couples with 
Crumbs complex to provide Hpo-dependent control of cell density (Varelas et al., 2010), it is 
interesting how TGF-β signalling and Ocln function seem to intersect                                
(Barrios-Rodiles et al., 2005).  
 
The Rho Kinase (ROCK) previously shown to regulate epithelial paracellular permeability 
(Walsh et al., 2001),  has been suggested to have a critical role in TJ assembly              
(Terry et al., 2010; Walsh et al., 2001); however Rho regulation of TJ organization has not 
been reported to be directly associated with Ocln. As shown in the previous chapter, 
Chapter 4, dobutamine, a currently approved drug in clinic to treat acute heart failure, 
induces the re-establishment of functional cell-cell contacts that have been lost or reduced in 
epithelial cancers. Several studies have suggested the potential adjuvant effect of 
dobutamine in the treatment of several epithelial cancers (Bao et al., 2011; Sun et al., 
2014a); no studies have yet reported the potential benefit in using this β-agonist in the 
treatment of pancreatic cancer.  
 
In this chapter, the actions of dobutamine on pancreatic cancer cell lines in vitro to identify 
possible applications for the treatment of PDAC, were evaluated. The actions of dobutamine 
on pancreatic cancer cell viability, proliferation and apoptotic induction were examined alone 
and in combination with gemcitabine as a potential adjuvant chemotherapeutic approach. 
Finally, aiming at increasing the selectivity and reducing off-target interactions, PepT1 
expressing cells were treated with a PepT1 targeted gemcitabine chimera combined with 
dobutamine and cell proliferation rates were assessed. 
 
Chapter 5 
Dobutamine – a potential Adjuvant Molecule in the Treatment of Pancreatic Cancer  
176 
 
5.2 Materials and methods 
5.2.1 Cell viability and proliferation assays 
 
AsPc-1 (passage 15) and HPAFII (passage 10) cells were seeded in 96-well plates at a cell 
density of 500 and 1000 cells per well respectively and allowed to attach. Following this, 
cells were supplemented with fresh medium containing either dobutamine or gemcitabine; 
for β-adrenergic mediation, cells were treated either with dobutamine on its own or in 
combination with the antagonists: atenolol (600 nM – Santa Cruz) and propranolol 
(12 nM - (Briley et al., 1980)). After 48 h incubation, in order to assess cell proliferation or 
cell viability, either CyQuant™ or MTT solution respectively, were added to each well as 
outlined in sections 2.7 and 2.8, Chapter 2. Each assay was done in triplicate in independent 
experiments. 
 
5.2.2 Ocln knock-down 
 
A pool of 4 individual siRNA (Accell Human OCLN, siRNA-SMARTpool, Thermo Scientific) 
targeting different sequences in the Ocln gene was used (Table 2.4, Chapter 2). For 
proliferation assays, HPAFII (passage 15) and AsPc-1 (passage 12) were grown on a 96 
well plate to about 70 % confluency at a cell density of 1000 and 500 cells per well, 
respectively. For paracellular studies, HPAFII cells (passage 17) were seeded onto the 
apical chamber of polyester filters, as outlined in section 2.3.1, Chapter 2.  For both 
proliferation and paracellular assessment studies, cells were treated with siRNA in parallel 
with a scrambled control siRNA, as described in section 2.11.5.  After removing the 
treatment media, a cell proliferation assay was carried out following the procedure described 
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in section 2.7, Chapter 2. For protein levels, cells were harvested and run on a gel for 
Western Blot analysis, as mentioned in sections 2.4 and 2.6 respectively, Chapter 2. 
 
5.2.3 TER measurement and paracellular permeability studies 
 
For polarization experiments, HPAFII cells (passage 15) were seeded onto the apical 
chamber of polyester filters, as outlined in section 2.3.1, Chapter 2. TER measurements 
were performed on a daily basis (section 2.3.2, Chapter 2) and on day 7, cells were treated 
with 20 μM ROCK inhibitor or 50 µM PKCζ pseudosubstrate (PKCζ-PS) either alone or in 
combination with 20 μM dobutamine (Cerruti et al., 2013). At day 11, paracellular studies 
were carried out as outlined in section 2.3.3, Chapter 2. For TGF-β experiment, HPAFII cells 
(passage 21) were allowed to grow for 10 days. On day 11, TGF-β was applied apically 
either alone or in combination with 20 µM dobutamine. After 48 h, paracellular permeability 




At the end of paracellular studies, filters were carefully cut and cells were blocked and 
permeabilised. Following this, cells were mounted on slides and examined through confocal 




AsPc-1 (passage 20) and HPAFII (passage 6) were seeded in T 25 cell culture flasks till 
approximately 70 % confluency. Dobutamine and gemcitabine, either alone or in 
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combination, were added to each flask in a total volume of 5 mL of cell media and left 
incubating for 48 h. Subsequently, cells were trypsinized and centrifuged as outlined in 
section 2.1, Chapter 2; cell pellet was re-suspended in 100 µL of annexin-V-FLUOS and 
analysed through FACS as referred in section 2.12, Chapter 2. Controls for this experiment 
can be seen in Appendix (Figure 8.1 and 8.2, Chapter 8). 
 
5.2.6 Annexin V/PI cell staining 
 
AsPc-1 (passage 22) and HPAFII (passage 7) were seeded in plastic micro-dishes with high 
glass bottom (Thistle Scientific Ltd) till reaching approximately 70 % confluency. Dobutamine 
or gemcitabine, both alone or in combination, were added to each flask in a total volume of   
300 μL cell media and left incubating for 48 h. As a positive control for apoptosis, cells were 
treated with staurosporine, a well-established apoptotic cell inducer (Chae et al., 2000). As a 
positive control for necrosis, cells were treated with 1 % Triton X-100, a reported necrotic  
inducer (Goto et al., 2009). Subsequently, cells were stained for annexin V/PI and analysed 
through confocal microscopy as outlined in Chapter 2, sections 2.12.1.1 and 2.9 
respectively. 
 
5.2.7 ELISA: nucleosome detection 
 
AsPc-1 (passage 19) and HPAFII (passage 10) were seeded in 96 well plates at a cell 
density of 500 and 1000 cells per well respectively. Dobutamine or gemcitabine, both alone 
or in combination, were added to each well in a total volume of 100 μL. After 48 h 
incubation, a photometric enzyme immunoassay for in vitro detection of cytoplasmic  
histone-associated DNA fragments as referred in section 2.12.1.2, Chapter 2, was carried 
out. As a positive control for apoptosis, cells were treated with staurosporine for 4 h (Chae et 
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al., 2000). As a positive control for cell necrosis, cells were treated with cell media 
supplemented with 1 % Triton X-100 (Goto et al., 2009). 
 
5.3 Results 
5.3.1 Dobutamine suppresses cell proliferation in vitro 
 
While the barrier properties of TJ network have been extensively studied, it is now becoming 
more evident the complexity of TJ as a platform that integrates multiple signals involved in 
cell polarity and tissue homeostasis comprising cell differentiation, proliferation and 
migration (Farkas et al., 2012). Induction of cell proliferation and suppression of apoptotic 
pathways are the two critical features of Hpo pathway deregulation. As previously 
mentioned, YAP binds to the TEAD family of transcription factors which are involved in the 
regulation of CTGF which in turn drives cell proliferation . Since the transcriptional co-
activator YAP/TEAD is known to affect cell proliferation rates (Camargo et al., 2007) and 
YAP is involved in the regulation of proliferative and anti-apoptotic pathways (Bao et al., 
2011; Strano et al., 2005), the goal was to examine the effects of dobutamine treatment on 
cell proliferation (Figure 5.1). Under normal conditions, HPAFII cells were grown from a 
seeding density of ~10 % confluence, reaching ~50 % confluence by 24 h and ~70 % 
confluence by 48 h; dobutamine treatment of HPAFII cells, seeded at a low cell density, 
significantly reduced their proliferation in a dose-dependent manner when examined at both 
24 h and 48 h (Figure 5.1-A). A comparable dobutamine-induced reduction in proliferation 
rates was observed for AsPc-1 cells at 24 h but significantly more pronounced at 48 h 
(Figure 5.1 –B). 
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Figure 5.1 The β-agonist, dobutamine, suppresses cell proliferation in two pancreatic cancer 
cell lines in vitro. Cell proliferation of HPAF II cells (A) and AsPc-1 cells (B) exposed to 10, 20 and 
50 µM dobutamine over 24 h and 48 h; values are expressed as mean ± SEM from 3 independent 
experiments; * p < 0.05; ** p< 0.01; *** p<0.001 compared to non-treated cells.   
 
After confirming that 48 h was the optimal exposure time to observe a pronounced 
anti-proliferative effect, we intended to characterize HPAFII and AsPc-1 pharmacological 
responses in terms of cell proliferation and viability mediated through dobutamine treatment. 
Through live cell fluorescent labelling and MTT assay, dobutamine half maximal effective 
concentration (EC50) for reducing cell proliferation and viability was determined. As this data 
shows, dobutamine affected differently cell viability and cell proliferation in these two 
pancreatic cell line models. The concentration needed to decrease cell viability after 48 h 
was much higher in AsPc-1 compared to HPAFII cells. Conversely, AsPc-1 cells showed a 
slightly reduced EC50 for proliferation compared to the slow growing epithelial cell line model, 
HPAFII. From this analysis, it can be concluded that dobutamine decreased cell viability 
more markedly in HPAFII than in AsPc-1 cells and decreased cell proliferation in a slightly 
more pronounced manner in AsPc-1 cells in comparison to HPAFII cells (Figure 5.2). 
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Figure 5.2 Dobutamine decreases cell viability more strikingly in HPAFII in comparison to 
AsPc-1 cells and decreases cell proliferation in a slightly more pronounced manner in AsPc-1 
cells compared to HPAFII cells.  Sigmoidal dose response curves showing the EC50 values obtained 
for cell proliferation and cell viability studies during a 48 h time course. Values are expressed as 
mean ± SEM from 3 independent experiments. 
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5.3.2 The suppression of cell proliferation via dobutamine is β-adrenoreceptors 
mediated 
 
Being primarily a β1-adrenergic agonist (Rang, 2003), it was investigated if the cellular 
responses induced by dobutamine were mediated through adrenergic β-receptors. Firstly, 
the expression profile of β-adrenergic receptors in the pancreatic cancer cell lines: AsPc-1 
and HPAFII, was assessed through the database Oncomine (http://www.oncomine.org). 
AsPc-1 and HPAFII cells are reported to express both β2 adrenergic receptors whereas only 
AsPc-1 cell lines express the β1 sub-type (Figure 8.7-8.10, Chapter 8). In order to assess 
this, cell proliferation assays were carried out and in parallel bright field images were taken; 
In order to fully address if  dobutamine actions could be antagonised by either propranolol or 
atenolol, AsPc1 and HPAFII cells were exposed to a much higher dobutamine concentration 
than the obtained EC50 for these cell lines. Cells were treated with dobutamine alone and in 
the presence of the non-selective and the β1- selective receptor antagonist, propranolol 
(Black et al., 1964) and atenolol respectively (Brown et al., 1976). As mentioned before, 
dobutamine acts primarily on β1 receptors and atenolol is a selective β1 receptor antagonist 
(Brown et al., 1976). As shown in Figure 5.3-A, 500 μM dobutamine completely inhibited cell 
proliferation in HPAFII and AsPc-1 cells; however the β1 selective antagonist atenolol, 
blocked dobutamine-induced suppression of proliferation in AsPc-1 but not in HPAFII cells 
(Figure 5.3-B). This is consistent with the fact that AsPc-1 cells are reported to express β1 
adrenoreceptor sub-type, whereas HPAFII only express β2 (Chapter 8, Figure 8.7-8.10). 
Treating these cells with the antagonists on their own, produced a comparable effect (Figure 
8.6, Chapter 8). Atenolol decreased cell proliferation in AsPc-1 whereas in HPAFII it did not 
produce any effect whereas propranolol produced the opposite effect by reducing 
proliferation levels in HPAFII and not in AsPc-1 cells (Figure 8.6, Chapter 8). Conversely, 
propranolol did not abrogate the anti-proliferative effect of dobutamine as shown by the 
phenotype presented by AsPc-1 cells and cell proliferation assays. These data suggests 
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that, opposite to HPAFII cells, the anti-proliferative effect of dobutamine in AsPc-1 appears 
to be β-receptor mediated, as the selective antagonist atenolol blocked the actions of 
dobutamine. Propranolol also blocked dobutamine-induced effects, however being a non-
selective antagonist it cannot be ruled out that the reduction in cell proliferation observed in 
both cells lines is mediated through β-adrenergic receptors.  Nevertheless, these results are 
consistent with the study carried out by Bao and co-authors, in which propranolol supressed 
the dobutamine induced phosphorylation and translocation of YAP, whereas a non-specific α 
adrenergic receptor inhibitor, phentolamine had no effect (Bao et al., 2011).  
 
Figure 5.3 Decrease of cell proliferation induced by dobutamine is likely to be β-adrenergic 
dependent. (A) Bright field images of HPAFII and AsPc-1 cells exposed to 20 μM dobutamine, either 
alone or in combination with the antagonists 12 nM propranolol and 600 nM atenolol during 48 h; 
scale bar 50 μm; (B) Cell proliferation assay after HPAFII (top panel) and AsPc-1 (bottom panel) cells 
were exposed to 500 μM dobutamine, either alone or in combination with the antagonists 12 nM 




Dobutamine – a potential Adjuvant Molecule in the Treatment of Pancreatic Cancer  
184 
 
5.3.3 Dobutamine inhibition of HPAFII and AsPc-1 cell proliferation involves Ocln 
 
Suppression of cell proliferation and the activation of cell death mechanisms have been 
associated with the presence of stable and functional tight junction structures as well as a 
functional apical-basal polarity complex (Farkas et al., 2012). The presence of stable Ocln 
structures at the cell membrane after dobutamine treatment, as previously shown in Chapter 
4: Figure 4.9, would shift the nuclear distribution of the co-activator factors YAP and TEAD 
to the cytoplasm, hence leading to a reduction in cell proliferation. Since the transcriptional 
co-activator YAP/TEAD is known to affect cell proliferation rates (Chen et al., 2010), we 
wished to determine if the dobutamine-induced effects on cell proliferation would involve 
Ocln regulation. To assess this, Ocln expression was transiently knocked down through 
siRNA and cell proliferation was assessed through a live cell fluorescent label. Knock-down 
of Ocln expression blocked the dobutamine-induced decrease in proliferation observed in 
both HPAFII and AsPc-1 cells (Figure 5.4). Interestingly, siRNA-mediated Ocln knock-down 
did not, by itself, result in a change in cell proliferation rates; it should be noted that the 
siRNA was added at the beginning of these experiments and it would have taken several 
hours and probably repeatedly dosing to affect significantly Ocln levels. These studies 
suggest that dobutamine, through events that involve Ocln, can reduce proliferation rates in 












Figure 5.4 Ocln stabilization at the cell membrane induced by dobutamine treatment reduces 
cell proliferation.  (A) Immunoblot showing Ocln knock-down; HPAFII (B) and AsPc-1 (C) cells 
treated with siRNA targeting Ocln or a scrambled, control siRNA at the same time as dobutamine was 
added to initiate the time course of the study. Cell proliferation was determined using a live cell 
fluorescent label. Values are mean of 3 independent experiments compared to siRNA treated levels   
± SEM; * p < 0.05; *** p < 0.001.  
 
5.3.4 Dobutamine treatment reduces size-selectivity of tight junction paracellular 
permeability 
 
After confirming the involvement of Ocln in reducing cell proliferation, we wished to examine 
if after dobutamine treatment Ocln would be functionally active in limiting the diffusion of a 
fluorescently molecular probe across the TJ network. HPAFII cells were seeded on 
trans-well filters and 10 and 20 μM dobutamine was applied apically. As shown by               
Figure 5.5-A, the dobutamine-induced decrease in paracellular permeability was statistically 
significant compared to non-treated monolayers of HPAFII. To exclude the possibility of 
more than one HPAFII mono-layer growing on top of each other, z-stacks were taken and 
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confirmed single mono layers of HPAFII cells was being analysed (Figure 5.5 – B). This data 
suggests that Ocln stabilization at the cell membrane induced by dobutamine treatment 
plays an important role in TJ integrity. 
 
Figure 5.5 Dobutamine reduces paracellular permeability in HPAFII monolayers. (A) Tight 
junction paracellular permeability was assessed using fluorescently labelled 4 kDa Dextran;                       
(B) Z-stacks of HPAFII monolayers either non-treated (top panel) or 20 µM dobutamine treated 
(bottom panel). Values are expressed as mean ± SEM from 3 independent experiments; ***p< 0.001.   
  
5.3.5 Dobutamine rescues the effect of cell polarity disruptors through Ocln 
reactivation 
 
Tissue disorganization and disturbance of cell polarity are both a hallmark of cancer 
accounting for more than 90 % of epithelial cancers. Three protein complexes are involved 
in establishing and maintaining apical-basal polarity: Crumbs, PAR, and Scribble (Bryant 
and Mostov, 2008). The core polarity complex is located at the cytoplasmic surface of the 
plasma membrane and is composed of three proteins: an atypical protein kinase C, PAR-3, 
and PAR-6 (Paris et al., 2008). Importantly, the hydrophobic surface of the cytoplasmic 
coiled-coil domain of Ocln can directly interact with at least three different proteins known to 
regulate TJ organization/disorganization and cell polarity: PKCζ, the regulatory subunit of 
phosphoinositol-3-kinase (RS-PI3K), and the proto-oncogene c-yes (Nusrat et al., 2000). 
PKCζ and Rho kinase have both been demonstrated to play critical roles in TJ organization 
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and stabilization (Etienne-Manneville and Hall, 2002; Suzuki et al., 2001) and more 
specifically, PKCζ has been reported to interact directly with Ocln (Nusrat et al., 2000). 
Inhibition of PKCζ leads to disassembly of cell polarity, thus we wished to test its role in 
processes involving dobutamine mediated TJ stabilization through pharmacological 
suppression using the PKCζ-PS peptide inhibitor (Lim et al., 2008). Firstly, phenotypic 
features of HPAFII in the presence of PKCζ-PS were examined either alone or in 
combination with the β-agonist dobutamine. HPAFII clusters of cells shrank considerably in 
the presence of the inhibitor and when dobutamine was added to the system, a more 
epithelial-like appearance could be observed, albeit these changes were very subtle            
(Figure 5.6 – A). To check for epithelial integrity, TER measurements were taken throughout 
the duration of the study. At day 7 an unexpected drop in TERs could be observed in cells 
treated with PKCζ-PS in combination with dobutamine, whereas cells that were treated with 
the β-agonist alone showed a progressive increase in TERs (Figure 5.6 – B). Despite the 
fact that an increase in Ocln production in cells treated simultaneously with dobutamine and 
PKCζ-PS inhibitor was observed, Ocln distribution was not observed at the cell surface 
(Figure 5.6 - C).  
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Figure 5.6 Dobutamine does not rescue the disruption of cell polarity induced by PKCζ-PS. (A) 
Bright field images of HPAFII cells seeded on 6 well plates after being treated with 50 μM of PKCζ-PS 
or 20 μM dobutamine, either alone or in combination compared to non-treated cells; scale bar, 50 μm; 
(B) TER measurements in HPAFII confluent monolayers seeded in trans-well filters - 50 μM of PKCζ 
inhibitor or 20 μM dobutamine, either alone or in combination, was added to the apical chamber on 
day 7; Values are expressed as mean ± SEM from 3 independent experiments; (C) Confocal 
microscopy images of HPAFII cells seeded on trans-well filters, after being exposed to PKCζ-PS 
either alone or in combination with dobutamine compared to non-treated cells; Scale bar, 20 μm. 
 
 
Following this, other inhibitors of TJ function were tested to examine if dobutamine could 
reverse the disruption of cell polarity. ROCK posed as a good candidate to test as Rho 
GTPases play a crucial role in controlling cell adhesion and migration, actin cytoskeleton 
organization, microtubule dynamics, gene expression and vesicle transport (Etienne-
Manneville and Hall, 2002). There are two Rho-Kinase members, Rho-Kinase α also known 
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as ROCK2 or ROKα and Rho-kinase β also called ROCK1 or ROKβ (Amano et al., 2010). 
Y-27632 inhibitor is a cell-permeable and selective inhibitor of ROCK1 activity (Ishizaki et 
al., 1997; Uehata et al., 1997). The Y-27632 inhibits ROCK by competing with ATP at the 
catalytic site. Inhibition of ROCK presumably disrupts actin-myosin contractility to induce a 
disorganization of cortical tension elements (Ishizaki et al., 2000; Matthews et al., 2006). 
Importantly, ROCK inhibition via Y-27632 can shift nuclear localisation of YAP in neuron 
cells (Sun et al., 2014b). In endothelial cells, dominant-negative ROCK constructs or ROCK 
inhibitors have been reported to decrease permeability suggesting that the activation of 
ROCK proteins lead to loss of TJ architecture (Wojciak-Stothard and Ridley, 2002). In 
epithelial cells, however, the compound Y-27632, has been shown to increase permeability. 
These controversial studies suggest that there are differences in cell signalling cascades 
linked to ROCK signalling in endothelial and epithelial cells (Walsh et al., 2001). To test 
whether reactivation of Ocln expression at the cell surface would rescue the phenotype 
induced by Y-27632, cells were treated in parallel with dobutamine and the ROCK1 inhibitor. 
After adding the ROCK inhibitor, TERs dropped in HPAFII cells which are consistent with 
several studies reporting the crucial role for ROCK in TJ assembly (Terry et al., 2010; Walsh 
et al., 2001). In cells treated simultaneously with dobutamine and the ROCK inhibitor, TERs 
decreased but in a less pronounced manner. Even though dobutamine was not able to 
restore completely the TERs levels back to the baseline (cells treated with dobutamine), at 
day 9 there was a significant difference of ~70 % in the TERs between cells treated 
simultaneously with dobutamine and the inhibitor compared to cells treated with the 
compound Y-27632 only (Figure 5.7-A). Although Ocln has been shown not to have a 
preponderant role in TJ formation (Saitou et al., 2000), it has been shown to have an 
important role in the regulation of paracellular barrier function (Saitou et al., 1998). It was 
hypothesised that the partial phenotype recovery induced by the compound Y-27632 
administered together with dobutamine, was mediated through re-expression of Ocln at the 
Chapter 5 
Dobutamine – a potential Adjuvant Molecule in the Treatment of Pancreatic Cancer  
190 
 
cell surface. To test this, Ocln expression was reduced through siRNA and the paracellular 
permeability of fluorescently labelled dextran was assessed in confluent epithelial 
monolayers of HPAFII. Cells treated with Ocln siRNA only presented considerably leaky 
epithelium which is consistent with previous studies (Balda et al., 2000; Bamforth et al., 
1999); Knock-down of Ocln blocked the dobutamine-induced Ocln stabilisation at the cell 
membrane in HPAFII cells (Figure 5.7-B, Figure 8.3, Chapter 8). Conversely, dobutamine as 
expected, significantly decreased the permeability in HPAFII by ~ 60 % compared to 
non-treated monolayers; in cells that were exposed to the ROCK inhibitor, paracellular 
permeability was significantly enhanced suggesting the disruption of the epithelial barrier 
(Figure 5.7-B). After cells were treated simultaneously with siRNA and Y-27632, paracellular 
permeability had an increase of ~ 40 % compared to non-treated levels and when these 
cells were treated simultaneously with dobutamine, permeability levels decreased in a 
statistically non-significant manner (Figure 5.7-B). Walsh and co-workers suggested that 
ROCK inhibition and increase in paracellular permeability was not associated with 
redistribution of TJ and AJ proteins (Walsh et al., 2001) . Here it is proposed that through   
re-expression of Ocln at the cell surface induced by dobutamine, the molecular effects on TJ 
disruption induced by ROCK inhibition can be partially recovered.  The addition of 
dobutamine in the presence of Ocln siRNA had no effect when added simultaneously with 
the ROCK inhibitor. A study suggested that knock-down of Ocln in MDCK cell lines did not 
affect the fence function of cells (Yu et al., 2005), however in this study we reported the 
decrease in paracellular permeability as Ocln function gets suppressed, These observations 
are consistent with our previous data in which it was showed that dobutamine reduced 
proliferation rates in two pancreatic cancer cell lines through events that involve Ocln  
(Figure 5.1 and 5.4). Because ROCK inhibition enhanced paracellular permeability and this 
biological effect appeared to be mediated through Ocln, we examined the distribution of this 
TJ marker by immunofluorescence labelling.  Subsequently, we wanted to check Ocln 
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distribution after cells were treated with the ROCK inhibitor alone or with dobutamine   
(Figure 5.7-C). Ocln was detected at the cell surface of cells treated with dobutamine and  
Y-27632 whereas in the cells treated with the inhibitor only, Ocln distribution was restricted 
to the cytoplasm and cell nuclei (Figure 5.7-C). Walsh reported no changes in TJ distribution 
were detectable after ROCK inhibition (Walsh et al., 2001). In our cell model, however, 
phenotypic changes were observed; confluent cultures of HPAFII grown on plastic and 
exposed to the ROCK inhibitor presented with a fibroblastic-like appearance whereas cells 
treated with dobutamine and Y-27632 demonstrated subtle changes in phenotype consistent 
with an increase in the extent of cell-cell contacts mediated through dobutamine exposure 
(Figure 5.7-D). These data are consistent with work carried out by Ishizaki and co-workers in 
which Swiss 3T3 cells that were incubated with Y-27632 showed disruption of actin stress 
fibres (Ishizaki et al., 2000).  
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Figure 5.7 Dobutamine rescues the disruption of cell polarity induced by the ROCK inhibitor   
Y-27632; (A) TER measurements in HPAFII confluent monolayers seeded in trans-well filters with   
20 μM of Y-27632 or 20 μM dobutamine, alone or in combination, being added to the apical chamber 
on day 7. Values are expressed as mean ± SEM from 3 independent experiments; * p<0.05;                           
(B) Paracellular permeability of HPAFII cells cultured on trans-well filters, using 4 kDa fluorescently 
labeled FITC-dextran - 20 μM of Y-27632 or 20 μM of dobutamine, alone or in combination that were 
added to the apical chamber on day 11; afterwards fluorescence levels were measured in the receiver 
outer chamber; Values are expressed as mean ± SEM from 3 independent experiments, ** p<0.01,  
***p< 0.001; (C) Confocal microscopy images of HPAFII cells seeded on trans-well filters, after being 
exposed to Y-27632 alone or in combination with dobutamine compared to non-treated cells; Scale 
bar, 20 μm;  (D) Bright field images of HPAFII cells seeded on 6 well plates after being treated with   
20 μM of Y-27632 or 20 μM dobutamine, alone or in combination compared to non-treated cells; scale 
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5.3.6 Dobutamine is able to rescue the disruption of cell polarity induced by TGF-β 
 
TGF-β is a cytokine involved in the modulation of cell differentiation, proliferation, migration, 
adhesion and apoptosis and contributes to the formation of the extracellular matrix (ECM). 
Being a pleiotropic molecule, TGF-β activity has a tight biological regulation             
(Kamaraju and Roberts, 2005). TGF-β has been shown to be a potent inhibitor of pancreatic 
acinar and ductal cell proliferation in vitro (Sanvito et al., 1994) and genetic mutations in 
pancreatic cancer may lead to loss of TGF-β responsiveness contributing therefore to 
tumour progression (Villanueva et al., 1998). In cancer, TGF-β has a dual role                
(Wakefield and Roberts, 2002); in the early stage of tumourigenesis, cells are still sensitive 
and responsive to the growth inhibitory effect of TGF-β thus acting as a tumour suppressor; 
in the later stages, though, it acts as a pro-metastatic agent as cells have escaped from its 
growth inhibitory effects (Nicolas and Hill, 2003). Nevertheless, certain TGF-β signalling 
pathways remain functional in these cells (Wakefield and Roberts, 2002). SMADs are the 
intracellular effectors of TGF-β (Derynck et al., 1996; Itoh et al., 2000). In some cell types, 
TGF-β-dependent SMAD signalling intersects with Ras/MAPK/MEK signalling pathway, in 
others it has been shown to be SMAD-independent utilizing instead the RhoA and the PI-3 
kinase pathways (Bhowmick et al., 2001). The Rho/ROCK pathway has been reported to be 
crucial in mediating the growth inhibitory effects of TGF-β in MCF-10A breast cancer cell line 
(O'Mahony et al., 1998). After showing that loss of TER resulting from ROCK1 inhibition 
could be partially recovered with dobutamine treatment, we wanted to examine the 
contribution of TGF-β on its own and in combination with the β-agonist to TJ integrity   
(Figure 5.8).  To test this, the rate of 4 kDa fluorescent dextran as a marker for paracellular 
flux was evaluated (Matter and Balda, 2003). Tight junction permeability in cells treated with 
TGF-β was higher compared to non-treated cells, although at 20 nM no significant changes 
between treated and non-treated cells were observed. At 40 nM of TGF-β treatment, tight 
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junction permeability decreased again. Dobutamine treatment however, in combination with            
TGF-β, diminished paracellular permeability in a statistically significant manner. Despite the 
dose response in paracellular permeability reduction at 5, 10 and 20 nM of TGF-β, we failed 
to observe a significant increase in the TER values. At the time this experiment was carried 
out, HPAFII cells were at a higher passage number (passage 21) than those used in 
previous studies and we have observed, surprisingly, that HPAFII cells start to lose their 
epithelial junctions after they have been cultured and passaged for a long time. When grown 
on plastic, these higher passage HPAFII cells formed small clusters in which lateral cell-cell 
contacts could be detected, but when cultured on filters the highest TER values obtained 
were around 250 Ώ.cm2 (data not shown).  
 
Figure 5.8 TGF-β in combination with dobutamine, reduces paracellular permeability in 
comparison with TGF-β on its own. Paracellular permeability was assessed after HPAFII have 
been exposed to TGF-β for 48 h. Values are expressed as mean ± SEM from 3 independent 
experiments, **p<0.01. 
 
5.3.7 Dobutamine as a possible adjuvant therapy for the treatment of pancreatic 
cancer 
 
Previous in vitro and in vivo studies have demonstrated that some β2–adrenoreceptor 
agonists inhibited the growth of human breast cancer cells by blocking the Raf-1/ERK 1/2 
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pathway (Carie and Sebti, 2007). Moreover activation of GPCRs was suggested to be a 
potential valuable chemotherapeutic strategy in the treatment of a variety of tumours.  As an 
example of this, histamine has been approved to be used in combination with interleukin-2 in 
the treatment of acute myeloid leukaemia (Toll et al., 2011). In light of previous studies 
discussed in this thesis, since YAP and Ocln seem to interact as regulators of apical-basal 
polarity and cell proliferation, it was hypothesised that dobutamine may represent a novel 
adjuvant treatment for pancreatic cancer by enhancing the cytotoxic actions of the current 
standard anti-cancer drug gemcitabine. To examine this further, the effect on proliferation 
rates of AsPc-1 and HPAFII cells following exposure to 20 μM dobutamine in combination 
with different doses of gemcitabine (AsPc-1 EC50 Gemcitabine: 40 µM;                                        
HPAFII EC 50 Gemcitabine: 11 µM; Data not shown) (Figure 5.9) was examined. As seen in 
Figure 5.9-A, proliferation levels were significantly reduced when HPAFII cells were treated 
with dobutamine in combination with gemcitabine; in AsPc-1, although there was a trend in 
the reduction of cell proliferation rates after the double treatment, this difference failed to 
reach statistical significance (Figure 5.9-B). Finally, it was examined if the action of 
gemcitabine could be potentiated in combination with different doses of dobutamine. When 
treated with 2 and 5 μM of dobutamine in combination with 40 μM gemcitabine, cell 
proliferation rate of HPAFII cells decreased in a statistically significant manner             
(Figure 5.10-A). In AsPc-1, despite the fact that there was a trend in the reduction of cell 
proliferation, these differences were not statistically significant (Figure 5.10-B). Overall, 
these results suggest that there seems to be a synergistic interaction between dobutamine 
and gemcitabine in the context that both compounds given in combination seem to have a 
stronger anti-proliferative effect in vitro than if given alone.  
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Figure 5.9 Dobutamine enhances the cytotoxic effect of gemcitabine. Cell proliferation was 
assessed in HPAFII (A) and in AsPc-1 (B) after cells were exposed to gemcitabine alone or in 
combination with dobutamine compared to non-treated cells; Values are expressed as mean ± SEM 
from 3 independent experiments, **p<0.01; ***p<0.001. 
 
Figure 5.10 Gemcitabine enhances the anti-proliferative effect of dobutamine in HPAFII cells. 
Cell proliferation was assessed in HPAFII (A) and in AsPc-1 (B) after cells were exposed to 
dobutamine alone or in combination with gemcitabine compared to non-treated cells. Values are 
expressed as mean ± SEM from 3 independent experiments, ***p<0.001. 
  
5.3.8 Dobutamine induces apoptosis in pancreatic cancer cells 
 
The presence of stable TJs has been correlated with the suppression of proliferative 
pathways and the activation of cell death pathways (Hatakeyama, 2008). Recently there has 
been a great focus on developing drugs that selectively target apoptotic pathways 
anticipating a maximization of the therapeutic response while minimizing their toxicity profile. 
GPCRs have been shown to have a role in activating intra-cellular signal transduction 
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pathways and, ultimately, cellular responses including programmed cell death                  
(Gu et al., 2000). 
 
This work has already demonstrated that treatment of pancreatic cancer cells with 
dobutamine, decreased nuclear expression of YAP (Chapter 4, Figure 4.9), sustained cell 
surface Ocln distribution and re-established cell-cell contacts which in turn suppressed cell 
proliferation. In the light of previous results, it was hypothesised that dobutamine as a 
β-agonist might be able to inhibit pancreatic cancer cell proliferation by inducing cell 
apoptosis. To test this hypothesis, Ocln expression levels were evaluated in response to 
dobutamine either alone or in combination with gemcitabine (Figure 5.11). As expected, 
Ocln was detected in whole cell lysates of non-treated HPAFII cells whereas in AsPc-1 cells 
Ocln expression was diminished. When treated with a single dose of dobutamine, Ocln 
levels remained approximately the same in non-treated HPAFII cells while on AsPc-1 this 
increase was more than two-fold higher. Gemcitabine treatment had the opposite effect in 
terms of Ocln expression, in both cell lines. In HPAFII, gemcitabine induced a decrease in 
Ocln expression. This could partially be explained by its mechanism of action. Being a 
pro-drug, gemcitabine requires a phosphorylation step by deoxycytidine kinase to an active 
form that then gets incorporated into DNA, ultimately causing cell death (Plunkett et al., 
1995). It might be that the gemcitabine exposure time as well as the concentration used in 
these studies was not optimal for this specific cell line. In AsPc-1 cells, Ocln levels after 
dobutamine treatment were higher compared to non-treated levels; when combined with 
gemcitabine, there was a statistically significant increase in Ocln expression levels in both 
cell lines, being more pronounced however in the AsPc-1 in vitro model (Figure 5.11).  
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Figure 5.11 Dobutamine and gemcitabine combined treatment increased Ocln production in 
AsPc-1 cell lines. (A) Immunoblot showing Ocln levels after HPAFII cells were treated with 20 μM 
dobutamine either alone or in combination with 40 μM gemcitabine during a 48 h period;                           
(B) Immunoblot showing Ocln levels after AsPc-1 cells were treated with 20 μM dobutamine either 
alone or in combination with 40 μM gemcitabine during a 48 h period. Values are expressed as mean 
± SEM from 3 independent experiments, p*<0.05; **p<0.01; ***p<0.001 compared to non-treated 
levels; Abbreviations: D. – Dobutamine; G. – Gemcitabine; G.+ D. – Gemcitabine and 
dobutamine 
 
To check for apoptosis induction, different assays were carried out after cells were treated 
with dobutamine and gemcitabine, either alone or in combination. As previously discussed in 
section 2.12, Chapter 2, any cell that has been committed to apoptosis will have exposed 
phosphatidylserine residues in the outer cell membrane that will bind to annexin V               
(Krysko et al., 2008); however in the late stages of apoptosis, if the cell membrane is 
compromised, any residue inside the cell will stain positively as well. Only a negligible 
fraction of DNA staining could be observed in AsPc-1 cells treated with dobutamine only, 
whereas in both cell lines treated with gemcitabine, apoptotic and necrotic features were 
equally observed. PI is a marker of late stage apoptosis, as its ability to enter a cell is 
dependent upon the permeability of the membrane, thus PI does not stain live or early 
apoptotic cells due to the presence of an intact plasma membrane (Vermes et al., 2000). 
This data suggests that dobutamine and gemcitabine treatment elicit apoptotic events and at 
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this specific time course of 48 h, the combined treatment has also triggered a necrotic 
response in HPAFII cells (Figure 5.12).  
 
Figure 5.12 Dobutamine induces apoptosis in the pancreatic cancer cell line models:  AsPc-1 
and HPAFII. Annexin V/PI staining in AsPc-1 (left hand side) and HPAFII cells  (right hand side) after 
being exposed to 40 μM gemcitabine and 20 μM dobutamine either in combination or alone for a 48 h 
period; scale bar, 20 µm. Abbreviations: Gem- Gemcitabine; Dob- Dobutamine. 
 
Apoptosis and necrosis refer to two mechanistically different processes in the context that 
necrosis is the passive result of cellular injury whereas apoptosis forms an integral part of 
physiologically normal processes (Vermes et al., 2000). Apoptosis ensures a dynamic 
equilibrium between cell proliferation and cell death, playing a crucial role in the size of cells 
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and tissues. In malignancy, however, resistance to apoptosis has been shown to be one of 
the hallmarks of cancer, as outlined by Hanahan and Weinberg (Chapter 1: Figure 1.11, 
(Hanahan and Weinberg, 2000). It was predicted that apoptosis would be the primary 
mechanism of cell death induced by dobutamine and/or gemcitabine. All the experiments 
performed were based on a 48 h time window; so that, the percentage of apoptotic versus 
necrotic stained cells was examined after cells were treated with dobutamine, either alone or 
in combination with gemcitabine during a 48 h time-course. Dobutamine treatment had a 
slightly more pronounced effect in prompting an apoptotic cell response in HPAFII cell line 
model: ~38.2 % compared to AsPc-1 cells: ~22.7 % (Figure 5.13). No PI/necrotic staining 
was detected in HPAFII and only negligible amounts could be observed in AsPc-1 cells 
(~5.8%) consistent with the data showed in Figure 5.12. Treatment with gemcitabine alone 
had a stronger effect in HPAFII (~57.3 %) than in AsPc-1 cells (~24.9 %), which was 
expected given the different aggressiveness profile of these two cell lines (Figure 5.13). It 
was anticipated that dobutamine treatment would enhance the cytotoxic actions of the 
current standard chemotherapeutic drug, gemcitabine. Unexpectedly, however, the 
combined treatment of dobutamine and gemcitabine had a very subtle effect on stimulating 
an apoptotic and/or necrotic response. In both cell lines, ~50 % of cells were alive, and only 
~11.5 % and 24.4 % of HPAFII and AsPc-1 cells respectively, were labelled as apoptotic 
and necrotic (Figure 5.13). These observations were not consistent with the annexin/PI 
immune-labelling as shown in Figure 5.12 as the combined treatment produced a marked 
effect in AsPc-1 cells as no adherent cells could be observed, and in HPAFII cells, both 
apoptotic and necrotic staining could be detected (Figure 5.12). 
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Figure 5.13 Fast growing and aggressive cells, AsPc-1, were more resistant to the effects of 
gemcitabine either alone or combined with dobutamine compared to HPAFII. Histogram 
showing the percentage of apoptotic and/or necrotic AsPc-1 (A) and HPAFII (B) cells from parent cell 
population after annexin/PI staining through FACS analysis. 
 
The features of end stage apoptosis overlap with necrotic parameters such as compromised 
membrane integrity and leakage of proteins in the supernatant (Denecker et al., 2001). To 
circumvent this, an enzyme-linked immunoabsorbent assay (ELISA) was used to quantify 
DNA fragmentation after cells were exposed to gemcitabine and dobutamine either alone or 
in combination. To evaluate the presence of histones and nucleosomes in cell lysates of 
AsPc-1 and HPAFII cells after being exposed to different concentrations of dobutamine 
and/or gemcitabine, absorbance measurements were taken at 490 nm (Figure 5.14 and 
Figure 5.15). Both cell lines showed a similar behaviour in terms of apoptotic induction after 
exposure to either combined or single treatment. AsPc-1 cells treated with a fixed dose of 
dobutamine supplemented with an increasingly higher concentration of gemcitabine showed 
concentration-dependent cell death response (Figure 5.14), consistent with the proliferative 
response (Figure 5.9). Conversely, HPAFII cells treated with a fixed dose of gemcitabine 
combined with increasingly higher concentrations of dobutamine showed considerably 
higher nucleosome detection compared to cells treated with a fixed dose of dobutamine and 
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increasingly higher concentrations of gemcitabine, consistent with the proliferative response 
observed in Figure 5.10.  
 
Figure 5.14 Gemcitabine and dobutamine treatment of AsPc-1 cells was more efficient at 
inducing an apoptotic response than a single treatment. AsPc-1 cells were cultured at different 
concentrations with dobutamine and gemcitabine either alone or in combination, for a 48 h period. 
After cell lysis, the cytoplasmic fractions were pre-diluted 1:10 with incubation buffer and then 
analysed through an ELISA immunoassay and absorbance measurements were taken at 490 nm. 
Enrichment factor was calculated by dividing the absorbance of dying/dead cells by the corresponding 
control (viable cells). Each data point refers to the absorbance of dead cells divided by the 
absorbance obtained from the non-treated sample (without a cell-death inducing agent). Data 
presented are the mean ± SEM of triplicates from three independently performed experiments. 
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Figure 5.15 Combined treatment of gemcitabine and dobutamine in HPAFII cells was more 
efficient than single treatments in inducing an apoptotic cell response. HPAFII cells were 
cultured at different concentrations with dobutamine and gemcitabine either alone or in combination, 
for a 48 h period. After cell lysis, the cytoplasmic fractions were incubated with buffer and then 
analysed through an ELISA immunoassay; absorbance measurements were taken at 490 nm. 
Enrichment factor was calculated by dividing the absorbance of dying/dead cells by the corresponding 
control (viable cells). Each data point refers to the absorbance of dead cells divided by the 
absorbance obtained from the non-treated sample (without a cell-death inducing agent). Data 
presented are the mean ± SEM of triplicates from three independently performed experiments. 
 
5.3.9 Compound C and dobutamine as a possible adjuvant therapy in the treatment 
of pancreatic cancer 
 
Despite the aggressive surgical treatment combined with adjuvant chemotherapy and 
radiotherapy, pancreatic cancer remains one of the deadliest epithelial cancers. Lack of 
selectivity and specificity are still the main hurdles that contribute to such unsuccessful 
outcome. To overcome this, a potential new therapeutic avenue was explored by directing 
the uptake of a specific gemcitabine chimera that can act as a substrate of PepT1. Studies 
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have also suggested the involvement of α2–adrenergic receptors in the transport of 
peptidomimetic drugs in cultured epithelial cells devoid of innervation (Berlioz et al., 2000). 
Adrenergic receptors have been shown to stimulate intestinal absorption of the β-lactam 
antibiotic cephalexin through oligopeptide transport in a human intestinal cell line. (Berlioz et 
al., 2000). Clonidine, an α2–agonist, has been reported to cause the stimulation of 
cephalexin uptake through PepT1; this stimulatory effect was hypothesised to be the 
consequence of a higher affinity of the oligopeptide transporter for its substrate and/or an 
increase in the number of functionally available transporter molecules located at the apical 
side of Caco 2 (Berlioz et al., 2000).  
 
As it was previously shown, PepT1 provides a potential strategy to target pancreatic cancer 
cells for the delivery of chimeric agents designed to affect cell proliferation and viability. We 
have tested this concept using chemically modified gemcitabine chimeras. After showing the 
suppression of cell proliferation induced by a β-agonist, we sought to test the potential 
cytotoxic action resulting from the combined treatment of dobutamine and the PepT1 
specific gemcitabine containing compound C.  
 
AsPc-1 PepT1-/- cell line and AsPc-1 WT were exposed to compound C either alone or in 
combination with dobutamine during a 48 h period (Figure 5.16). Cell proliferation rate was 
reduced after PepT1 expressing cells were treated with the combined treatment in 
comparison to the single treatment (Figure 5.16-B), even though statistical significance was 
only obtained for 5 µM of gemcitabine. As expected, dobutamine given in combination with 
the compound C had no effect on PepT1-/- cells. To further support this evidence, a study 
carried out by Sundaram and co-authors described that after stimulation of α2–adrenergic 
receptors by clonidine, the Na+/H+ exchanger activity increased due to a higher intracellular 
pH in enterocytes (Sundaram, 1995). The decrease in cell proliferation observed in the 
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AsPc-1 cell line could be partially explained by an increased affinity induced by the              
β-agonist, dobutamine, towards the PepT1 specific gemcitabine chimera.  
 
Figure 5.16 Dobutamine did not affect PepT1
-/-
 cells. Cell proliferation assay after AsPc-1 PepT1
-/- 
(A) and AsPc-1 (B) cells were treated with Compound C alone or in combination with 20 μM 
dobutamine during a 48 h period. Abbreviations: C. C – Compound C 
 
Quite striking and unexpected was the lack of effect of dobutamine treatment on PepT1-/- 
cell line; proliferation rates were two-fold higher compared to non-treated cells. This 
prompted us to further characterize cell proliferation and viability of the PepT1-/- cell 
response towards dobutamine treatment. In terms of cell proliferation, PepT1-/- cells 
presented an EC50 Dobutamine nearly three-fold higher (98.4 µM) than the WT AsPc-1 (39.8 µM) 
(Figure 5.17-top panel and Figure 5.2). With regards to cell viability, the EC50 Dobutamine 
obtained for PepT1-/- was nearly two-fold higher (207 µM) when compared to the WT cell line 
(117 µM) (Figure 5.17-bottom panel and Figure 5.2).  
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Figure 5.17 Cell proliferation and viability studies after PepT1
-/- 
cells were treated with 
dobutamine for a 48 h period. Sigmoidal dose response curves showing the EC50 values obtained 
for cell proliferation and viability response during a 48 h time course. Values are expressed as mean 



















Dobutamine – a potential Adjuvant Molecule in the Treatment of Pancreatic Cancer  
207 
 
5.4 Summary of results 
 
 The suppression of cell proliferation induced by dobutamine in AsPc-1 cells is           
β-adrenergic mediated; 
 Dobutamine suppresses cell proliferation in vitro in pancreatic cancer cells: AsPc-1 
and HPAFII; 
 Dobutamine inhibition of HPAFII and AsPc-1 cell proliferation involves Ocln; 
 Dobutamine treatment reduces size-selectivity of TJ paracellular permeability; 
 Dobutamine rescues the effect of the ROCK inhibitor, Y-27632, through a 
mechanism involving Ocln reactivation; 
 Dobutamine rescues the effect of cell polarity disruption induced by TGF-β; 
 Dobutamine is a possible adjuvant therapy for the treatment of pancreatic cancer; 
 Dobutamine induces apoptosis in pancreatic cancer cells: AsPc-1 and HPAFII; 
 PepT1-/- cells are less responsive to dobutamine actions resulting in different cell 




In this chapter, dobutamine was presented as a potential adjuvant drug molecule with a 
direct application in the treatment of pancreatic cancer. Previously showed to induce YAP 
translocation from the nucleus to the cytoplasm (Figure 4.9, Chapter 4), dobutamine was 
evaluated as a possible anti-proliferative molecule (Figure 5.1). Consistent with Diep’s 
observations showing that down-regulation of YAP expression reduces cell proliferation and 
clonogenicity of pancreatic cancer cells (Diep et al., 2012), we have confirmed that through 
YAP translocation, dobutamine is also able to suppress cell proliferation in AsPc-1 and 
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HPAFII cells (Figure 5.1). Comparing pancreatic cell line viability and proliferation responses 
to dobutamine treatment, the compound appeared to produce a more pronounced effect in 
decreasing cell viability in HPAFII than in AsPc-1 cells and decreased cell proliferation in a 
slightly more pronounced manner in AsPc-1 compared to HPAFII cells (Figure 5.2).  
 
Fujita and co-authors suggested that β-adrenergic stimulation supresses microglia 
proliferation (Fujita et al., 1998) and Junker reported that such stimulation confers 
neuroprotection (Junker et al., 2002). More recently, adrenaline and norepinephrine, have 
been reported to inhibit cell proliferation in rat gastric mucosa (Olaleye et al., 2010). It was 
now shown that another catecholamine, dobutamine, was able to reduce cell proliferation in 
two in vitro models of pancreatic cancer in a time and dose-dependent manner (Figure 5.1).  
 
To check if the suppression of cell proliferation induced by dobutamine was β-agonist 
mediated, cells were treated with the selective β1 receptor antagonist, atenolol and with the 
non-selective antagonist propranolol (Figure 5.3, Chapter 8: Figure 8.6). Our results 
confirmed that the suppression of proliferation in several pancreatic cancer cell lines induced 
by dobutamine was β-adrenergic mediated. The β1 adrenergic receptor is a GPCR 
associated with the Gs heterotrimeric G-protein and is expressed extensively in cardiac 
tissue (Ungerer et al., 1993). In pancreas, GPCRs are a major class of receptors and have 
been reported to be involved in islet cell signalling mediating the extracellular messages to 
intracellular signalling pathways (Winzell and Ahren, 2007). In exocrine pancreas, PDAC 
has been reported to frequently overexpress the enzymes Cox-2 (Yip-Schneider et al., 
2000) and 5-lipoxygenase (Hong et al., 1999) that mediate the metabolic conversion of 
arachidonic acid into prostaglandins, thromboxanes and leukotrienes (Goetzl et al., 1995). 
Since the physiological effects of prostaglandins are mediated in part by GPCRs            
(Breyer et al., 2001), we assessed the level of for β1 – adrenergic receptor expression in the 
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pancreatic cancer cell lines that had been examined in these studies. According to a public 
dataset, (http://www.oncomine.org) the ductal adenocarcinoma derived cell lines, AsPc-1 
and HPAFII, both express β2 adrenergic receptors but only AsPc-1 expresses the β1                
sub-type. This data suggests that the observed effects of dobutamine, which acts 
predominantly on β1 receptors, on cell proliferation are mediated by β1- adrenoreceptors; this 
was observed by the reduction in cell proliferation induced by the selective antagonist 
atenolol when given alone (Chapter 8, Figure 8.6) and relatively unaffected cell proliferation 
levels when the antagonist selectively counteracted the agonist effects (Figure 5.3).  
 
In this study, β-adrenergic stimulation through a single cell proliferation assessment was 
assessed. To fully address β-adrenergic involvement in pancreatic cancer cells in response 
to dobutamine, cAMP levels should have been measured. Elevation of intracellular 
concentration of cAMP is a direct result from agonist binding (Pak et al., 2002). An 
understanding of the specific role of β-receptor expression and function in pancreatic cancer 
will involve a more robust knowledge about receptor concentration in a specific type of cell 
line as well as the persistence of receptor activity after being induced by an agonist. In order 
to confirm that the reduction in proliferation and viability was mediated through β-adrenergic 
receptors, mRNA expression for β1- and β2- adrenergic receptors in both cell lines needs to 
be assessed. Additionally, an analysis of the transcription factors and genes targeted by 
β-adrenergic stimulation and their role in the dobutamine anti-proliferative effect should be 
carefully explored. Further studies will need to address how downstream factors such as 
protein kinase and phosphorylated proteins respond to β-adrenoreceptor activation in the 
context of cell proliferation inhibition.  
 
Nevertheless, this work has shown some therapeutic potential in targeting 
β-adrenoreceptors in cancer. Being expressed at the cell surface, the hurdles posed by drug 
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penetration to reach their target can be overcome and thus would not be subject to loss of 
efficacy from the action of multidrug resistance transporters. However, a downside worth 
mentioning involving the targeting of β-adrenoreceptors in cancer concerns the fact that, 
given their relatively narrow pharmaceutical window, any therapeutic strategy based on 
receptor targeting should have only short-term side effects. Major problems in adrenergic 
therapy involve the fact that receptor down-regulation limits the potential in using β-agonists 
in controlling cell replication. Conversely prolonged receptor stimulation generates a loss of 
functional response leading to the sequestration of receptor proteins (Slotkin et al., 2000). 
 
Carcinogenesis is perceived to be a multistep process that arises from a disrupted balance 
between cell proliferation and apoptosis. Molecular pathways involved in tissue 
homeostasis, such as the Hpo pathway, are critical in establishing a tight control between 
cell division and death. The Hpo pathway poses therefore as a prime target for dysregulation 
in cancer. A hallmark of aggressive epithelial cancers, such as PDAC, is the loss of cell-cell 
contacts and resistance to apoptosis induction with these contacts, in particular those 
involving Ocln, being related to suppressing cancer progression and metastasis                 
(Martin et al., 2010; Tobioka et al., 2004a).  
 
A number of TJ-associated proteins have been demonstrated to regulate epithelial cell 
proliferation, with some of these proteins being directly related to pathways and mechanisms 
that have been linked to cytoplasmic elements and to transcriptional factors. In the previous 
chapter, modulation of YAP function was shown to facilitate Ocln stabilization at the plasma 
membrane as well as increasing the extent of functional TJs. Now it was shown that 
knock-down of Ocln levels in dobutamine treated cells resulted in no proliferation changes in 
the fast growing cell line AsPc-1 compared to non-treated cells. In HPAFII, however, 
knock-down of Ocln produced a non-significant decrease in proliferation rate compared to 
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the control, but significantly higher compared to the wild type (Figure 5.4). These 
observations highlight the potential role of Ocln as an extracellular sensor that could 
coordinate the completion of apical-basal polarity with the suppression of lateral cell 
proliferation.  
 
Although the Ocln knockout mouse suggests that Ocln does not play an essential role in 
epithelial barrier function in vivo (Saitou et al., 2000), mutant and chimeric Ocln expression 
has been shown to affect the regulation of paracellular permeability (Balda et al., 2000). 
Bamforth and co-workers also reported that in murine submandibular gland carcinoma cells, 
the expression of an N-terminally truncated mutant of Ocln caused a decrease in TER 
simultaneously with an increase in paracellular permeability (Bamforth et al., 1999). 
Retention of Ocln at the plasma membrane and its ability to interact with YAP and TEAD 
would shift the distribution of these co-activation factors from the nucleus to reduce their 
proliferative actions and increase the Ocln-mediated TJ barrier properties                           
(Al-Sadi et al., 2011). To test this, the rate of 4 kDa fluorescent dextran as a marker for 
paracellular flux was evaluated (Matter and Balda, 2003). Paracellular permeability in 
HPAFII monolayers decreased significantly after dobutamine was applied at the apical side 
of these cells   (Figure 5.5). This confirmed that the dobutamine induced effects on Ocln 
stabilization at the cell membrane contributed to the TJ integrity in this system.  
 
Loss of Ocln expression or disruption of its normal cellular organization is associated with 
epithelial cell transformation (Li and Mrsny, 2000). PKCζ participates in both polarity 
complex function and Hpo signalling pathways and Ocln has been shown to selectively bind 
to this molecule through a C-terminal coiled-coil domain (Nusrat et al., 2000). To test the 
involvement of PKCζ in processes involving stabilization of Ocln at the cell membrane 
through dobutamine mediation, HPAFII monolayers were incubated with PKCζ inhibitor. As 
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expected and given its role in cell polarity, PKCζ-PS caused a drop in TER values and 
treatment with dobutamine failed to correct this outcome (Figure 5.6). These observations 
are consistent with previous roles of PKCζ in being critical for TJ structure/function through 
its actions with Ocln (Nusrat et al., 2000). ROCK phosphorylates the regulatory subunit of 
MLC (myosin light chain kinase) and it also inhibits the action of phosphatases which in turn 
inhibits MLC phosphorylation (Totsukawa et al., 2000). Not surprisingly, TER values 
dropped after exposing cells to the ROCK inhibitor, which could possibly be due to the 
sustained activation of phosphatases and consequently the inhibition of MLC 
phosphorylation, essential for the actin-myosin interaction in the cytoskeleton. Because TJs 
play a crucial role in regulating paracellular permeability and this seems to be influenced by 
ROCK inhibition, we analysed mechanisms by which modulation of Ocln re-expression 
through dobutamine exposure could regulate epithelial barrier integrity. In this study, 
enhanced permeability induced by ROCK inhibition could be partially rescued by 
dobutamine and this mechanism appeared to be Ocln mediated (Figure 5.7). These studies 
support the hypothesis that ROCK may influence not only the maintenance of normal actin 
dynamics (Ishizaki, 2000) but might also affect epithelial TJ function. 
 
TGF-β has been found to be abundantly expressed in malignant epithelial tissues            
(Derynck et al., 1985); studies have suggested that these particular molecules were able to 
induce the disruption of TJs and the acquisition of a mesenchymal phenotype in breast 
epithelial culture models (Seton-Rogers et al., 2004). Besides, Hpo signalling is involved in 
cross talk with other signalling pathways including TGF-β/SMAD (Varelas et al., 2010) and 
an association between Ocln and TGF-β signalling has been reported in murine hepatocytes 
(Barrios-Rodiles et al., 2005; Ozdamar et al., 2005). The second extracellular loop of Ocln, 
which is essential for reversing Raf-driven epithelial to mesenchymal events  (Li and Mrsny, 
2000), functions as a binding site to bring TGF-β receptor I to TJ structures where it can 
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control cell density through SMAD-based transcriptional events (Varelas et al., 2010). As 
dobutamine is involved in Ocln stabilization at the cell membrane, we sought to test if it 
would affect the biological role of TGF-β in TJ integrity by measuring paracellular 
permeability. As it has been previously reported, TGF-β displays a bell-shaped 
dose-response (Lebrin et al., 2005). In this system, at low concentrations (5, 10 and 20 nM), 
the cytokine stimulated TJ formation and consequently permeability reduction, whilst at 
higher concentrations (40 nM) it did not (Figure 5.8). TGF-β disrupted functional TJs and 
increased cellular permeability. Consequently dobutamine was able to significantly recover 
the paracellular permeability loss induced by TGF-β treatment (Figure 5.8). This is 
consistent with the partial recovery in TER values after dobutamine application in 
combination with the ROCK inhibitor (Figure 5.7). Being involved in mediating the growth 
inhibitory effects of TGF-β, dobutamine modulation of Rho/ROCK pathway represents an 
attractive approach to target pancreatic cancer. To fully address the effect of TGF-β on 
HPAFII cells, a fresher and lower passage number of these cells should have been cultured 
and TER values should have been assessed in parallel with the paracellular permeability 
studies. Also, another valuable approach would be to follow dobutamine actions after cells 
were treated with TGF-β inhibitor negatively affecting SMAD2 phosphorylation. 
 
Given the fact that YAP is hyper-activated in many human malignancies (Baldwin et al., 
2005; Overholtzer et al., 2006; Snijders et al., 2005; Steinhardt et al., 2008; Zender et al., 
2006) together with its role in promoting cell proliferation (Chen et al., 2010) and inhibiting 
cell death (Strano et al., 2005), any therapeutic intervention for cancer would involve 
reducing or ablating the oncogenic function of YAP. Studies have suggested that by 
reducing YAP activity, tumour growth suppression would be effective (Diep et al., 2012; 
Lamar et al., 2012; Wang et al., 2012; Zhang et al., 2012). Huang and co-workers, reported 
that knock-down of YAP would increase the sensitivity of cancer cells to standard 
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chemotherapeutic agents such as cisplatin, erlotinib and the small molecule antagonist of 
surviving, S12 (Huang et al., 2013). Dobutamine has been reported to inhibit YAP nuclear 
accumulation and YAP-mediated transcriptional activation (Bao et al., 2011). This compound 
was examined as a possible adjuvant molecule in the current standard treatment of 
pancreatic cancer. HPAFII cells treated with dobutamine showed a synergistic decrease in 
cell proliferation when treatment was combined with gemcitabine but AsPc-1 did not    
(Figure 5.9 and Figure 5.10). This was probably due to an insufficient exposure time to the 
combined treatment in this particular cell line. These findings suggest that dobutamine might 
increase sensitivity towards gemcitabine treatment in pancreatic cancer cells. The use of 
other cancer drugs, in this case gemcitabine, in combination with YAP targeted therapies, 
posed therefore as an attractive strategy that could maximize therapeutic outcome. 
 
Next, it was investigated if not only dobutamine was able to trigger an apoptotic response in 
pancreatic cancer cells, but it was also explored if a combined treatment of dobutamine and 
gemcitabine would maximize the apoptotic response followed by necrosis. It was speculated 
that dobutamine was able to inhibit proliferation and induce apoptosis in pancreatic cancer 
cells through the stabilization of Ocln at the cell membrane. Studies have reported the 
function of Ocln in a fail-safe mechanism for cell death induction (Liu et al., 2012; Osanai et 
al., 2006; Rachow et al., 2013). Further to this, Ocln expression in Raf-activated epithelial 
cells activates multiple apoptotic pathways such as Bid, Caspase 6 and 12 (Mrsny, et al., in 
preparation). Dobutamine treatment significantly induced Ocln production in the fast and 
aggressively growing AsPc-1 cells, whereas in HPAFII, Ocln levels remained approximately 
the same as in non-treated levels (Figure 5.11).  
 
Apoptosis is a multi-step cellular event that starts with cell shrinkage; initially the cell 
membrane remains intact until caspases are activated leading to intracellular shifts in Ca2+ 
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and pH that result in the mitochondrial membrane potential (MMP2) function impairment and 
lysosomal membrane pumps lose their function. At this stage, endogenous endonucleases 
are activated and phosphatidylserine gets redistributed culminating in cell disintegration into 
apoptotic bodies (Vermes et al., 2000). It is very challenging, not only from the conceptual 
point of view but also from a technical perspective, to detect apoptosis in a cell system. 
There is no inflammatory reaction involved and as well as this the apoptotic bodies due to 
their reduced size undergo rapid phagocytosis, and scattered single cells might escape 
detection at the early stages of apoptosis (Wyllie et al., 1980). Through a simple annexin 
and PI staining, it was confirmed that dobutamine as a single treatment induced an apoptotic 
response in both AsPc-1 and HPAFII and when combined with gemcitabine elicited 
apoptotic events followed by a necrotic response in HPAFII cells (Figure 5.12). Next, cells 
stained for annexin/PI through FACS, were analysed. Unpredictably, dobutamine and 
gemcitabine had a very subtle effect on stimulating an apoptotic and/or necrotic response 
(Figure 5.13). It is possible to postulate that due to receptor down-regulation, the apoptotic 
induction stimulated by β-agonists may not be sufficient to trigger a more robust apoptotic 
response. However, the 48 h time point and the doses tested were the chosen to be 
consistent with the previous data showing the activity modulation of specific Hpo pathway 
elements in response to dobutamine. Finally, through a specialised ELISA immunoassay, 
the presence of nucleosomes was detected in cells treated with a fixed dose of dobutamine 
complemented with increasingly higher concentrations of gemcitabine or vice versa. 
Together, this data suggests that dobutamine in combination with gemcitabine induces Ocln 
production in AsPc-1 cells and an apoptotic response measured through annexin staining 
and nucleosome detection (Figure 5.14 and Figure 5.15). Dobutamine seems to have the 
potential to work as an adjuvant to conventional chemotherapeutics for the treatment of 
pancreatic tumours that have high levels of YAP expression. 
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As this data suggests, dobutamine might represent a promising adjuvant molecule in the 
treatment and management of pancreatic cancer. After showing PepT1 over-expression in 
pancreatic cancer cell lines (Chapter 3), the possibility of increasing therapeutic efficacy 
using a gemcitabine-amino acid chimera that functions as PepT1 substrate together with 
dobutamine was explored (Figure 5.16). As anticipated, the cell proliferation rate was 
reduced after PepT1 expressing cells were treated with the dobutamine and gemcitabine. In 
PepT1-/- , however, this effect was not observed. cAMP plays a crucial role in controlling the 
movement of hydroelectrolytic particles across the intestinal epithelium (Schimmel et al., 
1980). PepT1 transport is proton dependent, so it seems likely that the β-agonist 
dobutamine might favour the uptake of gemcitabine in the cells. Nevertheless, to determine 
if administration of dobutamine results in a rapid enhancement of pancreatic absorption of 
gemcitabine through increased activity of PepT1, a cell line stably expressing alpha or 
β-adrenergic receptors and PepT1 should be used as a model to determine whether alpha 
or β-agonists can directly modulate the activity of PepT1 in the absence of nerve endings 
(Berlioz et al., 2000). 
 
The possibility of other β-adrenoreceptor subtypes being involved in the mechanism 
described was not investigated.  Enhanced absorption of peptides and peptidomimetic drugs 
opens up new avenues for the therapeutic application of β1 agonists as potential new drug 
delivery agents. To pursue such a line of study should incorporate efforts to examine the 
irresponsiveness of PepT1-/- cells to dobutamine. In order to address this, EC50 Dobutamine 
values were assessed in the AsPc-1 WT and PepT1-/- cell lines (Figure 5.17). In terms of cell 
proliferation, PepT1-/- cells presented a much higher EC50 Dobutamine compared to the WT 
(Figure 5.17-top panel and Figure 5.2). In terms of cell viability, the EC50 Dobutamine obtained 
for PepT1-/- was higher compared to the WT cell line (Figure 5.17-bottom panel and Figure 
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5.2). All together these results suggest that dobutamine has a stronger cytotoxic potential in 
AsPc-1 expressing PepT1 compared to AsPc-1 PepT1-/- cells. 
 
Our experiments using dobutamine as a β1 -adrenergic agonist, show that it can slow 
pancreatic cancer cell proliferation by re-establishing cell-to-cell contacts and augmenting 
gemcitabine-induced apoptosis (Figure 5.18). To establish the potential utility in the use of 
sympathomimetic drugs as a therapeutic strategy, studies using in vivo models will be 
required. Similarly, neuropeptide therapy is a highly active area and there are studies 
reporting the targeting of opioid receptors to control cell growth and replication in colon 
cancer (Hytrek et al., 1996; Zagon, 1996). 
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6.1 General discussion and future work 
 
Currently, chemotherapy continues to represent the preferred therapeutic option for most 
malignancies. Severe side effects and inefficient delivery to the tumour site, however, are 
still the main hurdles that limit the effectiveness of this treatment option. Particularly in 
pancreatic cancer, conventional and targeted therapies have largely failed to prolong 
survival and decrease mortality rates. Indeed, no current treatment option has shown 
long-term benefit to treat patients with advanced metastatic disease, which accounts for 
the majority of pancreatic cancer cases (80 %)(Hotz et al., 2007). Thus, there is an 
urgent need to find better-targeted therapies to pancreatic cancer. 
 
The role of epithelial cell de-differentiation in improving current chemotherapies applied 
to pancreatic cancer was investigated in this thesis. Our work started by exploring the 
potential use of oligopeptide transporters expressed in pancreatic cancer cells as drug 
delivery targets. Following this, the interplay between the Hpo pathway signaling and TJ 
network was investigated in the context of cell proliferation suppression coordinated with 
apical-basal polarity completion. These studies concluded by elucidating the potential 
use of a β-adrenergic agonist drug, dobutamine, in the treatment of pancreatic cancer.  
 
Chapter 3 outlined the potential use of PepT1 as a drug delivery target to treat CP and 
PDAC. In mammalian cells, the transport of amino acids across the plasma membrane is 
an essential physiological process that has been extensively studied. Drug transporters 
opened up a new arena of cancer cell targeting opportunities. In particular, PepT1 was 
found to be overexpressed in cancer tissue, including in pancreatic cancer, providing a 
promising new targeting strategy for the delivery of anti-cancer therapeutics. PepT1, 
normally restricted to the apical surfaces in polarised intestinal epithelial cells, was found 
to be distributed at the cell membrane of non-polarised cancerous cells and at the 
basolateral surface of ductal cells in CP biopsies. Further, inhibition of the amino acid            
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L-transporter system, also shown to affect the transport of oligopeptides through PepT1, 
suppressed the proliferation of human pancreatic cancer cells expressing PepT1 in a 
more pronounced manner compared to the cell line with reduced levels of PepT1 
expression. These results shed light on the idea that PepT1 is required by AsPc-1 cells 
to divide and proliferate, highlighting the potential in targeting this system to inhibit 
pancreatic cancer progression.  
 
Conjugation of potent anti-inflammatory molecules, like ibuprofen or the anti-cancer drug 
gemcitabine, to dipeptide analogues specific for the oligopeptide transporter, made these 
complexes into PepT1 substrates resulting in an enhanced uptake by pancreatic cancer 
cell lines. Quite remarkable was PepT1 expression in tissue from patients diagnosed with 
CP. Despite controversy, there seems to be a relationship between CP and pancreatic 
cancer. Detection of PepT1 in pancreatitis biopsies may provide a novel way to target 
inflamed pancreas prior to malignant transformation. This work has also highlighted a 
potential new way of specifically targeting anti-cancer drugs to tumour cells increasing 
clinical efficiency and reducing side-effects.  
 
As for future work, further studies about transporters’ overexpression in cancer stem 
cells may provide new insights into new targets for cancer chemotherapy. Given their 
importance in cancer biology and chemotherapy, translational research of drug 
transporters assumes a pivotal role. Moving towards an era of personalized cancer 
therapy, the inclusion of the wide variety of human drug transporter proteins into 
individual genetic screens would then allow for an optimization and individualized use of 
specific cancer medicines.   
 
Oncologists are currently seeking to “tailor therapies” to better target and treat specific 
malignancy. The fundamental goal is to develop new therapeutic strategies that exploit 
unique biological tumour properties to increase their sensitivity to the modulation of a 
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specific cell-signaling pathway. Hpo pathway signaling mediated by YAP represents a 
newly delineated opportunity for therapeutic intervention as it is frequently deregulated in 
a variety of cancers. Hpo signaling pathway regulates planar cell polarity and thus 
modulates cell proliferation within epithelial cell sheets. As Chapter 4 presented, it was 
hypothesised that a plasma membrane component involved in cell-cell contacts, Ocln, 
could function as a sensor of apical-basal epithelial cell polarity with proliferation control 
through the Hpo pathway. To address this, interactions between Ocln and Hpo pathway 
elements were examined. Previously shown to bind to and be regulated by the 
non-receptor tyrosine kinase c-Yes, Ocln was shown here to also bind to the Hpo 
pathway element, YAP, and its co-activating element TEAD.  
 
Given the widespread involvement of YAP in tumours from different origins, the 
distribution of Hpo pathway signaling elements as well as Ocln was evaluated in human 
biopsies from patients diagnosed with CP and PDAC. Ocln, c-Yes, YAP, and TEAD 
localisation in epithelial cells from normal pancreas tissue were more similar to the 
distribution of these proteins in HPAFII cells, while the distribution of these proteins in CP 
and PDAC biopsies was more consistent with the distribution pattern observed in AsPc-1 
cells. In addition, it was also shown that pharmacological attenuation of YAP using 
dobutamine to alter TEAD-dependent transcription, increased functional TJ structures 
and diminished growth rates of HPAFII and AsPc-1 cells. Importantly, dobutamine 
treatment of HPAFII cells resulted in a striking loss of the transcription factor TEAD. 
Generally, these results suggested an additional link between Hpo and signals 
proceeding from the TJ network involving Ocln that may regulate proliferation in a 
manner that could affect epithelial cell homeostasis and oncogenesis.  
 
As shown earlier, proteins from the polarity complex are suggested to interact with Hpo 
elements and negatively regulate YAP by altering its subcellular location. ZO-2, AMOT 
and YAP interactions have been described (Oka et al., 2012); this work has shown         
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co-localisation between Ocln and Hpo pathway elements such as YAP. As ZO-2 and 
AMOT proteins are localised at TJs (Guillemot et al., 2008), it cannot be discarded that 
YAP might be co-localised with Ocln through the interaction with ZO-2 and AMOT. More 
studies will need to address whether YAP directly binds to Ocln. 
 
Stabilization of cell-cell contacts restores abnormal epithelial cell polarity representing an 
interesting therapeutic strategy in cancer. Despite the molecular mechanisms involved in 
the Hpo pathway and the YAP/TAZ-TEAD being clearly established, the activators, the 
upstream regulators and how these elements regulate tumour progression through Hpo 
signaling remain to be elucidated. Still, the efficacy of YAP inhibitors and low toxicity on 
normal tissues is also subject to further investigation. A more advanced understanding 
on how cells generate, receive and transmit Hpo signals will give further insights into the 
molecular paradigms for tumourigenesis. 
 
In Chapter 5, the cytotoxic actions of dobutamine on pancreatic cancer cell viability and 
proliferation were confirmed. Dobutamine was shown to elicit an apoptotic response in 
AsPc-1 and HPAFII cells detected through nucleosome quantification. Given the role of 
proteasome inhibitors in inducing apoptosis in various cancer cells (Wente et al., 2005), it 
would be interesting to explore if the mechanism by which dobutamine reduces YAP and 
TEAD levels is mediated through a proteasome-mediated degradation of these proteins. 
If so, suppression of proteasome activity should block dobutamine actions. The 
compound MG-132 has been suggested to be a specific, potent, reversible, and 
cell-permeable proteasome inhibitor, reducing the degradation of ubiquitin-conjugated 
proteins in mammalian cells (Jensen et al., 1995). Thus, it would be interesting to 
examine the effect of MG-132 treatment on AsPc-1 and HPAFII cell proliferation and 
polarisation, cytotoxicity and apoptosis in the presence and absence of dobutamine.  
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The suppression of cell proliferation via dobutamine in AsPc-1 cells was suggested to be 
β-adrenergic mediated, although a more exhaustive experimental setup needs to be 
carried out to fully address this outcome. Most β-agonist mediated actions go through 
adenylyl cyclase/cAMP/PKA pathways, so the effects of phosphodiesterase inhibitors, 
which might mimic or potentiate dobutamine, are of interest to this system, particularly in 
the distributions of Ocln, YAP, and TEAD, and the enhancement of TER. 
 
Forskolin is the standard adenylyl cyclase activator and acts synergistically with receptor 
agonists in elevating endogenous levels of cyclic AMP (De Vries et al., 1988). To check if 
dobutamine is acting via cAMP pathways, this compound should mimic the effects of the 
β-adrenergic agonist in the pancreatic cancer cell lines used, or not if other pathways are 
involved. Another possible compound to use in these studies would be 
3-isobutyl-1-methylxanthine, IBMX, a methylated xanthine derivative (Kashiwagi and 
Foley, 1982); as the standard phosphodiesterase inhibitor that acts upon raising 
intracellular cAMP, if β-adrenergic mediation would be involved, this compound would be 
expected to mimic dobutamine effects in this system.  
 
This current work did not address if the dobutamine effect is being mediated through 
receptor activation or if it is a consequence of receptor down-regulation. Hence, 
considering the involvement of arrestin pathways might be of some value. Once bound, 
β-arrestins prevent G-protein coupling (Luttrell and Lefkowitz, 2002), so then this would 
block the actions of dobutamine in the system tested.  
 
Dobutamine was suggested to affect paracellular permeability through its actions on Ocln 
expression and stabilization at the cell membrane. Transient knock-down of Ocln 
expression confirmed that the actions induced by dobutamine on HPAFII cells were 
mediated through this TJ element. This work has also observed an essential role for 
PKCζ in the formation of functional TJs where the loss of action of this kinase could not 
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be compensated by dobutamine.  The fact that dobutamine could not enhance TER in 
the presence of PKCζ inhibitor would imply that PKCζ acts down-stream of dobutamine. 
As the ROCK inhibitor attenuates dobutamine effect, ROCK might also be placed 
down-stream of dobutamine. Therefore in the first scenario, it would be proposed that 
dobutamine acts to recruit Ocln to TJs via PKCζ and/or ROCK, and then Ocln inhibits 
YAP. Alternatively, dobutamine inhibits YAP and then the inhibition of YAP-dependent 
transcriptions and/or the physical interaction of YAP with Ocln might cause the 
redistribution of Ocln and the maturation of TJs. To test the first scenario, Ocln 
knockdown model and inhibitors of PKCζ and ROCK would block the 
dobutamine-induced YAP inhibition. To test this, nuclear localisation of YAP and mRNAs 
of YAP target genes such as CTGF could be used as read-outs. If the second scenario is 
true, YAP knockdown should facilitate the redistribution of Ocln and enhance TER. 
Dominant active YAP mutant should block the effect of dobutamine on the redistribution 
of Ocln and the enhancement of TER. To follow up these studies, a collaboration has 
been established with Heidi Wilson´s group at the University of Colorado in Denver, 
whereby the mechanisms induced by dobutamine will be elucidated in an Ocln null 
mouse model. These studies will shed light on dobutamine regulation of downstream 
mechanisms in the absence of Ocln and will firmly establish the mechanism and clinical 
impact of dobutamine as an adjuvant therapy for pancreatic cancer. 
 
In Chapter 5 it was also shown the potential in combining the cytotoxic actions of 
gemcitabine and dobutamine as an adjuvant chemotherapeutic approach to treat 
epithelial derived pancreatic cancer cells. PDAC, however, is characterized by an intense 
desmoplastic reaction composed of epithelial-derived cancer cells that are intimately 
associated with fibroblasts, macrophage, stellate cells, etc. It is perceived that a major 
challenge to effectively treat PDAC is the resistance of this desmoplastic environment to 
chemotherapeutics (Li et al., 2012). As shown, dobutamine was able to suppress 
proliferation of pancreatic epithelial cancer cells through the down-regulation of YAP and 
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TEAD resulting from Ocln-Ocln interactions; however this benefit might be nullified by the 
presence of non-epithelial cells that are commonly present in desmoplastic pancreatic 
tumours.  Thus, the effect of desmoplastic components on dobutamine actions would 
address the usefulness in using this compound to target PDAC. 
 
Although dobutamine was not tested in an in vivo model, this work highlighted a novel 
pharmacological approach that targets the Hpo pathway by potentially disrupting 
transcriptionally active complexes. Instead of inhibiting exclusively enzymatic activities or 
ligand-receptor interactions, this work might have opened new avenues into a possible 
new era of anti-cancer drugs: those that by interfering with the formation of complexes 
regulate the transcriptional machinery of a growth regulatory pathway. Importantly, being 
a drug that acts by increasing the cardiac output, studies need to evaluate carefully the 
potential benefit /risk ratio in using dobutamine as an adjuvant therapy to treat pancreatic 
cancer. Since smoking is indeed the most common cause of pancreatic cancer, these 
patients are therefore likely to carry a considerable risk of heart attack. Allied to this, 
many patients receiving chemotherapy would also be taking cardiovascular medications. 
  
This work speculated about the activity of dobutamine in sensitizing pancreatic cancer 
cells to treatment with gemcitabine. Important to this discussion is also the translation of 
pre-clinical data into the clinic as these studies were performed in two pancreatic cancer 
cells line which are likely to display marked heterogeneity in sensitivity to gemcitabine. 
To fully address the potential of these findings, gene expression profiling and other 
analytical strategies should be employed to allow determining more precisely whether 
cell lines recapitulate the biological heterogeneity present in pancreatic tumours. 
Moreover, these findings also require comparisons of tumour biological properties in cells 
cultured in different ways: 2-D and 3-D culture in vitro and in subcutaneous and 
orthotopic xenografts derived from these cells.  
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Overall, cancer therapies still strive to identify an effective targeted drug delivery system 
that reaches primarily the tumour site and sparse the adjoining tissues and organs. An 
infallible drug delivery method, however, is still beyond our grasp. To achieve this 
desired outcome, it is essential that pre-clinical models become better predictors of 
clinical activity allowing for an effective drug screen improving safety and efficacy 
outcomes in patients.  
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A.1 – Supplementary figures 
 
Figure 8.1 Controls used for the annexin/PI staining technique in AsPc-1 cells. Refers to 
Figure 5.13-A:  Chapter 5. Abbreviations: nt – non-treated;  no pt – no pre-treatment 
 
 
Figure 8.2 Controls used for the annexin/PI staining technique in HPAFII cells. Refers to 
Figure 5.13-B: Chapter 5.Abbreviations: NT – non-treated; Cells in each quadrant can be 
interpreted in the following manner: Lower left quadrant – P1:  These cells are negative for both 
annexin V and PI and can be regarded as viable non-apoptotic cells; Lower right quadrant – P3: 
Cells are positive for annexin V but negative for PI. These are cells that are at an early stage of 
apoptosis as the cell membrane remains intact and annexin V binds to phosphatidyl residues 
located in the outer membrane. Upper left quadrant – P4: Cells are negative for annexin V but 
positive for PI. These are cells that are at an end-stage of either apoptosis or necrosis and have 
lost their cell membrane or are dead. Upper right quadrant – P5: These cells are positive for 
both annexin V and PI. Although the cells show evidence of phosphatidyl residues these are not 






Figure 8.3 Immunoblot confirming Ocln knock-down in HPAFII cells. Refers to Figure 5.7-B: 
Chapter 5. 
 
                    
Figure 8.4 IHC controls for normal, chronic pancreatitis and pancreatic cancer human 
biopsies. Tissue sections were blocked for 30 min at RT with serum blocking reagent as 
described in section 2.10, Chapter 2 and incubated with a rabbit non-immune immunoglobulin 
(rabbit - DA1E; Cell Signalling) with the same concentration as the primary monoclonal antibody 
(1:100 dilution). Tissue sample was then incubated with the secondary antibody and detection 
reagents. Scale bar, 50 µm. 
 
 
Figure 8.5 Immunofluorescence controls. No primary antibody controls for AsPc-1 (Top panel) 
and HPAFII (Bottom panel) cells. Confocal images of indicated fluorescent secondary antibodies 
(Mouse -Texas Red and Rabbit -FITC). Cells were stained as outlined in section 2.9 Chapter 2, 
with the exception that no primary antibody was added. Images are representative of three 






           
Figure 8.6 Cell proliferation in AsPc-1 (left hand side) and HPAFII (right hand side) cells in 
response to different concentrations of antagonists, atenolol and propranolol during 48 h. 
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